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ABSTRACT 
 
The primary aim of the thesis was to report new cost-effectiveness evidence in the clinical 
area of heart disease. Following a review of published empirical work, this was achieved by 
undertaking three new cost-effectiveness studies: one in nurse-led secondary prevention 
clinics for coronary heart disease in primary care, one on cardiac resynchronisation therapy 
with or without an implantable cardioverter defibrillator in chronic heart failure, and the final 
one on a new drug therapy, nebivolol, compared with standard treatment in elderly patients 
with heart failure. Nurse-led clinics in primary care are highly cost-effective.  Nebivolol is a 
cost-effective treatment to an elderly population with chronic heart failure. Cardiac 
resynchronisation therapy (CRT-P) is a cost-effective treatment option compared with 
medical therapy (MT) alone.  However, adding an implantable cardioverter-defibrillator to 
CRT appears to be beyond the traditional willingness-to-pay threshold of £20,000 per QALY 
gained and might not be a cost-effective option. 
 
The second aim of the thesis concerned the application of modelling methodology, with the 
intent being the provision of general recommendations in using Markov modelling 
approaches in economic evaluation conducted in the heart disease area. The focus was on 
extrapolation of cost-effectiveness of an intervention beyond a trial both in terms of the time 
horizon of the analysis and in relation to the population involved. Fundamental issues in 
parametric distribution functions and Markov modelling approaches have been revisited, with 
detailed consideration of which parametric distribution functions should be employed when 
extrapolating beyond a trial and how they could be adopted into model-based analyses.  The 
need for further methodology investigations in this area is discussed in conclusion. 
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CHAPTER 1  INTRODUCTION 
 
 
1.1  Background on the epidemiology of heart disease 
  
Heart disease or cardiovascular disease (CVD) is a range of conditions which includes 
coronary heart disease (CHD), cerebrovascular disease, hypertension, peripheral artery 
disease, rheumatic heart disease, congenital heart disease and heart failure (WHO, 2008).   
 
CHD is the most common form of CVD. It is also known as coronary artery disease which 
refers to disease characterised by narrowing of the blood vessels supplying the heart muscle 
(BHF, 2007). The condition can cause angina and heart attack. Angina is most often felt as 
chest pain. Heart attack, also called myocardial infarction (MI), happens when an artery to the 
muscles of the heart is suddenly and completely blocked.  Heart failure is also known as 
congestive heart failure which causes the heart to become less effective and not to supply 
enough oxygen containing blood to the needs of the body. It results from coronary heart 
disease in most cases but it can be caused by high blood pressure.  Most often it is a chronic 
condition that worsens over time in the absence of treatment. 
 
Other common forms of CVD include stroke, aneurysm, and cardiac arrhythmia 
cardiomyopathy, all of which are related to dysfunction in different parts of the heart or blood 
vessels.  
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CVD is the most common cause of death globally.  WHO estimated that 17.5 million people 
died from cardiovascular disease in 2005, representing 30% of all global deaths. Of these 
deaths, 7.6 million were due to heart attacks and 5.7 million due to stroke. In the UK, 
according to British Heart Foundation statistics (BHF, 2007), more than 208,000 deaths a year 
(36% of all deaths in the UK) are accounted for by CVD. Nearly 48% of all deaths from CVD 
(approximately 101,000 deaths a year in the UK) are due to CHD. Heart attack is the major 
cause of death from CHD. About 260,000 people in the UK suffer a heart attack each year, 
with about 30% of the heart attacks leading to death before the patient reaches hospital (BHF, 
2005). Other forms of heart disease cause around 32,000 deaths a year. In 2005 heart disease 
was responsible for around 133,000 deaths. 
 
In 2003 the estimated prevalence of CHD in England was 7.4% in men and 4.5% in women 
based on the Health Survey of England (DOH, 2003). Prevalence increased with age with 
around 25% in men and 20% in women aged 75 and over living with CHD. Figures based on 
British Heart Foundation statistics (BHF, 2007) indicate that there are over 1.5 million men 
and 1.1 million women living in the UK suffering from CHD, either as angina or heart attack.  
 
Treatments for heart disease depend on the type of disease and severity of the condition. Most 
people with coronary heart disease can be managed or controlled on medications. However, 
acute or worsening conditions, such as a heart attack, require urgent medical or surgical 
interventions. The UK National Health Service (NHS) National Service Framework for CHD, 
announced in March 2000, set national standards for the prevention, diagnosis and treatment 
for CHD in England (DOH, 2007). 
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The economic costs of CHD are very high. It is estimated to have cost the publicly financed 
health care system in the UK around £15 billion in 2003, of which care for those patients in 
hospital accounted for about 76% and medications and dispensing expenses accounting for a 
further 18% (BHF, 2007).    
    
1.2  Economic evaluation in health care  
 
The increasing demand for health care, as seen in the case of CHD, places ever growing 
pressure on limited health care budgets.  It is therefore important for decision-makers, when 
deciding whether to cover or reimburse a particular technology, to consider not only safety 
and efficacy but also efficiency. Economic evaluation provides information on efficiency by 
estimating the cost and effectiveness of two or more health care alternatives and comparing 
the relative difference in the outcomes (Drummond et al., 2005). It provides decision-makers 
with a means for setting priorities in allocating resources.     
 
In recent years, economic evaluations alongside randomised controlled clinical trials have 
become increasingly popular as a route for generating evidence to allow the evaluation of 
health care programs. A recent study by Sculpher and his colleagues indicates that nearly 30% 
of published economic evaluations since 1994, recorded on the NHS Economic Evaluation 
Database are based on data from a single randomised control trial (RCT) (Sculpher et al., 
2006).     
 
The growing popularity of trial-based economic evaluation has called for a further advance 
and methodological development in the analytic approaches for conducting economic 
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evaluation alongside clinical trials. As will be shown in the next chapter, most analytic 
methods in economic evaluation running alongside clinical trials rest upon traditional 
statistical analysis methods. Traditional statistical methods in analyzing cost and quality-
adjusted life years (QALYs) face several challenges in economic evaluation at the level of 
individual data (Barber & Thompson, 1998). For example, missing data is common in clinical 
trials; and it tends to be a more severe problem when the collection of resource usage data is 
also considered.  In addition, cost data are often characterized by highly skewed distributions 
with a few patients incurring a very large cost (Barber & Thompson, 2000). This challenges 
the normality assumption in traditional statistical methods for estimating the difference in 
means.   
 
Clinical trials are usually designed for specific clinical outcomes.  In most cases, they focus 
on clinical endpoints. In addition, the follow up periods in most trials tend to be relatively 
short. It is most likely that the impact of an intervention on costs and effectiveness are not 
reflected within a trial period. Furthermore, trial populations may not commonly be 
representative of general patient groups (Buxton et al., 1997). Therefore, methods for 
extrapolating beyond a trial are often sought in order to explore the potential implication in 
cost-effectiveness over a longer period and when applying the results to more general settings. 
 
However, literature reveals inconsistency on different analytic approaches in conducting 
economic evaluation (Barber & Thompson, 1998; Richardson & Manca, 2004). Different 
methods might lead to different conclusions about the same intervention. Therefore, it is 
necessary to improve the quality and consistency of the methodology applied in conducting 
 5 
 
analyses in economic evaluation. Such a development would enhance the usefulness and 
reliability of economic evaluation to decision-makers. 
 
1.3  Aims of the thesis 
 
The thesis has two primary aims, one empirical and the other methodological.  On the 
empirical side, the primary focus of this thesis is to provide new economic evaluation 
evidence relating to selected interventions in cardiovascular heart disease. It focuses on the 
situation where economic evaluation was conducted alongside a randomised clinical trial. The 
cost and effectiveness of three interventions in cardiovascular disease are investigated: 
 
1. Nurse led clinics in secondary prevention care; 
2. Cardiac resynchronization therapy (CRT) with and without the addition of an 
Implantable Cardioverter-Defibrillator (ICD); 
3. Nebiviolol treatment in an elderly patient group with chronic heart failure.   
 
The second aim of the thesis, relating to methodological work, is to provide practical 
illustrations on the application of methodological aspects when conducting economic 
evaluation based on individual data from a trial. The thesis illustrates how to extrapolate cost 
and survival data beyond a trial period and how to conduct model-based analysis when input 
data are populated from a trial.  
 
1.4  Outline of the thesis 
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Chapter 2 contains the literature review in economic evaluation conducted in the area of heart 
disease. It focuses on full economic evaluation conducted within cardiovascular disease 
excluding stroke. The review also includes an extensive discussion of modeling approaches 
used in the literature and provides a critique of their application. 
 
Chapter 3 documents an empirical study of cost-effectiveness analysis of nurse led clinics in 
secondary prevention in primary care for cardiac patients. The study was a within trial 
analysis and details of statistical methods are illustrated. This chapter was based on a 
published paper in the British Medical Journal (Raftery et al., 2005) and was further 
developed specifically for the thesis using a different analytic approach.  In the published 
paper, only t-tests are presented in the analysis cost and quality of life data, whereas in the 
thesis, bootstrapping methods were used for all analyses.  
 
Chapter 4 discusses statistical properties of different distribution functions and their use in 
extrapolating survival curves from a trial to beyond a trial period.  One of the clinical case 
studies of the thesis, the CARE-HF study, was used as an illustration of the approach. The 
focus of this analysis was on methods for dealing with the different time perspectives for cost 
and QALYs within a trial period, in which a large cost occurred with the implementation of 
the intervention and where, by the end of trial, benefit was still accruing. Methods employed 
in extrapolating beyond the trial, based on a parametric survival analytic approach, are 
presented.  The case study in this chapter was published in European Heart Journal (Calvert et 
al., 2005) 
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Chapter 5 discusses methods based on a modeling approach in extrapolating beyond a trial. 
An individual simulation model based on a Markov modeling framework is reviewed and 
details on how to overcome the limitations of the Markov model are discussed. The focus is 
on step-wise approaches to estimate transition probabilities from individual data, including 
Matrix algebra in converting different lengths of cycles, and how to estimate hazard ratios. An 
example used for illustration throughout the chapter is based on a renal transplantation model 
(Yao et al.,  2006).  
 
Chapter 6 contains a case study using a model to go beyond a trial and draws also on the 
CARE HF study. This chapter focuses on modeling approaches in extrapolating beyond a 
trial. Details of the modeling approach and model validation is illustrated. This study was 
published in European Heart Journal (Yao et al.,  2007).  
 
Chapter 7 is a case study using the SENIORS trial. This chapter focuses on one approach 
covering both within and beyond trial analyses. Further, the analyses extrapolated beyond the 
end of the trial, but I also extended the approach to extrapolate into different populations. This 
study was published in Pharmacoeconomics (Yao et al., 2008).   
 
Chapter 8 contains a general discussion of all the issues and final remarks on economic 
evaluation conducted in heart disease. The overall conclusions of the thesis and the 
implications for future research are discussed.  
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CHAPTER 2 LITERATURE REVIEW OF ECONOMIC EVALUATION 
IN HEART DISEASE 
 
2.1 Introduction 
 
The previous chapter gave an overview and outline of the thesis. The aim of this 
chapter is to present an overview of methods used in economic evaluations based on 
individual data conducted in the area of heart disease. It focuses on the analytic 
methods adopted by other researchers in this disease area. Emphasis was placed on how 
costs and outcomes were collected and estimated, how cost-effectiveness was analysed 
and presented, modelling methods used in extrapolating beyond a trial period and 
assumptions made on treatment effects and methods in estimation on survival or time-
to-event curves beyond a trial period.  
     
The first part of the chapter considers how the papers to be reviewed were identified 
and methods used in data extraction from each study. This is followed by a broad 
critical review of the identified papers using an established review framework, namely 
the Drummond checklist.  In the second part of the chapter (from section 2.6), it 
focuses on critical review of the modelling methods used in those papers, where 
modelling was undertaken.  The literature on methodological issues related to 
modelling approaches was discussed.    
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2.2 Search strategy 
 
To identify published economic evaluation studies based on individual data from 
randomised clinical trials for cardiovascular disease, a search was undertaken through 
the MEDLINE database. The search used the terms “heart”, “cost” or “economic” and 
“clinical trials” in the title and abstract or “heart disease” in MeSH heading. Full details 
of the search strategy for this review are presented in Appendix 1.  
 
The database search was conducted on October 1st 2007, covering the period from 
January 2005 to August 2007, the most up-to-date literature available at the time of 
search. The literature search has been conducted in a thorough and rigorous manner but 
is not ‘systematic’ in a formal sense.  The reason for this is that it was not intended to 
identify treatment effects but to provide a broad view on the current approaches to 
conducting economic evaluation based on clinical trials in the clinical area of heart 
disease.    
 
The narrow time frame was selected because the aim of the search was to report current 
practice at the time the research was carried out. MEDLINE was chosen as it is 
recognized as having excellent coverage of English Language papers and is well 
indexed, making it the first choice database for searching by most reviews. Since the 
work was not resourced to look at non-English articles, and since it was not conducting 
a review of a specific treatment effect (but instead a methodological review), the return 
from the substantial additional work required to extend to EMBASE (the second choice 
database) was judged unlikely to be worthwhile. 
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2.3 Inclusion and exclusion criteria 
 
Two broad categories of studies were considered for inclusion in the review: economic 
evaluations conducted alongside clinical trials, and modelling based studies in which 
model inputs were populated by individual data from a trial. The disease area was 
defined as including all cardiovascular disease but excluding stroke. The types of 
economic evaluations include cost-minimisation, cost-effectiveness, cost-utility, and 
cost-benefit, which means only full economic evaluations (Drummond et al., 2005) 
were included in the review. Studies that compared treatment effects and concluded no 
significant difference between comparators, which is cost-minimisation studies, were 
included. Studies that did not compare both costs and effectiveness of alternatives were 
excluded as were studies in which the authors did not access individual patient data 
from a trial. 
 
2.4 Data extraction strategy 
 
To review the included studies, information was extracted from each paper into four 
categories: 
 
1. The overview of the studies including study population (disease area), 
interventions, comparators, results on clinical outcome and costs and setting of 
economic evaluation.   
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2. The economic evaluation methods used in each study, including type of 
economic evaluation, study perspective, outcome measurements, whether a 
within trial analysis or extrapolating beyond a trial and whether model based 
analysis were used.  
 
3. Statistical analytic methods used within a trial analysis, including costing 
analysis, cost- effectiveness analysis, the use of statistical inference on the point 
estimates and statistical methods in conducting analysis.   
 
4. When extrapolating beyond a trial was conducted, the review explored whether 
a model-based analysis was conducted, how the input data were populated and 
how the model was defined and assumptions relating to the model. 
 
At the end of the section, a critical review of modelling work was undertaken. It 
focused on critical review of the modelling methods used in those papers, where a 
decision analytic model was used. Literature on methodological issues related to 
modelling approaches was also discussed.  
 
2.5 Results 
 
The literature search identified 220 studies. Details of the paper selection process are 
illustrated in the flow diagram (Figure 2.1). Screening on the titles and types of 
publications led to 77 papers being excluded because the studies were review articles. 
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On further review of the titles and abstracts of the remaining papers, an additional 90 
papers were excluded because the study focus was trial design, they were not relevant 
to heart disease or heart disease was not the main area of study focus, or only a partial 
economic analysis with no comparison of two or more interventions in terms of cost 
and outcome was carried out. The full text of the remaining 54 potentially relevant 
studies was obtained. Of these, 29 randomised clinical trial based studies met the 
inclusion criteria for review. A list of excluded studies from the review can be found in 
Appendix 2. 
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Full search identified Papers 
N= 220  
Publication type defined as review 
Excluded n=77 
 
Excluded N=25:  
Heart disease is not main study area (7) 
Not base on individual data (8) 
Not full EE (10) 
 
Total number of studies: Included N=29 
 
Full copies retrieved and screened 
 Included N=54 
 
Excluded n=90: 
Not economic evaluation (30) 
Study design (11) 
Not focus on heart disease (32) 
Commentaries (3) 
Not based on individual data (10) 
Methodology (3) 
Review (1) 
Review title and abstract 
Included N=143 
Screen title and type of Publication  
                        Total N=220 
 
Figure 2.1 Flow diagram of selecting studies in the review 
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2.5.1 Overview of the included studies  
Table 2.1 outlines the general information of the included studies in the review. Among 
the included 29 studies, 17 concerned chronic heart failure (HF), 3 in atrial fibrillation 
(AF), 3 in myocardial infarction (MI), 5 in coronary heart disease and 1 in other heart 
diseases. 
 
Among the 29 studies, 17 focused on drug interventions, 5 were for device 
interventions, 4 were for care management interventions and 3 were for diagnostic 
tests. All of the included studies have their original clinical trials designed to compare 
interventions with placebo or current standard care. Table 2.1 reported the overall view 
of information which were reported on all included studies. 
 
Ten of the economic evaluations were conducted in the US, 11 in the UK and eight in 
other countries. Reed and colleagues (2005) conducted an economic evaluation based 
on a multinational clinical trial setting and used country specific costing, while 
McMurray and colleagues (2006) conducted their economic evaluations in France, 
Germany and the UK.  
  
Seventeen of the studies stated that the result of their corresponding clinical trials 
demonstrated positive intervention benefits and the objective was to examine the cost- 
effectiveness implications of the interventions.  Ten of the studies did not demonstrate a 
significant benefit of the intervention from the clinical trial, 2 of those aimed to 
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investigate the cost implications of the interventions, and the others investigated the 
cost-effectiveness result.   
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Table 2.1 Overview of all included studies  
Study Population Intervention Comparator Clinical result Cost result Setting 
Angus 2005 HF Isosorbide dinitrate 
/hydralazine 
Standard care Effective Cost more USA 
Beinart 2005 CHD Clopidogrel Placebo Effective Cost more U.S and Canada 
*Bond 2007 CHD Pharmacy-led 
medicines 
Standard care NS Cost saving UK 
Briffa 2005 MI /angina Rehabilitation Standard care Effective Cost more Austria 
Briggs 2007 CHD Perindopril Placebo Effective Cost more European1  
Calvert 2005 HF CRT-P Medical 
therapy 
Effective Cost more European1  
Caro 2006 HF Metoprolol succinate Standard care Effective Cost more US 
Di 2005 HF Bisoprolol Placebo Effective cost saving 18 Countries-  
Feldman 2005 HF CRT-P or CRT-D Medical 
therapy 
Effective Cost more US 
Inglis  2006 HF Home-based 
intervention 
Usual post Inglis  2006 HF Home-based intervention 
*Corresponding authors 
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Table 2.1 Overview of all included studies (continued) 
Study Population Intervention Comparator Clinical result Cost result Setting 
Mark 2006 HF Amiodarone Medical 
therapy 
NS Cost more US, Canada &
 ZealandNew 4  
McMurray 2006 HF Candesartan Placebo Effective Cost more countries  26 2  
Mihaylova 2005 CHD simvastatin Placebo Effective Cost more UK 
Mueller 2006 HF B-Type Natriuretic 
Peptide 
Conventional 
strategy 
NS but reduced 
mortality 
Cost saving Swiss 
O'Brien 2005 HF Physiologic 
pacemaker 
Ventricular 
pacemaker 
Effective Cost less Canada 
Pietrasik 2007 AF Rate control Rhythm 
control 
NS Cost saving Polish 
Radeva, 2005 Heart 
transplantation 
Everolimus Azathioprin Effective Cost more Multinational 
Raftery 2005 CHD Nurse led Standard care Effective Cost more Scotland 
Reed  2005 HF Valsartan Captopril NS Cost more 24 countries6  
Rinfret 2005 HF Valsartan Captopril or 
both 
Not effective Cost more US 
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Table 2.1 Overview of all included studies (continued) 
Study Population Intervention Comparator Clinical result Cost result Setting 
Scuffman & 
Kosa2006 
PCI Fluvastatin Control Effective Cost more Europe, Canada and 
Brazil5  
Scuffham & 
Chaplin 2005 
PCI Fluvastatin Control Effective Cost more Europe, Canada and 
Brazil1  
Szucs 2006 HF Eplerenone Placebo Effective Cost more Switzerland 
Taylor 2005 MI Home-based  
rehabilitation 
Hospital-based 
rehabilitation 
NS Cost same UK 
Walker 2006 CHD-angina Nicorandil Standard care NS but reduced 
events 
Cost more UK 
Weintraub 
2005a 
Angina or MI Clopidogrel Placebo Effective Cost more 28 countries 
EE: US 
Weintraub  
2005b 
HF Eplerenone Placebo Effective Cost more 37 countries 
EE: US 
Van. Hulst 2005 Valve surgery Lucodepleted 
erythrocytes 
Buffy-coat-
depleted 
packed cells 
Effective Cost saving Netherland 
Yao  2006 HF CRT-P or CRT-D Medical 
therapy 
Effective Cost more European 
EE: UK 
NS: Not significant. 
The economic evaluation was conducted: 1, UK; 2, France, Germany and the UK; 3, Italy; 4, USA;  5, Hungary; 
6,country specific cost 
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2.5.2 Economic evaluation   
When economic evaluation is conducted alongside a clinical trial, the “piggyback” method is 
usually used to prospectively collect resource data (Gold et al., 1996). This simply refers to 
the collection of resource use and/or quality of life data within an otherwise typical clinical 
trial. This might be achieved through the use of interviews, questionnaires, case record forms, 
hospital notes or patient recorded diary.  
 
The study perspective defines which resource items should be collected. For example, if the 
UK National Health Service (NHS) perspective was taken, the cost burden to the NHS only 
should be considered. If the perspective was from societal point of view, then further 
resources used should be considered such as the cost of traveling, out of pocket expense, 
family or relative care and loss of productivity.   
 
Clinical trials are usually designed for clinical end points. In cardiovascular disease, the 
primary outcome of a study is usually on clinical interests, such as the number of 
cardiovascular events avoided, or time of first unplanned cardiovascular hospitalisations. 
Decision-makers are interested in assessing the marginal benefit of additional cost of a 
technology for difference patients groups. This required measuring additional cost per quality-
adjusted life-year (QALY) gained or per life-year gained.  QALYs are the recommended 
outcome in economic evaluation (Pearson & Rawlins 2005).  The Public Health Services 
Panel on Cost-effectiveness in Medicine (Gold et al., 1996) and the NICE health technology 
assessment (HTA) process in the UK have recommended using QALYs in its guideline for 
economic evaluation (NICE, 2007). Those are two most influence bodies which had on the 
conduct of cost-effectiveness analysis generally. The US panel recommendations form the 
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basis of the standard US textbook on cost-effectiveness analysis. While the NICE setting the 
standards  are increasingly being adopted in other UK-based analysis. 
 
QALYs are the summary measurement of each life-year weighted by its corresponding utility 
values, which are usually measured as preference based utility scores.  The commonly used 
for such measurement is EuroQol EQ-5D (EuroQol Group, 1990).  The EQ- 5D index has a 
scale where 0 is equivalent to death and 1 full health. A negative value represents a state of 
‘‘worse than death’’ (Drummond et al., 2005).  Other measurements of preference based 
quality of life include SF-6D (Brazier et al., 2002), and the Health Utility Index (HUI2) and 
the Health Utility Index 3 (HUI3) (Feeny et al, 2002). 
 
In this section, the Drummond definitions on the type of economic evaluation were adopted 
(Drummond et al., 2005). Similarly, all studies were classified into health sector, societal, 
hospital and health sector plus private perspectives.   
 
Table 2.2 gives a summarisation of information on economic evaluation employed on the 
papers. Among the 29 studies, 27 conducted a cost-effectiveness analysis, in which 12 
incorporated cost-utility analyses, and 2 were cost-minimisation analysis in which the authors 
had provided no significant treatment effects.   
 
Of the 29 studies, 26 adopted a health care sector perspective, in which 4 of the studies 
claimed to take the societal point of view. However, three of the 4 studies, which claimed to 
be from a society point of view, did not collect any cost data related to non-health care or 
productivity loss.  Raftery and colleagues (2005) included direct NHS health care costs and 
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private hospital visit costs and justified excluding productivity costs as the majority of 
patients were over 64 years.   
 
Among the 29 studies, 12 used quality-adjusted life-years (QALYs) as the outcome measure, 
27 used a life-year or mean survival time, among those 5 studies used the trial’s primary end 
point as the measure of effectiveness in the economic evaluation.  Among the 12 cost-utility 
analyses, 8 collected preference-based utility measures as part of the trial, 2 were based on 
published utility values and 2 were taken from publicly available survey data.  
 
Twenty-three studies conducted economic evaluation alongside the clinical trial, in which 6 
conducted within-trial period analysis and investigated the longer-term cost-effectiveness 
results by extrapolating beyond the trial without actually using a decision model. Six studies 
conducted a model-based analysis to investigate the long-term economic implications.  
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Table 2.2 Summarised information on economic evaluation 
Study Type of EE Perspective Outcome 
measure 
Trial follow-up 
(month) 
Extrapolating 
beyond a trial 
Analytic type 
 
Angus 2005 CEA Societal Life years 12.8 Yes Statistical analysis 
Beinart 2005 CEA Health care sector Life years 12 Yes Statistical analysis 
*Bond  2007 CMA Health care sector QALYs 
Life years 
12 No Statistical analysis 
Briffa 2005 CEA &CUA Health care sector QALYs 12 No Statistical analysis 
Briggs 2007 CEA &CUA Health care sector QALYs 
Life years 
50 Yes Model based analysis 
Calvert 2005 CEA &CUA Health care sector QALYs 
Life years 
29.4 Yes Statistical analysis 
Caro 2006 CEA Health care sector Life years 12 Yes Model based analysis 
Di 2005 CEA Health care sector Clinical outcome 15 No Statistical analysis 
Feldman 2005 CEA&CUA Health care sector QALYs 
Life years 
11.5 to 16.2 
(median) 
Yes Model-based analysis 
Inglis 2006 CEA Not stated Life years 48 (median) Yes Statistical analysis 
CMA, Cost-minimisation analysis; CEA, cost-effectiveness analysis; CUA, cost utility analysis; EE, Economic 
evaluation. 
*Corresponding author 
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Table 2.2 Summarised information on economic evaluation (Continued) 
Study Type of EE Perspective Outcome 
measure 
Trial follow up 
(month) 
Extrapolating 
beyond a trial 
Analytic type 
 
Mark 2006 CEA&CUA Societal perspective QALYs 
Life years 
45.5 (median) Yes Statistical analysis 
McMurray  2006 CEA Health care sector Clinical outcomes 38 (median) No Statistical analysis 
Mihaylova 2005 CEA Health care sector Clinical outcomes 60 No Statistical analysis 
Mueller 2006 CEA Health care sector Mortality 6 No Statistical analysis 
O'Brien 2005 CEA Health care sector Life years 62 No Statistical analysis 
Pietrasik 2007 CMA Health care sector Clinical outcomes 12 No Statistical analysis 
Radeva 2005 CEA Health care sector 
(Societal) 
Clinical outcomes 12 No Statistical analysis 
Raftery 2005 CEA &CUA Health care sector 
(Societal) 
QALYs 
Life years 
53 No Statistical analysis 
Reed 2005 CEA &CUA Health care sector QALYs 24 No Statistical analysis 
Rinfret 2005 CEA &CUA Health care sector 
(Societal) 
QALYs 
Life years 
33 (median) Yes Model-based analysis 
CMA, Cost-minimisation analysis; CEA, cost-effectiveness analysis; CUA, cost utility analysis; EE, Economic 
evaluation,  
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Table 2.2 Summarised information on economic evaluation  (Continued) 
Study Type of EE Perspective Outcome 
measure 
Trial follow up 
(month) 
Extrapolating 
beyond a trial 
Analytic type 
Scuffman & 
Kosa2006 
CEA &CUA Health care sector QALYs 
Life years 
48 Yes Model-based analysis 
Scuffham & 
Chaplin 2005 
CEA &CUA Health care sector QALYs 
Life years 
48 Yes Model-based analysis 
Szucs 2006 CEA &CUA Health care sector QALYs 
Life years 
16 Yes Statistical analysis 
Taylor 2005 CEA Health care sector QALYs   Yes Health care sector 
Van 2005 CEA Health care sector Life years 3 No Statistical analysis 
Walker 2006 CEA Health care sector Clinical outcomes 18 No Statistical analysis 
Weintraub 2005a CEA Heath care sector 
(Societal) 
Life years 12 Yes Statistical analysis 
 
Weintraub 2005b CEA Health care sector 
(Societal) 
Life years 16 Yes Statistical analysis 
 
Yao 2006 CEA &CUA Health care sector QALYs 
Life years 
29.4 Yes Model-based analysis 
CMA, Cost-minimisation analysis; CEA, cost-effectiveness analysis; CUA, cost utility analysis; EE, Economic 
evaluation,  
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2.5.3 Statistical methods in analysing cost and cost-effectiveness  
 
One of objectives in economic evaluation is to compare the difference in mean cost per person 
between treatment groups.  The arithmetic mean of the cost is an appropriate focus for decision-
making (Drummond et al., 2005). Cost data are often characterised by highly skewed 
distributions with a few patients having large costs (Barber & Thompson, 2000). This challenges 
the normality assumption in traditional statistical methods for estimating difference in means. To 
deal with this problem, bootstrap methods, which are highly attractive methods in conducting 
cost analysis (Barber & Thompson 2000), do not need the assumption of normality.  Recent 
studies have explored the use of generalised linear models and generalised linear mixed models 
in dealing with heavily skewed data in cost analysis (Nixon & Thompson, 2004).   
 
Cost-effectiveness analysis seeks to estimate the difference in mean costs between treatments 
divided by the difference in effectiveness, such as QALYs or life years. The ratio is termed as an 
incremental cost-effectiveness ratio (ICER), and in cost-utility analysis it refers to incremental 
cost per QALY gained.  
 
Inference of the point estimate of the ICER has brought a further challenge for analysis, in which 
the variance of the ratio has no obvious functional form. There are four methods in producing 
confidence intervals: the box method, the Taylor series method, non-parametric bootstrapping 
methods and Fieller methods (Polsky et al., 1997).  The box method calculates the confidence 
intervals (CI) by dividing the lower CI in costs by the upper confidence limit for effects to 
produce the lower limit of the confidence interval for the ratio and the upper limit of the CI by 
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dividing the upper limit for costs by the lower limit for effects. This can lead to an 
inappropriately wide confidence interval for the ICER (Wakker et al., 1995). The Taylor series 
method involves estimating the standard error of the cost–effectiveness ratio itself by a Taylor 
series approximation (O’Brien et al., 1994). This method assumes that both cost and 
effectiveness and ICER estimate are normally distributed, which is it not always the case.  The 
Fieller theorem method is a parametric method for computing the confidence intervals of a ratio. 
It is based on the assumption that the costs and effectiveness of the ratio follow a bivariate 
normal distribution (Willan & O’Brien, 1996).   
 
The bootstrap approach is a nonparametric method that makes no distributional assumptions 
concerning the statistic in question. It employs the original data in a resampling exercise in order 
to give an empirical estimate of the sampling distribution of that estimate. The use of 
nonparametric bootstrapping methods to produce confidence intervals around the estimates of the 
ICER has been advocated by many authors (Chaudhary et al., 1996; Briggs et al., 1997; Briggs et 
al., 1999 & Lord, et al., 1999). 
  
There are 25 studies that were undertaken within a trial or within and beyond a trial with 
statistical analysis conducted using individual data of these.  Table 2.3 provides a summarised 
information on statistical analysis used on those papers. Seventeen studies recognised the skewed 
nature of the costing data and used bootstrap methods for estimation and made inference on the 
point estimates.  Four of the studies only reported summarised cost and point estimates without 
any inference on the point estimates, and two employed generalised linear models.  
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Among the 18 studies that conducted cost-effectiveness or cost-utility analysis, 10 used 
bootstrapping methods and made inference about the point estimates for the incremental cost-
effectiveness ratios, and 14 produced cost-effectiveness acceptability curves (CEAC) in 
illustrating the probability of intervention being cost-effective at given level of willingness to pay 
per QALY or per life year gained.   
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Table 2.3 Summarised information on statistical analysis   
Study Cost difference Inference Incremental cost 
effectiveness (ICER) 
Inference on ICER Assumptions beyond the 
trial 
Angus 2005 Bootstrap CI and P-value Bootstrap CI and P -value No 
Beinart 2005 Bootstrap CI Bootstrap CI External source 
Bond 2007 Point estimates Inter Quartile Regression No No 
Briffa 2005 Point estimates None Point estimate None No 
Calvert 2005 Bootstrap CI Bootstrap CI and CEAC Parametric survival function 
Di 2005 Point estimates None No No No 
Inglis 2006 Point estimates none Point estimates None No 
Mark 2006 Bootstrap P-value Bootstrap CEAC Parametric survival function 
McMurray 2006 Bootstrap CI and P-value Bootstrapping CI No 
Mihaylova 2005 Bootstrap Standard error Bootstrap CI NO 
Mueller 2006 Bootstrap Standard error Bootstrap CI NO 
O'Brien 2005 Bootstrap CI Bootstrap CI NO 
  
+-  
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Table 2.3 Summarised information on statistical analysis  (Continued) 
Study Cost difference Inference Incremental cost 
effectiveness (ICER) 
Inference on ICER Assumptions beyond the 
trial 
Pietrasik 2007 Bootstrap P-value N/A N/A N/A 
Radeva 2005 Bootstrap CIs Bootstrap CI No 
Raftery 2005 Bootstrap and T-test P-value Point estimate CEAC None 
Reed 2005 Bootstrap CI Bootstrap scatter plots No 
Rinfret 2005 Kaplan-Meirer CI Point estimate No Random 
Szucs 2006 point estimates No Bootstrap No Observational data 
Taylor 2005 Bootstrap CI Bootstrap N/A Mean 
Van Hulst 2005 Bootstrap CI Bootstrap Not defined No 
Walker 2006 Bootstrap Point 
estimate 
Mean Point estimate No 
Weintraub 2005a Bootstrap CI Bootstrapping CEAC and scatter plot Constant hazard and used 
observational data 
Weintraub 2005b Bootstrap CI Bootstrapping CEAC and scatter plot Used on observational data 
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2.5.4 Extrapolating beyond a trial  
The choice of time horizon is an important consideration in economic evaluations (Drummond et 
al 2005) and it should be long enough to capture the major health and economic consequences.  It 
is common for an economic evaluation, when conducted alongside a clinical trial, to estimate the 
cost-effectiveness result at the end of a follow-up period. However, clinical trials are designed to 
investigate a treatment effect on clinical outcomes.  Certain treatments or interventions involve a 
large initial cost, such as surgery or implantation of a medical device.  However, their treatment 
benefit may last much longer than a trial period. The cost-effectiveness result estimated at the end 
of a trial period may be substantially different if the treatment effects over a longer-term were 
considered. Therefore, economic evaluation often requires projection of treatment effects and 
costs over a longer time.  
  
Extrapolating beyond a trial using a modelling approach is a common method in conducting 
economic evaluation.  In the review, 7 studies have conducted beyond trial analysis by employing 
a model. Table 2.4 reported the summarised result of those model-based analyses. Among the 7 
studies, 2 were based on cohort simulation while 5 were are based on individual simulation, of 
which 1 was based on a discrete event simulation approach and 4 employed a Markov modelling 
framework by allowing individuals to carry history and baseline characteristics in adjusting time-
varying risks for different events.  
 
For extrapolating beyond the trial, all the studies assumed constant hazard ratios for the 
intervention benefit beyond the trial; One of the studies assumed a declining rate of treatment 
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benefit; Three of the studies investigated the baseline function by employing parametric survival 
functions.    
   
Four of the studies used probabilistic sensitivity analysis (PSA) to investigate second order 
uncertainty on the cost-effectiveness result and produced incremental cost-effectiveness 
acceptability curves (CEAC).   
  
In the following sections, a more detailed critique of the modelling approaches used in the 
modelling papers is presented. It starts by developing an appropriate checklist for such a review, 
followed by the review of the modelling methods and approaches.  
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Table 2.4 Summarised information on model based analysis 
Study Type of model Analysis approach Transition probability 
fixed or varying? 
Assumptions on baseline 
survival beyond a trial 
Uncertainty 
Briggs 2007 Markov Individual 
sampling 
Time and individual 
based dependence 
Exponential survival 
function 
PSA and CEAC 
Caro 2006 Discrete event 
simulation 
Individual 
sampling 
N/A Trial property PSA 
Feldman 2005 Markov Individual 
sampling 
Time and individual 
based dependence 
Trial property PSA 
 
Rinfret 2005 
 
Markov Individual 
sampling 
Time and Individual 
based dependence 
Trial property PSA 
Scuffman & 
Kosa2006 
Markov Cohort simulation Fixed Exponential One way sensitivity 
analysis 
Scuffham & Chaplin 
2004 
Markov Individual 
sampling 
Fixed Exponential One way sensitivity 
analysis 
Yao 2006 Markov Individual 
sampling 
Time and Individual 
based dependence 
Weibull survival function PSA and CEAC 
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2.6 Critique of modelling studies 
 
2.6.1 Introduction to modelling review 
The literature review presented thus far provides an overview of methods used in economic 
evaluation conducted alongside randomised clinical trial data in the area of heart disease.  In the 
last section, all included papers were critically reviewed.  In the following sections, the focus of 
the review changes to a critique of modelling quality for those studies where a model approach is 
used. 
 
To critique the quality of the models, it is helpful to use a checklist.  There are several papers in 
the literature that provide guidelines for good practice of decision models (Halpern et al., 1998, 
Chilcott et al., 2003, Weinstein et al., 2003, Sculpher et al., 2000 & Philips et al., 2004 & 2006). 
In this section, the items list was largely adopted from the ‘Philips and colleagues’ checklist’ 
(Philips et al., 2006). The checklist was recommended to inform critical appraisal of 
methodological quality of economic modelling studies in the Cochrane handbook.  
 
In Philips and colleagues’ checklist, three general themes were suggested. Those were 
“Structure”, “Data” and “Consistency”. The same headings were adopted in this critique and in 
the following sections I will discuss the three themes in turn.  
 
2.6.2  Structure  
In Philips and colleagues’ checklist, the structure theme focuses on more general principles. This 
review aims to critique the suitability of model types and simulation methods, particularly the 
comparison of using cohort simulation versus individual simulation.  Therefore, a broader and 
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more detailed review is sought. The model types are classified by Barton and colleagues (2004), 
and enhanced by Brennan and colleagues (2006), Briggs and colleagues (1998) and Sonnenberg 
and colleagues (1983). The reason for reviewing model types and simulation methods explicitly 
was to critique the relevant merits in using cohort versus individual simulation methods. While 
certain types of models are deemed to be individual simulation methods, e.g. the discrete event 
simulation model, for Markov model and decision trees, the analytic methods are cohort based or 
individual patient level based simulation. To judge whether the choice of certain types of models 
are appropriate for the characteristics of the studied disease area, the Barton et al., 2004 and 
Brennan et al., 2006 classifications were adopted. 
 
The structure was reviewed first on type of models and whether the selection of models is 
appropriate for the clinical questions in study. Secondly, simulation methods and the 
appropriateness of the methods chosen were reviewed. The following section details these 
criteria.   
 
2.6.2.1 Classification of types of models 
In Barton’s paper, selecting a model type was firstly based on the judgment on whether 
individuals in the model were independent or whether there was interaction between individuals.  
If it was independent, the most common types of model used in health economic evaluation 
would be decision trees, Markov models and individual sampling methods. However, for certain 
kinds of diseases, e.g. infectious disease, individuals are not independent.  In the case of 
interaction, discrete event simulation models had to be sought to account for the dependency 
among subjects.   
 
Decision Trees 
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The decision tree has a simple and clear structure in which all possible patient pathways can be 
illustrated explicitly in a tree structure.  Probabilities and outcome measures can be attached to 
each branch of the tree.   
  
Markov models 
Markov models are generally used to represent stochastic processes, which evolve over time. 
The disease in question is divided into mutually excluded health states.  Transition probabilities 
from current state moving to another state in the next cycle are applied over a fixed time period 
(Briggs et al., 1998 and Sonnenberg et al., 1993).   
 
For a Markov chain transition probabilities are constant. This means that the transition 
probability moving from one health state to another does not depend either on the time a patient 
has spent in a given state or the patient’s previous history before entering that state. Markov 
models thus assume that patients in a given state can be treated as homogeneous groups and the 
Markov chain does not have any memory for a patient’s past disease history. These homogeneity 
and non-memory assumptions are inherent in a classical Markov chain model.  
 
The simulation methods of a typical Markov model are classified by two types. Briggs classified 
them as the cohort simulation and individual simulation methods.  Cohort simulation refers to a 
homogenous cohort of patients distributed in an initial disease state at the start of the model. At 
the end of each cycle, patients will be distributed into different health states by applying 
appropriate transition probabilities. Hence the numbers of patients in each health state at a given 
cycle can be estimated. Individual simulation method in a Markov model is also referred to as 
Monte Carlo simulation (Briggs et al., 1990). This refers to a situation where a large number of 
patients are generated at the beginning of the model and each patient is followed through the 
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model over time, individually. The difference between these two methods is that although 
individual patients are subjected to the same probabilities of transition as the cohort of patients, 
each individual will go through different disease progression pathways depending on random 
variation at a particular time.  Following the patient through the model allows an overall profile 
of costs and outcomes to be generated for that patient according to the path that they follow 
through the model.  
 
Individual sampling models 
In more general forms, a Markov process may allow the probabilities to vary with time and the 
relaxing of homogeneity assumptions. In Barton’s paper, one of approaches was to use a Monte 
Carlo simulation.  Individual patient simulation using Monte Carlo methods can provide a 
vehicle to relax the traditional non-memory and homogeneity assumptions in a Markov chain 
model.  This may be achieved by allowing individuals to carry baseline characteristics and the 
individual disease process can be recorded.  When simulated individuals have attributes attached, 
such as age or gender, the transition probabilities can be adjusted or updated based on those 
profiles.  Thus, the transition probabilities can be changed according to individual characteristics 
or time on treatment.  Furthermore, attributes can be updated while the model is running.   
 
However, the definitions of modelling types are not always consistent, especially in the case of a 
Markov model with a Monte Carlo simulation. Barton and colleagues state that it is common to 
use the terms of discrete event simulation model or state-transitional models to refers the same 
thing (Barton et al., 2004).  Barton proposed that a model that has the ability to track individuals 
is an essential part of the model structure but in which only one individual is modelled at a time 
is should be called an “individual sampling model”. Individual sampling models can also be 
based on Markovian states but it can be based on non-Markovian states (Brennan et al., 2006). 
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When individual level simulation is applied in a Markov modelling framework, the model should 
be classified as an individual sampling model.  
 
Discrete event simulation model  
In Barton’s paper, when individual patients in a model are not independent, two circumstances 
are considered.  First, in the case of infectious diseases, the risk of an individual catching the 
disease depends on how many other people already have it. Individuals are not independent on 
the risk of the disease.  Second, in the case when there are limited resources, individual patients 
are competing for the available resources. Discrete event simulation (DES) and system dynamics 
models (SD) are appropriate in those circumstances. A DES model is an individual level 
simulation, which allows full representation of each individual’s history and the interaction 
between individuals. SD models which are modelling on aggregated levels are not of interest in 
this review.    
 
Table 2.5 lists the criteria in the assessment of model quality. There are five types of model 
classification: decision trees, Markov models, individual simulation models, discrete event 
simulation and system dynamics model. The individual sampling model is sub-grouped as based 
on a Markov model state or non-Markov states.   The judgment for an appropriate model is based 
on the following paragraph.    
 
2.6.2.2  The choice of an appropriate model type 
A decision tree model is simple and straightforward to illustrate a decision problem.  Barton 
suggests that if the time frame is short and if the mortality of patients does not differ across 
strategies, a simple decision tree is usually appropriate. Briggs and colleagues recommended that 
Markov models were particularly suited to modelling the progression of chronic diseases.  
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Barton agreed that the main benefit of a Markov model was the easy with which recurrent events 
could be represented.  When a disease is considered to experience recurrent events, such as in the 
case of chronic diseases, a Markov model is appropriate.  
 
Barton and colleagues study provided the choice of an appropriate model.  A simple diagram has 
been reproduced here for illustration of the steps in selecting an appropriate modeling type 
(Figure 2.2). As indicated in diagram (2.1), the selection of the appropriate model type for a 
particular health care intervention should be made on the key initial consideration of whether the 
individuals in the model may be regarded as independent. Where interaction is not thought to be 
an important issue then the choice is between decision trees, Markov models or individual 
sampling models. Where interaction is a significant issue in modelling, methods such as DES 
and SD are required.   
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Figure 2.2 Selecting an appropriate model type 
*Adapted from Barton (2004):  Figure 8 
  
Modelling problems 
Can patient pathways be 
represented adequately 
by probability tree? 
Can a Markov model be 
built without needing an 
excessive number of states? 
Individual sampling model 
System dynamics model 
Is interaction between 
individuals important? 
Is individual-level 
modelling needed? 
Decision tree 
Markov model 
Yes 
No 
Yes 
Yes 
Yes 
Discrete event simulation 
No 
No 
No 
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2.6.2.3 Cohort simulation versus individual patient simulation 
The taxonomy of model structure is classified into two broad categories: cohort models and 
individual level models (Brennan et al., 2006). Cohort models, also referred to as aggregate 
models, are used to examine the proportion of the population experiencing different events. The 
key assumption in cohort models is homogeneity within health states. Therefore the same costs 
and utilities are attached to each event to all patients.  Individual level models are used to sample 
individuals with specific attributes and follow their disease progression individually.  Therefore, 
each individual may have different costs and utilities based on their actual experience of events 
and clinical disease stages.  
 
Brennan and colleagues (2006) reasoned that the cohort model is simple and transparent, but that 
the homogeneity assumption may produce inaccurate and inadequate solutions.  Although cohort 
models can account for different attributes by increasing the number of states, they become 
unmanageable when the number of dimensions rises substantially.  Individual level simulation 
models overcome this problem. They are more flexible in simulating a real world situation.        
  
Barton and colleagues argue that the appropriate use of cohort or individual simulation methods 
should consider the questions of computational feasibility. Individual level simulation models 
such as DES and individual sampling methods usually demand more time to develop and run 
than cohort models. However, when individual histories or attributes need to be considered in a 
model, those based on individual level simulations can provide flexible ways to account for 
patient pathways.   
  
Table 2.5 lists all the items and questions to ask about simulation methods in this review. The 
judgment of cohort or individual level simulation is based on whether a decision tree or Markov 
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model can represent the clinical problem without the excessive number of states, in addition to 
whether individual level attributes or histories are needed to inform the disease progression in the 
model.  If a large number of states are needed or individual level attributes are important, an 
individual sampling model is appropriate.  
 
Table 2.5 Assessment of quality of model structure 
Quality criteria Question for critical appraisal 
Type of models What type of model is used? 
Is the chosen model appropriate for the clinical problem? 
Simulation methods Is it cohort or individual level simulation? 
Is the simulation method appropriate? 
 
2.6.3 Data  
To critique the data component in a model, a short form of the checklist from Philips’ paper was 
used. The rationale to make use of particular items from the checklist in this review was based on 
the judgment on whether they related to models developed alongside a randomised clinical trial. 
 
The Philips checklist was specially developed for NICE assessment, where input data are mostly 
gathered from systematic reviews. The papers reviewed in the current chapter are all economic 
evaluations conducted alongside a single clinical trial. Thus, the Philips check-list refers to a data 
source based on systematic review or meta-analysis, which is omitted from the checklist adopted 
here.  
 
The data component of the Philips checklist is divided into four sections as follows:  
 
Section D1: identification methods;  
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Section D2: pre-model data analysis; 
Section D3: incorporation of data; 
Section D4: assessment of uncertainty. 
 
Section D1 was related to data identification methods and hence not relevant to the assessment in 
this thesis, therefore it was not in the checklist used.   
 
Section D2 concerns methods of data synthesis, analysis of trial data, the incorporation of 
relative risks and the accurate calculation of transition probabilities. While data synthesis 
methods were omitted from the current checklist, the other three items are included in this 
review.   
 
Table 2.6 lists the items in the D2 section. While most of the checklist items were 
straightforward yes or no answer, the final column in the table gives a detailed explanation when 
judgments on appropriate methods are needed. Table 2.7 and 2.8 lists the items in D3 and D4 
section respective. All items in Philips checklist on those sections are included, respectively.  
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Table 2.6 List of items in Section D2 from Philips’ checklist   
Quality 
Criteria 
Data (D) 
Question(s) for critical appraisal Judgment for appropriate when 
applied 
D2: Pre-
model data 
analysis 
Is the pre-model data analysis methodology based on 
justifiable statistical and epidemiological techniques? 
 
D2a: baseline 
data 
Is the choice of baseline data described Yes/No 
Is the choice of the baseline data justified? Baseline probabilities may be based on 
natural history data derived from 
epidemiological/observational studies 
or relate to the control group of an 
experimental study. 
If a half cycle correction has not been 
used on all transitions in a state 
transition model (costs and outcomes), 
this should be justified 
Are transition probabilities calculated appropriately? Rates and interval probabilities should 
be transformed into transition 
probabilities appropriately. If there is  
evidence that time is an important 
factor in the calculation of transition 
probabilities in state transition models, 
this should be incorporated. 
D2b: 
treatment 
effects 
If relative treatment effects have been derived from trial 
data, have they been synthesised using appropriate 
techniques? 
Not relevant, omitted from this review 
Have the methods and assumptions used to extrapolate 
short-term results to final outcomes been documented 
and justified? 
The methods and assumptions that are 
used to extrapolate short-term results to 
final outcomes should be documented 
and justified. This should include 
justification of the choice of survival 
Function.  
Have alternative extrapolation assumptions been 
explored through sensitivity analysis? 
 
Have assumptions regarding the continuing effect 
of treatment once treatment is complete been 
documented and justified?  
 
Assumptions regarding the continuing 
effect of treatment once treatment is 
complete should be documented and 
justified.  
Have alternative assumptions been explored through 
sensitivity analysis? 
Yes/No 
If evidence regarding the long-term 
effect of treatment is lacking, 
alternative assumptions should be 
explored through sensitivity analysis  
*Philips et al 2006, section consistency from table II. Page 364-365 
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Table 2.7  Assessment of data incorporation 
Quality 
Criteria 
(Data: D) 
Question(s) for critical appraisal Judgment for appropriate 
when applied 
D3: Data 
incorporation 
 
Have all data incorporated into the model been described 
and referenced in sufficient detail? 
Yes / No 
All data incorporated into the 
model should be described and 
the sources of all data should 
be given and reported in 
sufficient detail to allow the 
reader to be aware of the type 
of data that have been 
incorporated 
Has the use of mutually inconsistent data been justified (i.e. 
are assumptions and choices appropriate)? 
 Not relevant, omitted from the 
review  
Is the process of data incorporation transparent? Yes / No 
The process of data 
incorporation should be 
Transparent.  It should be clear 
whether data are incorporated 
as a point estimate or as a 
Distribution.  
If data have been incorporated as distributions, has the 
choice of distribution for each parameter been described 
and justified? 
 If data have been incorporated 
as distributions as part of a 
probabilistic analysis, the 
choice of distribution and its 
parameters should be 
described and justified 
If data have been incorporated as distributions, is it clear 
that second order uncertainty is reflected? 
 Yes / No 
If data have been incorporated 
as distributions as part of a 
probabilistic analysis, the 
choice of distribution and its 
parameters should be 
described and justified 
*Philips et al 2006, section consistency from table II. Page 365 
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Table 2.8 Assessment of uncertainty 
Quality 
Criteria 
(Data: D) 
Criteria Question(s) for critical appraisal Judgement for appropriate when 
applied 
Assessment of 
uncertainty 
Have the four principal types of uncertainty been 
addressed? 
Yes / No 
 If not, has the omission of particular forms of 
Uncertainty been justified? 
 
D4a: 
methodological 
Have methodological uncertainties been addressed by 
running alternative versions of the model with different 
methodological assumptions? 
Yes/No 
 Methodological uncertainty relates 
to whether particular analytic steps 
taken in the analysis are the most 
appropriate (for example, discount 
rate used)o 
D4b: structural  Is there evidence that structural uncertainties have been 
addressed via sensitivity analysis? 
Yes/No 
There should be evidence that 
structural uncertainties have been 
evaluated using sensitivity 
analysis 
D4c: 
heterogeneity 
Has heterogeneity been dealt with by running the model 
separately for different sub-groups? 
Yes/No 
It is important to distinguish 
between uncertainty resulting from 
the process of sampling from a 
population and variability due to 
heterogeneity (that is, systematic 
differences between patient sub-
groups) 
D4d: parameter Are the methods of assessment of parameter 
uncertainty appropriate? 
Probabilistic analysis is the most 
appropriate method of handling 
parameter uncertainty because it 
facilitates assessment of the joint 
effect of uncertainty over all 
parameters  
 Are the methods of assessment of parameter uncertainty 
appropriate? 
Where data have been incorporated 
into the model as point estimates, 
the ranges used for sensitivity 
analysis should be stated and 
justified.  Probabilistic analysis is 
the most appropriate method of 
handling parameter uncertainty 
because it facilitates assessment of 
the joint effect of uncertainty over 
all parameters  
 If data are incorporated as point estimates, are the ranges 
used for sensitivity analysis stated clearly and justified? 
 
*Philips et al 2006, section consistency from table II. Page 365 
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2.6.4  Consistency  
The consistency theme focuses on two categories:  internal consistency (C1) and external 
consistency (C2).  Table 2.9 lists the questions to ask in assessment of the review.  Again, the 
last column explained in detail when judgment for appropriateness is applied.  
 
Table 2.9 Assessment of consistency 
Quality 
Criteria 
Consistency (C) 
Question(s) for critical appraisal Judgement for 
appropriateness when applied 
C1: Internal 
consistency 
Is there evidence that the mathematical logic of the 
model has been tested thoroughly before use? 
Yes/No 
There should be  evidence that 
the internal consistency of the 
model in terms of its 
mathematical logic has been 
evaluated 
C2: External 
consistency 
Are the conclusions valid given the data presented? Yes/No 
The results of a model should 
be explicable.  
Are any counter intuitive results from the model 
explained? 
Yes/No  
Results should either make 
intuitive sense or 
counterintuitive results should 
be fully explained 
Are any counter intuitive results from the model 
justified? 
All relevant data available 
should be incorporated 
into a model.  
Data should not be withheld for 
purposes of assessing external 
consistency 
If the model has been calibrated against independent 
data, have any differences been explained? 
Yes/No 
 
If the model has been calibrated against independent 
data, have any differences been justified? 
Yes / No 
Have the results of the model been compared with those 
of previous models and any differences in results 
explained? 
Yes/No 
The results of a model should 
be compared with those of 
previous models and any 
differences should be explained. 
*Philips et al 2006, section consistency from table II. Page 366 
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2.6.5 Critique the modelling papers 
 
Structure 
As shown in Table 2.10 and 2.11, five of the studies used Markov modelling approaches but 
different terms were used. Briggs used the name "state transition Markov model", Yao used 
"Individual simulation using Markov modelling framework" while Feldman simply stated that a 
model was used without giving a clear statement of the model type.  The rest just said "Markov 
model". Caro used the term "discrete event simulation model". In fact it was an individual 
sampling model based on the Barton classification. From the recommendation, all of these 
studies can be classified as individual sampling methods but none had adopted the term.  
 
Two of the studies were based on cohort simulation and the rest of papers were based on 
individual level simulations.  None of the papers reported computer running times, and only 
three of the five studies conducted PSA to explore the second order uncertainty.  
 
Data 
For pre-data analysis, all studies populated their model based on the corresponding clinical trial. 
Six of those studies were based on Kaplan Meier analysis for observed survival data and Cox 
models were used to estimate treatment effects.  Briggs presented regression analysis results to 
estimate the risk profile on different events and adjusted patient baseline characteristics. Rinfret 
reported using a Kaplan Meier survival function and bootstrapping in analysing cost and utility 
data.  
 
Referring to the estimated baseline function for extrapolating beyond the trial period, only two 
papers reported that selecting candidate function were based on the best fitting curves. Yao used 
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AIC to check the best fitting model; Scuffham (2005) graphically checked the fitting without a 
formal test.  
 
All studies assumed constant hazard ratios applied to the intervention effect over trial periods, 
but Briggs explored the assumption using reduced hazard by sensitivity analysis.  
 
None of these studies explored the full uncertainty of the four principal types of uncertainty as 
suggested by Philips and colleagues. One way sensitivity analyses were conducted in all the 
studies. Four of those studies explored second order uncertainty through probabilistic sensitivity 
analysis. 
 
Consistency 
For model consistency, none of those studies was calibrated against an independent data source.  
Instead, three of the studies investigated the model consistency by validating the result from the 
model against the trial observed events. Yao presented the validation by model estimate survival 
compared with trial observed survival which was estimated by Kaplan Meier methods from the 
CARE-HF trial. Rinfret (2005) validated their model by estimating the rate from the model to 
trial observed event.  
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Table 2.10 Assessment of quality of model structure 
Quality 
Criteria 
(Structure) 
Question for critical 
appraisal 
Briggs 2007 Caro  2006 Rinfret 2005 Yao  2007 
 
Type of 
models 
What type of model is used? 
(based on Barton definition) 
Individual sampling methods Individual sampling methods A Markov model Individual sampling methods 
What type of model is used? 
(as stated by author) 
A Markov state transition 
model 
Discrete event simulation A Markov model Markov modelling framework 
based on individual simulation 
Is the chosen model 
appropriate for the clinical 
problem? 
Yes , it reflected the natural 
history of the disease with 
recurrent events 
Yes, it provided a flexibility 
to allow  the risk of events to 
depend on individual patient 
history 
Yes, it reflected the 
recurrent events 
Yes. It is suitable to natural  
history of the disease which is 
recurrent and chronicle 
Simulation 
methods 
Is it cohort or individual 
level simulation? 
Individual  level simulation Individual level simulation Individual  level 
simulation 
Individual level simulation 
Is the simulation method 
appropriate? 
Yes.  Individual clinical and 
characteristics are important 
on risk of different events 
Yes. It simulated trial 
population. 
Individual risk profiles 
are important" 
Yes, it mirrored the trial and 
individual disease history is 
important 
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Table 2.10 Assessment of quality of model structure (continued) 
Quality 
Criteria 
(Data2) 
Question for critical appraisal Briggs 2007 Caro  2006 Rinfret 2005 Yao  2007 
D2 Is the pre-model data analysis methodology 
based on justifiable statistical and 
epidemiological techniques? 
Yes, reported details of 
modelling information 
No Yes, used Kaplan-Meier and  
bootstrapping methods  
Based on AIC to 
select best fit 
distributions   
D2a Is the choice of baseline data described Yes Reported Not clear Yes 
 
Is the choice of the baseline data justified? Based on risk equations 
derived from EUROPA data 
Based on the risk of 
events 
Based on bootstrapping 
methods 
Based on the curve 
best fitted to the trial 
data   
 
 
Are transition probabilities calculated 
appropriately? 
Yes, based on risk equation Not applicable Details not given Yes, estimated from 
the trial 
D2b If relative treatment effects have been derived 
from trial data, have they been synthesised 
using appropriate techniques? 
Not applicable. 
Based on a single trial 
Not conducted Not applicable.  
Based on single trial 
Not applicable.  
Based on single trial 
 
Have the methods and assumptions used to 
extrapolate short-term results to final 
outcomes been documented and justified? 
Yes. It mirrors the trial risk 
profile 
Yes, based on 
individual simulation 
and adjusted risk 
events 
Survival function fitted and 
used to extrapolate beyond 
the trial 
Probability function 
best fitted to the trial 
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Table 2.10  Assessment of quality of model structure (continued) 
Quality 
Criteria 
(Data 3) 
Question for critical appraisal Briggs 2007 Caro  2006 Rinfret 2005 Yao  2007 
D3 Have all data incorporated into the model been described 
and referenced in sufficient detail? 
Yes, details reported 
in  tables 
Yes, details reported 
in a diagram and table 
Yes, details reported in 
tables 
Yes, details reported 
in tables 
 
Has the use of mutually inconsistent data been justified 
(i.e. are assumptions and choices appropriate)? 
Not applicable Not discussed 
 
Not applicable Not applicable 
 
 
Is the process of data incorporation transparent? Reasonable and 
supported by a 
separate reference 
Yes Reasonable Yes 
 
If data have been incorporated as distributions, has the 
choice of distribution for each parameter been described 
and justified? 
Runs PSA and choice 
of distributions 
reported separately 
Details not given Not discussed Reasons for choice 
not given, but 
reported in tables 
 
If data have been incorporated as distributions, is it clear 
that second order uncertainty is reflected? 
Yes, second order 
uncertainty was 
addressed by PSA 
Second order was not 
addressed 
Not discussed Yes, second order 
uncertainty was 
addressed by PSA 
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Table 2.10 Assessment of quality of model structure (continued) 
Quality 
Criteria 
(Data4) 
Criteria Question(s) for critical appraisal Briggs 2007 Caro  2006 Rinfret 2005 Yao  2007 
D4 Have the four principal types of uncertainty been addressed? Yes Not fully No, only one way sensitivity 
analysis 
Yes 
 
If not, has the omission of particular forms of 
Uncertainty been justified? 
Not applicable Second order 
uncertainty 
should 
conducted 
Second order uncertainty 
should conducted 
Not applicable 
 
Have methodological uncertainties been addressed by 
running alternative versions of the model with different 
methodological assumptions? 
No No No 
 
No 
 
Is there evidence that structural uncertainties have been 
addressed via sensitivity analysis? 
Yes Yes Yes Yes 
 
Has heterogeneity been dealt with by running the model 
separately for different sub-groups? 
Yes No No Yes 
 
Are the methods of assessment of parameter uncertainty 
appropriate? 
Yes No, second 
order 
uncertainty not 
investigated 
One way sensitivity analysis 
performed 
Yes 
 
If data are incorporated as point estimates, are the ranges 
used for sensitivity analysis stated clearly and justified? 
Not applicable Yes Yes Not applicable 
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Table 2.10 Assessment of quality of model structure (continued) 
Quality 
Criteria 
(Consistency) 
Question for critical appraisal (Briggs  2007) (Caro 2005) (Rinfret 2005) (Yao 2007) 
C1 Is there evidence that the mathematical logic of 
the model has been tested thoroughly before use? 
Yes No Yes Yes 
C2 Are the conclusions valid given the data 
presented? 
Yes/No Yes Yes 
 
Yes 
Are any counter intuitive results from the model 
explained? 
No No 
 
No 
 
No 
Are any counter intuitive results from the model 
justified? 
Not applicable Not applicable Not applicable Not applicable 
If the model has been calibrated against 
independent data, have any differences been 
explained? 
Not applicable Not applicable Only used internal 
validation, validate from the 
trial 
Interval validation and 
external validation 
If the model has been calibrated against 
independent data, have any differences been 
justified? 
Yes Not done Not done Yes and explained 
Have the results of the model been compared with 
those of previous models and any differences in 
results explained? 
Yes Yes Yes Yes 
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Table 2. 11 Assessment of quality of model structure 
Quality 
Criteria 
(Structure) 
Question for critical appraisal Feldman 2005 Scuffham & Chaplin 2005 Scuffman & Kosa2006 
 
Type of models 
What type of model is used? 
(based on Barton definition) 
Markov model Markov model Markov model 
 
What type of model is used? 
(based on author stated) 
Not clear Markov model Markov model 
 
Is the chosen model appropriate 
for the clinical problem? 
Yes,  based on the events rate 
over time 
Yes,  the events are recurrent  
over a longer time period 
Yes the events are recurrent  over 
a longer time period 
Simulation methods Is it cohort or individual level 
simulation? 
Cohort simulation Cohort simulation Cohort simulation 
 
Is the simulation method 
appropriate? 
 
It only reflected second order 
uncertainty. But between 
individual variation can  be 
substantial 
Only second order uncertainty 
reflected 
Only second order uncertainty 
reflected 
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Table 2.11  Assessment of quality of model structure (continued) 
Quality 
Criteria 
(Data2) 
Question for critical appraisal Feldman 2005 Scuffham & Chaplin 2005 Scuffman & Kosa2006 
D2 Is the pre-model data analysis methodology based 
on justifiable statistical and epidemiological 
techniques? 
Details not givens Details not given Not given in details 
D2a Is the choice of baseline data described Exponential fitted to survival 
data from the trial 
Yes  Not given 
 
Is the choice of the baseline data justified? Can not judge as authors did not 
provide the rational for the 
choice 
Yes Not available 
 
Are transition probabilities calculated 
appropriately? 
Yes. Based on exponential 
survival function 
Yes Yes, rate translated to 
propabilities 
D2b If relative treatment effects have been derived from 
trial data, have they been synthesised using 
appropriate techniques? 
Not applicable Not applicable Not applicable 
 
Have the methods and assumptions used to 
extrapolate short-term results to final outcomes 
been documented and justified? 
Yes. Based on exponential 
survival function and rate of 
events were applied to it 
Yes Yes 
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Table 2.11  Assessment of quality of model structure (continued) 
Quality 
Criteria 
(Data 3) 
Question for critical appraisal Feldman 2005  Scuffham & Chaplin 
2005 
Scuffman & Kosa2006 
D3 Have all data incorporated into the model been described 
and referenced in sufficient detail? 
Yes, reported details in 
tables 
 
Yes, reported in table Yes reported in table 
 
Has the use of mutually inconsistent data been justified 
(i.e. are assumptions and choices appropriate)? 
Not mentioned Not applicable Not applicable 
 
Is the process of data incorporation transparent? Yes 
 
Yes Yes 
 
If data have been incorporated as distributions, has the 
choice of distribution for each parameter been described 
and justified? 
Yes 
 
Yes Not applicable, 
determinate analysis 
 
If data have been incorporated as distributions, is it clear 
that second order uncertainty is reflected? 
Yes,  PSA preformed Not Not 
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Table 2.11 Assessment of quality of model structure (continued) 
Quality 
Criteria 
(Data4) 
Criteria Question(s) for critical appraisal Feldman 2005  Scuffham & 
Chaplin 2005 
Scuffman & 
Kosa2006 
D4 Have the four principal types of uncertainty been addressed? Only addressed the 
parameters uncertainty 
Some of those 
detailed as below 
Some of those as 
detailed below 
 
If not, has the omission of particular forms of 
Uncertainty been justified? 
  PSA should conducted 
 
Have methodological uncertainties been addressed by running 
alternative versions of the model with different methodological 
assumptions? 
Not  Not  No 
 
Is there evidence that structural uncertainties have been addressed 
via sensitivity analysis? 
Yes, sensitivity conducted 
on the length of the benefit 
over two years 
Yes sensitivity 
analysis on 
discount rate  
Yes 
 
Has heterogeneity been dealt with by running the model separately 
for different sub-groups? 
Not performed  Yes Yes 
 
Are the methods of assessment of parameter uncertainty 
appropriate? 
Yes  Yes No 
 
If data are incorporated as point estimates, are the ranges used for 
sensitivity analysis stated clearly and justified? 
Not addressed  Yes Yes 
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Table 2.11  Assessment of quality of model structure (continued) 
Quality 
Criteria 
(Consistency) 
Question for critical appraisal Feldman 2005  Scuffham & Chaplin 2005 Scuffman & Kosa2006 
C1 Is there evidence that the mathematical logic of the 
model has been tested thoroughly before use? 
Not done Yes Yes 
C2 Are the conclusions valid given the data presented? Yes Yes Yes 
Are any counter intuitive results from the model 
explained? 
Not stated Not stated Yes 
Are any counter intuitive results from the model 
justified? 
Cannot judge as it did 
not provide 
Cannot judge as it did not 
provide 
Yes 
If the model has been calibrated against 
independent data, have any differences been 
explained? 
Not 
 
Not No 
If the model has been calibrated against 
independent data, have any differences been 
justified? 
N/A 
 
N/A No 
Have the results of the model been compared with 
those of previous models and any differences in 
results explained? 
Yes 
 
Yes No 
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2.7 Discussion 
 
 The aim of this chapter was to review recent studies in which economic evaluation was 
conducted in cardiovascular disease.  It focused on studies where economic evaluations had been 
conducted alongside clinical trials and modelling based studies in which model inputs were 
populated by individual data from a trial.  Only full economic evaluations were included in the 
review.    
 
The results were presented in separated categories, including an overview of the included 
studies: summarised economic evaluation methods used, statistical analytic methods used within 
a trial analysis and model based approaches when extrapolating beyond a trial.  The results show 
that most of the studies in the review covered the clinical areas of chronic heart failure, atrial 
fibrillation, myocardial infarction and coronary heart disease.  When most of the clinical studies 
were based on multinational trials, economic evaluation was usually conducted in one country 
setting.  Only one study used country specific cost.  
 
The most commonly used outcome measures in the studies were life years; only half of the 
studies employed QALYs.  Reviewing statistical methods in economic evaluation within trials 
has demonstrated that most of the studies have addressed the uncertainty around point 
estimations by using bootstrapping.  However, many studies lacked details on how costs data 
were collected and how aggregated costs were estimated.  
  
Nearly one quarter of the included studies have employed model based analysis to investigate 
long term economic implications beyond a trial.  Using a Markov model was the most common 
approach in the majority of studies.  However, there was a lack of consistency in defining the 
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type of models, simulation methods and pre-data analysis.  From the studies selected, it remains 
generally unclear how a model was developed, or how assumptions beyond a trial and 
assumptions on baseline survival beyond a trial were addressed. 
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CHAPTER 3 SECONDARY PREVENTION CLINICS  
 
3.1 Introduction 
 
The last chapter reviewed methods in economic evaluation conducted alongside a clinical trial 
and model-based studies, where the input data were populated from a trial data in the area of 
heart disease. In this chapter an empirical study of an economic evaluation conducted alongside 
the secondary prevention clinical trial in coronary heart disease (Raftery et al., 2005) is 
presented, with the aim of illustrating common methods which may be used to conduct an 
economic evaluation alongside a clinical trial.  This includes how cost and utility values were 
collected, how cumulated cost and QALYs over the trial period were calculated and how the 
cost-effectiveness of the interventions compared were estimated and presented.  This chapter was 
based on a published paper in the British Medical Journal (Raftery et al., 2005) and was further 
developed specifically for the thesis using a different analytic approach.  In the published paper, 
only t-tests are presented in the analysis cost and quality of life data, whereas in the thesis, 
bootstrapping methods were used for all analyses. 
 
3.2 Clinical background 
 
People with mild coronary heart disease are at particularly high risk of coronary events and 
death. Implementation of secondary coronary prevention in primary care can reduce this risk and 
this is widely advocated (Scottish Intercollegiate Guideline Network, 2000).  Effective secondary 
prevention, such as medical interventions and lifestyle measures, eg. smoking cessation, regular 
exercise, and healthy diets, can reduce the risk of coronary events and death in patients with 
coronary disease (Murchie et al., 2003).  Most people with coronary disease are cared for in 
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primary care, and general practitioners have been encouraged to target them for secondary 
prevention.  In the United Kingdom, general practitioners are rewarded financially for achieving 
target standards (BMA NHS Confederation, 2004).  Several mechanisms to improve secondary 
prevention have been evaluated, of which the most successful to date have been nurse-led 
secondary prevention clinics (McAlister  et al., 2001; Moher et al., 2001; Murchie et al., 2003). 
Several randomised trials demonstrated that nurse-led secondary prevention clinics for CHD can 
improve the uptake of secondary prevention in primary care (Campbell et al., 1998; Moher et al., 
2001; Khunti et al., 2007). 
 
3.3 Overview of the nurse-led secondary prevention clinics trial 
 
Full details of the trial design have been reported previously (Campbell et al.,1998).  In brief, a 
randomised controlled trial of nurse-led clinics for the secondary prevention of coronary heart 
disease was conducted in north-east Scotland between 1994 and 1995.  The trial was undertaken 
in a 19 randomly selected general practices.  Participants were a random sample of patients with 
coronary heart disease but without terminal illness or dementia and not housebound.  
 
The nurse-led clinics in primary care were designed to promote medical and lifestyle aspects of 
secondary prevention and provide regular follow up.  Patients in the intervention group were 
invited to attend nurse-led secondary prevention clinics at their general practice. For each visit, 
their symptoms and treatment were reviewed, including blood pressure and lipid management, 
the use of aspirin promoted and lifestyle factors reviewed and assessed.  In addition, their 
behaviour changes were advised.  In the control group, patients received the usual care from their 
general practitioners (GPs).  
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The principal aim of the trial was to evaluate at four years the effects of nurse-led secondary 
prevention clinics for coronary heart disease on the use and uptake of components of secondary 
prevention and to assess their impact on health and mortality.  A secondary aim was to estimate 
the cost-effectiveness of the interventions compared to usual care.      
 
The trial recruited a total of 1343 patients, of which 673 patients were randomised into the 
intervention group and 670 into the control group.  All patients recruited to the study were less 
than 80 years old.  Mean follow up was for 4.7 years.  Intervention and control groups were well 
matched for age, sex and practice characteristics at baseline. 
 
The clinical study reported that all components except smoking, were significantly different at 
one year (Murchie et al., 2003), but by four years the performance of the control group had 
improved and the differences were no longer significant. A longer period of clinic attendance 
was associated with better uptake of secondary prevention.  At four years the intervention group 
had fewer role limitations attributable to physical problems.  There were fewer coronary events 
in the intervention group with 100 out of 673 (14.9%) compared with 125 out of 670 (18.7%) in 
the control group (p= 0.062), demonstrating that there had been significantly fewer deaths in the 
intervention group with 100 (14.9%) compared with 128 (19.1%) in the control group (p=0.038). 
  
Running clinics, however, uses resources in primary care, especially nurses’ time, and the clinics 
incur further costs from increased prescribing.  The cost-effectiveness of the intervention is 
uncertain. In the next sections, a detailed cost and cost-effectiveness analysis is presented with 
the aim of determining whether the intervention was good value for money.   
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3.4 Methods  
3.4.1 Costing 
The economic evaluation was undertaken from a societal perspective, including both public and 
private health service costs.  As most participants were older than working age, the effects 
related to production costs were excluded. 
 
Resource use information was extracted from general practice case notes at baseline, one year 
and four years.  For each patient data were collected on use of cardiovascular drugs, blood 
pressure and lipid management, number of attendances at secondary prevention clinics, 
hospitalisation for cardiovascular events, eg. myocardial infarction, and procedures such as 
coronary artery bypass grafting and coronary angioplasty and use of private health care.  Data on 
deaths, hospital admissions and outpatient attendances were obtained from the Scottish 
Morbidity Records, linked anonymously. 
 
The cost of admissions to NHS hospitals was calculated by assigning the appropriate unit cost 
per case based on specialty in hospital.  Outpatient costs were based on the number of 
attendances multiplied by the relevant hospital unit cost.  Costing admissions to private hospitals 
was done using NHS unit cost by specialty. 
 
Costs to primary care of running the CHD clinics during the four years of the study were 
calculated.  The yearly and total attendances at clinics were calculated for each group.  It was 
assumed that each attendance lasted one hour.  The costs of clinic materials and training were 
included at year one.  At years two, three and four it was assumed that the only cost incurred in 
running the clinics was nurse time and this was estimated at £20.00 per hour, based on Unit costs 
of health and social care (Netten & Curtis,  2000).  The total cost and annual costs of 
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cardiovascular drug prescriptions were calculated based upon the Scottish Drugs Tariff (Scottish 
Drug Tariff, 1998).   
 
The costs of the secondary prevention clinic interventions were based on the best estimate of 
whether patients attended that year or not (earlier).  Based on an audit of nurse time in year one 
and interviews with the practices about the subsequent years, a number of assumptions were 
made.  Firstly, not all patients attended their clinics for a baseline assessment.  Secondly, patients 
who attended their clinics for the first year did so twice and patients who attended in any of the 
subsequent years did so only once. These assumptions were applied to both intervention and 
control groups.  The nurse-led clinics were only accessible to the control group after the second 
year.   
  
Nearly all medication usage data was collected for all patients who were followed up to the end 
of the study.  Data on all patients admitted to NHS hospitals were collected during those periods.  
Missing outpatient data were imputed on the basis of the average ratio of outpatient attendances 
per admission for cardiovascular diseases for surviving patients.  
 
3.4.2 Utility scores 
Health-related quality of life data were obtained by postal questionnaire using the SF-36 form at 
baseline, year 1 and year 4.  SF-36 scores were used to calculate SF-6D utility scores for each 
patient in those three years, based on a previously published algorithm (Brazier et al., 1998).  A 
utility score of zero was assigned at the time of a patient’s death and for patients who were lost 
to follow-up. 
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Utility scores of SF-6D were derived from the SF-36 at three time points: baseline, year 1 and 
year 4.  Missing values of the SF-6D scores at baseline, year 1 and year 4 were imputed by group 
mean imputation adjusted for age and gender and treatment groups.  
 
For values for cost and utility scores in years 2 and 3, which were not collected during the study, 
a linear interpolation based on the closest two point values were used. If a patient died or was 
lost to follow-up during these periods, the last value to either the time of death or lost to follow-
up (Billingham et al., 1999) was used.   
 
3.4.3 Estimating cost 
The total cost for each patient was derived by summing the itemised cost at each year and 
discounting at 3.5% annually.  The total cost per patient was calculated using the following 
formula: 
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Where i denoted patients, j denoted treatment group and r the annual discounting rate. 
    
3.4.4 Estimating life years and QALYs 
Effectiveness was defined in terms of life years and QALYs gained associated with intervention 
during the trial. 
 
Life years were estimated for each patient within the trial, defined by the survival length from 
randomisation to death.  Each year was discounted at 3.5% annually for years beyond the first 
year.   
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The total QALYs for each patient were derived by weighting survival time by the corresponding 
utility score from the SF-6D data.  QALYs were also discounted at 3.5% annually for years 
beyond the first year.   
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3.4.5 Analytic methods 
Analyses were conducted according to the intention-to-treat principle. Kaplan-Meier methods 
were employed to estimate the survival and the log rank test was used for testing the difference 
in overall mortality.  Bootstrap methods were employed for estimating difference in mean cost, 
life years and QALYs between treatment groups (Barber & Thompson, 2000).  The incremental 
cost per life-year gained and incremental cost per QALY was estimated for each replicate.  A 
bootstrap method based on 1000 replicates was used to estimate 95% confidence intervals (CI) 
for the incremental cost-effectiveness ratios and to produce cost effectiveness acceptability 
curves at different willingness-to-pay values.  All analyses were conducted using SAS software 
(version 9.12, SAS Institute). 
 
3.5 Results 
Table 3.1 reported the analysis results. In the following section, each of those results is presented 
separately.  
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3.5.1 Survival and QALYs  
Survival status was known for all patients at the end of study. There were 28 fewer deaths in the 
intervention group: 100 out of 673 (cumulative death rate 14.5%) compared with 128 out of 670 
(19.1%) in the control group (P = 0.038).  When a 3.5% discount rate was applied, the mean life 
years’ score was 4.35 (95% CI 4.29 to 4.41) for the control group compared with 4.39 (95% CI 
4.32 to 4.45) years for the intervention group. The QALYs were 3.01 (95% CI 2.94 to 3.07) in 
the control group compared with 3.11 (3.04 to 3.18) in the intervention group. 
 
Table 3.1 Cost-effectiveness result by intervention and control   
 
Control 
(N=670) 
Intervention 
(N=673) 
Difference 
Deaths 128 100 
28 
(P = 0.038) 
Mean of life Years 
(95% CI) 
4.35 
(4.29 - 4.41) 
4.39 
(4.32 - 4.45) 
0.04 
(-0.05 to 0.13) 
Mean of QALYs 
(95% CI) 
3.01 
(2.94 - 3.07) 
3.11 
(3.04 - 3.18) 
0.11 
(0.02 to 0.20) 
Total costs (£) 
(95% CI) 
879 
(824 - 934) 
1,015 
( 956 to 1,074) 
136 
(58 to 214) 
Incremental  Cost (£) per QALY 
(95% CI) 
 
 
 
1,261 
(913 to 23,516). 
 
3.5.2 Costs to primary care and overall costs to society 
Hospital admissions were lower in the intervention group, but part of this difference was 
accounted for by admissions for non-cardiovascular diseases.  For this reason we considered 
alternative estimates of overall costs to society, one including all types of admissions, the other 
confined to cardiovascular admissions.  Although both estimates were lower in the intervention 
group, neither difference was statistically significant.  When the costs to primary care of the 
intervention itself were combined with hospital costs, the higher cost to primary care was offset 
by the lower hospital costs in the intervention group, such that the differences between 
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intervention and control groups were insignificant.  Therefore, costs related to primary care and 
cardiovascular hospitalisation are discussed. 
 
As shown in table 3.1, the mean cost per patient for the control group within the trial periods was 
£879 (95% CI 824 to 934) compared with £1015 (95% CI 956 to 1074) per patient in the 
intervention group, £136 (95% CI 58 to 214) higher in the intervention group. The only 
difference in cost to primary care was the direct cost of the intervention. 
 
3.5.3 Incremental cost effectiveness  
Within the trial period, the incremental life years gained estimate was 0.04 (95% CI -0.05 to 
0.13) and 0.11 (95% CI 0.02 to 0.20) QALYs gained for intervention group compared with 
control group.  Costs were £136 (95% CI 58 to 214) higher in the intervention group, resulting in 
an incremental cost per QALY gained of £1261 (95 % 913 to 23516).  Figure 3.1 shows a scatter 
plot of incremental costs vs. incremental QALYs based on 1,000 bootstrapped replicates with 
90% confidence ellipis.  Figure 3.2 presents the cost effectiveness acceptability curve showing 
the probability of the intervention being cost-effective compared with control group even at the 
value of willingness to pay at £2,000. This is well below the accepted £20,000 threshold.    
 
 
Figure 3.1 Scatter plot with 90% confidence ellipse
 
 
Figure 3.2 Cost-effectiveness acceptability curve 
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3.6 Discussion     
In this chapter, a case study of an economic evaluation conducted within a trial was presented. 
Cost-effectiveness in this study was calculated on the basis that the trial already had a relatively 
long follow up period. The initial set-up costs were lower and the effectiveness of the 
intervention was observed within the trial periods. The initial setting up cost for running nurse-
led clinics had been generally balanced within the trial periods.    
 
This study was the first to examine the cost-effectiveness of secondary prevention clinics in 
primary care.  The findings were more consistent with current recommendations and practice on 
secondary prevention and provide a plausible explanation for the observed reduction in 
mortality. The cost- effectiveness result by the end of the trial period presented was favourable 
for nurse-led clinics.  Such clinics should be recommended in a general health care setting. 
 
Nurse-led clinics for the secondary prevention of coronary heart disease in primary care are 
relatively cost-effective compared with the threshold of £20,000 attributed to NICE (Rawlins & 
Culyer, 2004).  The intervention group gained a mean of 0.04 life years and 0.11 QALYs 
compared with the control group.  The incremental cost per QALY gained was £1261.  The 
clinical study demonstrated that improvements in processes of care and prescribing translated 
into reductions in total mortality.  The present study shows that the cost per QALY gained is less 
than £20,000.  The key difference in costs between nurse-led clinics compared with usual care 
was the increased £136 cost of the intervention to primary care, owing to attendances at the 
clinics and increased prescribing. 
 
The estimates of cost-effectiveness remain valid, however, as the benefits found will also have 
been reduced by allowing control group cross-over, allowing patients to attend the nurse-led 
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clinic after the first year. The increase in both benefits and cost in practice depends on the pre-
existing use of cardiovascular drugs, particularly statins, in the control group.  Some of the data 
were incomplete, particularly attendances at hospital outpatients, but these had relatively little 
effect on overall cost to society.  Data on high cost activities and important outcomes, such as 
mortality, were almost complete.  Where assumptions were made, the cost of the intervention 
tended to be overestimated.    
 
The study was based on a random sample of general practices and patients with good recruitment 
rates.  Therefore, the sample should be representative of general practice at that time, although 
the changes may have occurred in practice since the study began in 1995.  The uptake reported 
for some secondary preventive drugs, especially statins, was lower than is likely to be in the 
current climate of national standards and incentives for general practitioners.  Nevertheless, it 
was found that the clinics improved uptake of secondary prevention by similar absolute amounts 
whatever the baseline levels, even for high uptake of activities at baseline such as blood pressure 
management and in practices with higher baseline levels of secondary prevention. Newly 
recommended interventions, such as smoking cessation clinics, may improve secondary 
prevention further but are unlikely to alter greatly the cost-effectiveness as these changes are 
likely themselves to be highly cost-effective. 
 
Methodologically, bootstrap methods were used to estimate cost differences, QALY differences 
and cost-effectiveness ratios and produced confidence intervals around those estimates.  The 
bootstrap method is a convenient way of producing cost-effectiveness acceptability curves, 
which show the probability of the intervention being cost-effective at different willingness-to-
pay values.   
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The limitations of our study were, firstly, that just over half the control group attended at least 
one secondary prevention clinic after the initial study year.  Rather than compare secondary 
prevention clinics with usual care, the costs and benefits of having more patients attend 
secondary prevention clinics for longer were evaluated.  The total costs of running clinics to 
primary care will be higher than the cost difference between control and intervention groups in 
this study, as an intention to treat analysis, despite many patients in the control arm receiving the 
intervention in the period after the trial.  
 
The limitation due to the way in which missing values were dealt with is accepted. Multiple 
imputations have been suggested as a method for replacing missing values, which may produce 
more accurate estimates of uncertainty around the replaced values (Burton et al., 2007).  
However, a bootstrap method was used for the analysis, and its taking account of repeated 
sampling around each imputed data set would introduce further uncertainty.  In this chapter, 
standard methods in conducting a within trial analysis was focused on. 
 
In addition, the limitation on the analytic approaches is notable. The data has hierarchical 
structure with patients nested with practices. Ideally more advanced analytic approaches should 
be sought, i.e. multilevel modelling approaches (Manca et al., 2005). However, this part of the 
analysis aimed to present the most conventional methods using in economic evaluation 
conducted within a trial period. The influence on the potential inference may be theoretically 
acceptable.  
 
Other studies have evaluated the cost-effectiveness of primary prevention clinics in primary care 
(Wonderling et al., 1996; Langham et al., 1996; Turner et al., 2008). In Wonderling’s and 
Langham’s and colleagues’ studies, benefits were measured in terms of risk factors and data on 
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costs and savings to the health service were incomplete. Turner and colleagues conducted an 
economic evaluation of a nurse-led disease management programme compared with standard 
care alongside a cluster randomised control trial.  The study was implemented in 20 primary care 
practices in the United Kingdom and recruited total 1163 patients with coronary heart disease 
and chronic heart failure, and had a one-year follow up period.  They demonstrated that the 
nurse-led disease management programme was associated with an increase in the QALYs 
measured of 0.03 per year and an increase in the total NHS costs of £425. The clinics generated 
additional QALY at an incremental cost of £13,158 per QALY compared to the control group 
after one year.  Although their study had a relatively short follow up period, the results are 
supportive of the current study and proved that nurse-led clinics were good value for health care 
resources.   
 
Despite the limitations of other studies, some comparisons can be made with the current study.  
For example, the running costs for clinics per patient are reasonably consistent across the trials.  
Running costs for a practice population would, however, be much higher for primary prevention 
clinics because the target population would be much larger. The estimated cost-effectiveness is 
much better for secondary prevention (£1236 per life year gained) than for primary prevention 
(around £20,000 per life year gained).   
 
Compared with the wider range of health interventions, the cost-effectiveness of secondary 
prevention clinics remains favourable (Raftery, 2001).  The incremental cost per QALY is well 
under £20,000, due to the relatively small increase in cost per patient of £136, in turn due to 
modest increases in drug use, even the relatively costly statins.  This pattern, however, is 
consistent with other complex health service interventions, where incremental improvements in 
process outcomes are more likely to be achieved than wholesale changes.  Nonetheless, these 
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relatively low increases in cost were linked to health gains that were considerable in terms of 
deaths, life years and QALYs. 
 
3.7 Conclusions  
 
This chapter presented a case study for an economic evaluation conducted within a trial period. 
Cost-effectiveness analysis concluded that the intervention was highly cost-effective.  Longer-
term cost-effectiveness implications beyond the trial period were not explored.  In the next 
chapter methods of economic evaluation by extrapolating beyond a trial period will be presented.  
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CHAPTER 4 EXTRAPOLATION USING PARAMETRIC SURVIVAL 
FUNCTIONS 
 
4.1  Introduction  
 
In the last chapter, a case study of an economic evaluation conducted alongside a clinical trial 
was presented. Cost-effectiveness analysis concluded that the intervention was highly cost-
effective. Longer term cost-effectiveness implications beyond the stated trial period were not 
explored. Cost-effectiveness was estimated on the basis that the trial already had a relatively long 
follow-up period. The initial set-up costs were lower and the effectiveness of the intervention 
was observed within the trial periods.  
 
However, it is not uncommon to see the situation in which significant cost occurred at the 
beginning of an intervention, although the benefit of the intervention is still accumulated long 
beyond the end of the trial period (Buxton et al., 1997; Hlatky et al., 2002). It is ethically not 
possible to continue a trial beyond the point at which effectiveness has been established, even 
though the full economic benefit is still not seen fully. The economic evaluations concluded by 
the end of the trials in those situations more likely underestimate the cost-effectiveness of the 
interventions. Therefore, alternative approaches are needed to extrapolate cost and effectiveness 
beyond the trial periods.  Survival analysis is often a key approach in projecting outcomes in 
terms of life year or quality adjusted life year in cost-effectiveness analyses.  
 
Many survival analyses in the current medical literature use non-parametric methods. The 
Kaplan-Meier method is a simple approach in estimating survival probability for an observed 
follow-up only (Collett, 1994). Cox proportional hazards models are often employed to estimate 
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the relative risk of different interventions. Both of these methods are non-parametric, in which 
either survival distributions or hazard functions need to be specified.  In order to project survival 
time beyond an observed time period, parametric survival functions are frequently used in 
economic evaluation (Neymark et al., 2002). Whilst exponential and Weibull distributions are 
frequently used for this purpose, consideration of its appropriateness, given an observed data, has 
received little attention in the health economics literature.  Little work has been done on how 
best to fit a parametric survival function based on observed data and how to evaluate the 
appropriateness of a chosen distribution. 
 
In this chapter, five commonly used parametric survival functions are reviewed, stressing the 
characteristics of their hazard functions, and methods of choosing a best fit parametric survival 
function based on observed trial data are described. These approaches have been illustrated by 
using an updated data from CARE-HF study (Cleland et al 2006). The method was adopted from  
a cost-effectiveness study of cardiac resynchronisation therapy (CRT) based on the CArdiac 
REsychronisation in Heart Failure (CARE-HF) trial (Calvert et al, 2005).   The survival analysis 
methods reviewed in this chapter are based on the book by Collett (1994). 
 
4.2 Probability distribution functions in survival analysis  
 
Standard approaches in survival analysis assume that the time at which events occur follow a 
random process or a particular distribution (Collett, 1994; Lee & Wang, 2003). There are three 
different ways to describe a survival probability distribution: probability density function (PDF), 
survival function and hazard function. 
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Probability density function is typically used to define probability distributions.  It is the 
probability that if an event occurs at time t, the probability of x at a given time interval between a 
and b is often expressed in terms of an integral as follows 
 
)(Pr)()( bxadxfxF b
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Where f(x) is the probability density function, F(x) is the cumulative probability function from 
time a to b.   
 
The survival function is the probability that a subject survives longer than t.  
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The hazard function is the instantaneous failure rate at time t given its survival to time t . It is 
expressed as the ratio of the probability density function to the survival function )(tS .  
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The property of a hazard function may be of particular interest in health economic evaluation, 
due to many probability distributions corresponding to a specific process, for example, the 
clinical history of a particular disease.  Each of those distributions would have their own unique 
characteristics in its hazard function.  In the following section, parametric distribution functions 
commonly used in survival analysis literature are reviewed and their corresponding hazard 
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functions described. The basic concepts and properties of probability distribution functions are 
based on the book by Larson (1982). 
 
4.2.1 The exponential distribution 
An exponentially distributed survival time corresponds to the assumption of a constant hazard.  It 
can be presented as follows 
 
λ=)(th  
 
The corresponding survival function is 
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When survival time is assumed to follow an exponential distribution, the implication is that its 
hazard function is constant.  This means that the probability that an event occurs for the next 
time period, given survival at the current time, does not depend on the patient’s history.  As time 
progresses for a particular disease, the (conditional) probability of death in successive time 
intervals remains unchanged. This, however, is not plausible in most clinical settings. 
 
4.2.2 The Weibull distribution function 
The survival function of a Weibull distribution can be expressed as follows 
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There are two parameters in a Weibull distribution, the scale parameter λ and the shape 
parameter γ .  A Weibull distribution implies a monotone increase or decrease hazard.  The 
hazard function for a Weibull model is given by 
 
1)( −= γλγ tth  
 
The hazard function for Weibull survival time could be increasing or decreasing with time 
depending on the shape parameter γ . If the shape parameter is greater than 1, the hazard rate 
increases with time. If the shape parameter is less than 1, the hazard decreases with time. If the 
shape parameter is equal to 1, then the Weibull reduces to the exponential distribution.   From 
the hazard function, we can see that if 1=γ , the hazard function h(t) simplifies to the constant 
value λ, which is the hazard function for the exponential distribution. 
 
Figure 4.1 shows the hazard plot at different shape parameters (γ).  The limitation of a Weibull 
distribution is that its hazard function is a monotonic function of time.  When a hazard rate 
changes over time, for example, the hazard rate would increase where a patient developed 
resistance after responding well to initial treatments.  In this situation, an alternative distribution 
is needed to appropriately represent the disease progression process.   
  
  
81
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.1 The hazard plot at different shape parameters (γ) 
 
4.2.3 The log-logistic distribution 
If survival time follows a log-logistic distribution then its logarithm has a logistic distribution.  
Survival function of log-logistic distribution is represented as 
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 For a log-logistic distribution, its hazard function increases initially; reaches a peak and then 
decreases. The hazard function of a log-logistic distribution is given by  
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A standard log-logistic model has two parameters λ  and β .  The hazard function decreases 
monotonically if 1≤β , but if β  >1, the hazard has a single peak. The hazard function of a log-
logistic distribution has a single peak.  
 
The following diagram (Figure 4.2) shows the hazard plot at different values of lambda λ  and 
beta β  
 
Figure 4.2 The hazard plot at different values of lambda λ and beta β 
              
The advantage of the log-logistic hazard function is that it captures both inverted, U-shaped and 
monotonically declining rates. 
 
4.2.4 The log-normal distribution 
A log-normal distribution has a hazard function as the characteristic in log-logistic distribution. 
Its hazard functions can increase initially and then decrease over time. The hazard function of a 
standard lognormal distribution is given as 
 
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0 5 10 15 20 25 30 35 40 45
Beta=0.5, 
Lamda=0.1
Beta=1, lamda=0.5
beta=2, 
lamda=0.01
beta=5, 
lamda=0.00001
  
83
0;0
))ln((
))ln(()1(
))((log(),( >>
−Φ
=−= t
t
t
tts
d
d
th
t
σ
σ
σ
φ
σσ
  
 
Where φ  is the probability density function of the normal distribution, and Φ  is the cumulative 
distribution function of the normal distribution. 
 
The hazard functions of log-normal distribution are characterised by inverse U-shape which can 
increase, reach a peak and then decrease.   The following is the hazard plot for a log-normal 
distribution at different values of σ . 
  
Both log-logistic and log-normal distribution can be used to represent a typical clinical process 
of a disease. For example, following a renal transplantation a patient faces an increasing hazard 
of death over the first few months after the transplantation, the hazard then decreases with time 
as the patient adapts to the new graft.   
 
4.2.5 The Gamma distribution 
The formula for the hazard function of a standard gamma distribution, in which the case where 
location parameter equals to zero and scale parameter equals to 1, can be represented as  
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Where γ   is the shape parameter and Γ  is the gamma function which has the formula  
 
)(Pr)( bxadt tt <<=∫=Γ ∞ −−0 1εα α  
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The hazard function of a gamma distribution can provide varieties of forms depending on the 
value of the γ parameter.   
  
4.3 Choosing among survival distributions applied to observed data 
 
When individual data is available from a clinical trial one can fit a parametric survival function 
into the time-to-event data and use maximum likelihood methods to estimate its parameters. This 
is a standard method in statistical analysis and most statistical software has the functionality to 
do so.  
 
When a model is fitted it is important to assess the adequacy of the distribution for the data.  One 
way to perform such verifications is through residual plots.  A Cox–Snell residual is widely used 
to check model fit graphically in the analysis of survival data (Collett, 1994). If a model fitted to 
an observed data is satisfactory, the estimated survival for an individual at time t should be close 
to the true value of a survival function at time t.  The theory of the Cox-Snell residuals is that if a 
random variable t is the survival time of an individual and )(tS  is the corresponding survival 
function,  the random variable ))(log( tS− has an exponential distribution (Cox & Oakes, 1984).  
 
The goodness-of-fit tests can be performed formally based on likelihood ratio statistics when 
comparing two nested models. In this case, as the exponential model is a special case of a 
Weibull model in which the shape parameter is restricted as 1, and log-normal, Weibull and 
exponential are all nested within a generalised gamma model.  
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However, when comparing log-logistic or log-normal with Weibull or exponential, they are not 
nested. In this case a likelihood ratio statistic can not be used for this purpose. The Akaike’s 
Information Criterion (AIC) (Akaike, 1973) or Bayesian information criterion (BIC) (Schwarz, 
1978) can be used for model selections when the nesting restriction does not apply. Lindsey and 
Jones (1998) argued that in the case of analysing clinical trial data, both BIC and AIC will give 
similar results as the sample sizes are relatively small in clinical trials.  Several authors (Clayton 
& Hills, 1993; Collett, 1994; Lindsey, 1995; Burnham et al., 1995) have recommended the use of 
the AIC.  In this work the AIC was used to select models. 
 
The AIC can be used to compare different parametric models by a statistic that trades off a 
model’s likelihood against its complexity.  A lower value of AIC indicates a better model. 
 
  )(22 acLLAIC ++−=  
 
Where LL is the log likelihood statistic, c indicates number if parameters in the survival 
distribution function and a  denotes the number of parameters in the model.    
 
In the following section, the trial data from the CARE-HF study was used as an example to 
illustrate how to fit parametric survival distributions and how to select a best fit model for the 
data.  SAS software was used for all analysis in this section. 
 
4.4 The CARE-HF study  
 
The CArdiac REsynchronisation in Heart Failure (CARE-HF) trial (Cleland et al., 2005) was a 
multicentre, international, randomised trial.  The study compared the effect, on the risk of 
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complications and death, of standard pharmacologic therapy alone with that of the combination 
of standard medical therapy (MT) and cardiac resynchronisation therapy (CRT) without a 
defibrillator in patients with left ventricular systolic dysfunction, cardiac dyssynchrony and 
symptomatic heart failure.  Patients were enrolled at 82 European centres; enrolment began in 
January 2001 and ended in March 2003.  
 
The primary endpoint was the time to death from any cause or unplanned hospitalisation for a 
major cardiovascular event. The principal secondary endpoint was death from any cause. The 
cost-effectiveness analysis was specified a priori as a secondary outcome in the protocol and 
included data from all patients enrolled in the trial. The principal analysis was pre-specified as 
the incremental cost per QALY gained. 
 
Resource use information was collected at baseline, 1, 3, 6, 9, 12, 18 months, every 6 months 
thereafter, and at the end-of-study.  Patients’ quality of life was assessed using the EQ-5D at 
baseline and 90 days post-randomisation.    
 
A total of 813 patients were randomly assigned to receive medical therapy (MT) alone (404) or 
with a cardiac resychronisation device therapy (CRT+MT) (409). The mean duration of follow-
up was 29.4 months (range 18.0–44.7).  By the end of the study, the survival status of all patients 
was known; 383 patients had reached the primary endpoint, of which 159 patients were in the 
CRT+MT group, as compared with 224 MT patients (39% vs. 55%; hazard ratio, 0.63; 95%   CI, 
0.51 to 0.77; P<0.001).  There were 384 unplanned hospitalisations for the major cardiovascular 
events in the MT group and 222 in the CRT group.  An extension phase on all-cause mortality 
was reported in Cleland study with mean follow-up 37.4 months (Cleland et al 2006).  There 
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were 154 deaths (38.1%) in 404 patients assigned to medical therapy and 101 deaths (24.7%) in 
409 patients assigned to CRT (hazard ratio 0.60, 95% CI 0.47-0.77, P<0.0001).  
 
4.4.1 Estimation of time to death 
Time to death was fitted to the extended phase of the data using exponential, Weibull, log-
normal, log-logistic and gamma distributions based on accelerate time failure models. The Cox–
Snell residual was used for an initial check of model fitting, Figure 4.3 shows the Cox-Snell 
residuals from the five candidate models, from which it can be seen that both exponential and 
Weibull would provide a better fit than log-logistic, log-normal or gamma distributions.  A 
straight line with unit slope and zero intercept indicated the fitted survival model is satisfactory 
(Collett, 2004).  
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Figure 4.3 Cox-Snell residual plots by different survival functions (a) 
 
 
 
 
 
 
 
 
 
Figure 4.3 Cox-Snell residual plots by different survival functions (b) 
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Figure 4.3 Cox-Snell residual plots by different survival functions (c) 
 
 
 
 
 
 
 
 
 
Figure 4.3 Cox-Snell residual plots by different survival functions (d) 
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Figure 4.3 Cox-Snell residual plots by different survival functions (e) 
 
Table 4.1 reports negative 2 log likelihood statistics. This statistic is used to compare nested 
models.  The difference between the log likelihood statistics follows the chi-squared distribution. 
Table 4.1 reported the p-value for different comparisons. 
 
The exponential model was selected as it had the best model fit based on the AIC (Table 4.2).  
Table 4.3 reports the estimated hazard rate for the MT group and the hazard ratios of CRT+MT 
compared to MT.   
 
4.4.2 Survival gain in CARE-HF study over lifetime 
In the Calvert study is a trial-based analysis and cost-effectiveness result was presented over 29.4 
months mean follow-up period (Calvert et al., 2005).  A restricted mean survival was estimated 
for each patient within the trial on the basis of the time from randomisation until death or 
censorship. The gain in survival associated with CRT was estimated from the difference in mean 
survival times between treatment groups.   
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When the exponential was chosen as baseline function and fitted into the extended phase of the 
data, the estimates of baseline hazard for MT at 0.155 per year, and the survival function of the 
time to death as 
 
)155.0(exp)( ttS −=   
 
The estimated hazard ratio of CRT+MT vs MT was 0.604.  By applying this ratio to baseline 
hazard function, the survival over patient lifetime for the CRT+MT treatment group can be 
calculated.  Figure 4.4 shows the estimated survival function and observed survival function.  
 
 
Figure 4.4 Estimated based on fitted curves and observed curves 
 
Based on an area under the curve approach, the life year for CRT+MT and MT and the life year 
gain over different time points can be estimated.  This can be obtained by the different survival 
time between the treatments.  Table 4.4 shows the estimated life year gain at 3 years is 0.19 and 
5 years is 0.46 and over 20 years is 2.52. 
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4.5 Discussion 
 
In this chapter, the most commonly used survival functions in survival analysis were described 
and characteristics of their corresponding hazard functions compared.  Parametric survival 
analysis was conducted in the CARE-HF trial data for time to death.  Methods for selecting the 
best fitting survival functions for time to death over the observed periods were illustrated and the 
parameters estimated based on parametric survival analysis methods.  Life years gained over 
different time points after treatments were estimated.  
 
Using survival functions in extrapolating beyond a trial were studied. It is easy to implement and 
provides the longer-term survival property in economic analysis, but its limitation is that it is 
concerned with the overall survival property.  However, cost and quality of life can be quite 
different after trial periods and depend on different events in the future.  In the case of the 
CARE-HF trial, further cost is related to whether there was a cardiac hospital event or whether 
batteries needed to be replaced.  In order to catch the further cost-effectiveness implication, it 
would be more flexible to employ a modelling approach. In the next chapter methodological 
issues using modelling approaches are presented.    
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 Table 4.1 Likelihood ratio statistic in difference survival functions 
Contrast 
Likelihood ratio 
chi-square statistic 
 
Pr > ChiSq 
Weibull vs. Exponential 0.36686 0.54472 
Gamma vs. Exponential 2.10038 0.3498 
Gamma vs. Weibull 1.73352 0.1879 
Gamma vs. Log-normal 19.4868 >0.000 
 
Table 4.2 The likelihood statistic and AIC based on different parametric models 
Distributions No. Parameters AIC N2loglikelihood 
Exponential 1 1309.03 1303.03 
Weibull 2 1310.66 1302.66 
Gamma 3 1310.93 1300.93 
Log-logistic 2 1313.63 1305.63 
Log-normal 2 1328.42 1320.42 
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Table 4.3 Estimated hazard ratio based on exponential model 
Treatment class 
Hazard 
yearly 
95% CI lower 96% CI Upper 
Mean Survival 
time in years 
Life year 
saved 
CRT + MT group 0.155 0.132 0.181 6.6  
Hazard ratio      
CRT+MT vs. MT 0.604 0.470 0.777   
MT group 0.097 0.081 0.116 10.3 3.7 
  
Table 4.4 Projected life years using exponential function 
  
 
Life year 
 
Life save 
in years 
Life save in 
days 
Time (year) Controlled Intervention Different Days 
3 2.41 2.60 0.19 70 
4 2.99 3.31 0.32 115 
5 3.49 3.95 0.46 166 
10 5.11 6.36 1.25 456 
15 5.86 7.83 1.97 720 
20 6.21 8.73 2.52 921 
life time 6.49 10.15 3.65 1333 
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CHAPTER 5  EXTRAPOLATION USING A MARKOV MODELING 
FRAMEWORK 
5.1  Introduction 
 
In the last chapter methodological aspects of using parametric survival functions to project 
longer-term benefits beyond a trial follow-up period were discussed.  However, extrapolating 
costs might present different challenges.  For example, it might be the case that for an implanted 
device, battery replacement is required after a number of years and this is not observed within 
the limited trial follow-up (as in the CARE-HF study looking at cardiac resynchronisation 
therapy).  To incorporate the long-term events, and to utilize observational study data, it is more 
flexible to build a model to simulate the longer-term implications for both costs and 
effectiveness. In addition, a model developed using trial data could provide a means to 
extrapolate and consider related policy questions in different patient groups and different clinical 
settings.   
 
In chapter 2 model types were briefly reviewed and classified as decision trees, Markov models 
or individual sampling models.  In this chapter, the focus is on the Markov modeling approaches 
when applied to economic evaluations.  This includes classical Markov chain models and 
individual sampling models based on a Markov modeling framework. Methods to relax the 
Markovian limitations are explored. The basic concept and theoretical background of Markov 
modeling used in this chapter are based on the book by Hillier and Lieberman (1990). 
 
5.2  What is a Markov model? 
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A Markov model represents a stochastic process which evolves over time, defined by the 
following five properties (Hillier & Lieberman, 1990): 
1. A finite number of states  
2. Conditional probabilities 
3. A fixed cycle length 
4. A set of transition probabilities among Markov states 
5. A set of initial probabilities  
 
First, a finite number of states are defined, usually named as health states or Markov Health 
States. These states should be mutually exclusive and exhaustive. This property indicates that, at 
a given time, a simulated patient is always in one and only one health state.   
 
Second, the conditional probability refers to the probability that a patient moves from one health 
state to another, conditional upon his or her current state.   
 
The first two properties lead to the following conclusions: the conditional probability property 
requires all transition probabilities to be non-negative, and the exhaustive Markov states require 
that all transition probabilities at a given cycle sum 1.   
 
Third, a fixed cycle length is described as a fixed increment of time in which the stochastic 
process evolves in a fixed time step over the whole time horizon. The whole length of a Markov 
model time frame is, therefore, split into equal length Markov cycles.   
 
Fourth, transition probabilities refer to movements among Markov states from the current cycle 
to the next cycle. The movement between states in the following cycle is called an ‘event’. All 
events are represented as transitions from one state to another.  
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Finally, a set of initial probabilities refers to the starting point of all the elements in the stochastic 
process. In the medical field such elements are usually patients.  This property defines the 
starting state of a person or cohort when the patient enters a Markov model. 
 
5.3   The application of a Markov model in health economics 
 
A Markov model can present a clear structure in demonstrating a patient’s disease progression or 
treatment pathway, and is particularly useful in the health economic field. Cost is usually 
allocated to a single Markov state across a single cycle and utility scores are associated with 
health states, usually defined by the severity of a disease.  Therefore, cost and utility scores can 
be attached to each health state in a straight forward way.  A patient staying in one state has an 
associated cost and utility score attached to that state. Therefore, the total cost and utility could 
be easily summed based on a patient’s pathway during treatment periods. 
 
A Markov model is frequently used in health economic evaluation (Sinha & Das, 2000; Stewart 
et al., 1998; van Hout et al., 1997; Welsing et al., 2006), and especially widely used in the 
modelling of chronic diseases (Barber et al., 2006; Tilden et al., 2007; Wynia et al., 1998; Zhu et 
al., 2005). Sonnenberg and Beck (1993) provide an introduction to the Markov model approach 
in the medical field.  Briggs and Sculpher (1998) offer further details on the use of Markov 
modeling when performing economic evaluation. Recently such modelling approaches have 
emerged in economic evaluation for extrapolating beyond trials (Macario et al., 2006; Rinfret et 
al., 2005; Roze et al., 2006; Scuffham & Chaplin, 2005; Yao et al., 2007).  
 
Many studies have used Markov modelling approaches in economic evaluation, and several 
studies have addressed the limitations of a Markov model, employing various methods to 
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overcome them (Caro, 2005; Palmer et al., 2004).  However, relatively little work has focused on 
the methodological aspects of Markov modeling as an approach to extrapolating beyond a trial, 
especially when individual patient data from a trial are available. This chapter draws on the 
established foundations of the Markov modelling approach as used in the health economics field.  
In particular, the limitations of a Markov model are considered and how to overcome such 
limitations when employing this modeling framework to conduct economic evaluation alongside 
a clinical trial and extrapolating beyond the trial, are discussed. The aim is to provide details and 
a comprehensive introduction both on methodological and applied issues. To illustrate the 
methods, a simplified version of the renal transplantation model developed by Yao and 
colleagues was used (Miners et al., 2007; Woodroffe et al., 2005; Yao et al., 2006), examining 
long term cost and effectiveness of immunosuppressant therapy in renal transplantation. Renal 
transplantation is obviously not in the area of heart disease but the model has a simple three state 
structure and is used here as an example to describe the nature of Markov model.  The approach 
illustrated here can be readily projected to other disease areas.  
 
5.4   Renal transplantation model  
 
End stage renal failure occurs when the kidneys no longer function. Patients at this stage of the 
disease will either require a kidney transplant or dialysis, otherwise they will die. Successful 
renal transplantation is reliant on the use of immunosuppressant agents. To model the disease 
progression, Yao and colleagues (2006) employed a Markov modelling approach in assessing the 
long-term treatment effects of different therapies. 
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Figure  5.1 Illustrative example of a Markov model in renal transplantation 
 
Figure 5.1 presents a simple version of a Markov chain used to evaluate the cost and 
effectiveness of immunosuppressant therapies in the treatment of end-stage renal failure.  Three 
health states are defined in the Markov model structure, represented by oval shapes: graft 
functional state, dialysis and death. The arrows between health states indicate possible transitions 
between states.  
 
A one year cycle length was chosen in this model. Table 5.1 presents, in table form, the 
probabilities which need to be estimated in the model: P12 refers to the transition probability 
from graft function to dialysis and P13 refers to the transition probability from graft function to 
death, P11 = (1- P12 - P13) is the probability of a patient in graft function state remaining in a graft 
function state in the next cycle.  P23: the transition probability from dialysis state to death and P22 
is the probability of a patient in dialysis state remaining so. This equates to 1- P23.  The rest of 
the probabilities are zero, indicating no possibility of transition directly from one state to another 
in the following cycle. 
 Graft Function 
     Dialysis 
         Death 
P11 
P12 
  
P23 
     P13 
P22 
P33 
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  Table  5.1 Defining transition probabilities 
Transitions From time t 
to time t+1 
Graft function Dialysis Death 
Graft function P11( = 1- P12 - P13) P12 P13 
Dialysis P21   ( = 0 ) P22  (=1 -  P21 - P23) 
 
P23 
 
Death P31  ( = 0 ) P32  ( = 0 ) P33 ( = 1) 
 
This information is presented in matrix form below, which illustrates the transition probabilities 
matrix for the renal transplantation model. A meta-analysis (Miners et al., 2007; Woodroffe et 
al., 2005) based on a systematic review has estimated the transition probabilities among the three 
health states: 
 
 
 
 
Where Pij (i, j = 1, 2, 3) where i denotes to state i at current cycle and j refers to state j in the 
next cycle) refers to the probability that a patient at state i in the current cycle will move to state j 
in the next cycle.  Please note: all Pij are independent from time or any other variables apart 
from a patient’s current state. 
 
5.5  Analysis of a Markov model  
 
The analysis of a Markov model in a health economic evaluation refers to recording a patient’s 
disease progress pathway over time and predicting which health state the patient will occupy at a 
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given time in the future, based on their starting state.  Once a patient’s pathway is identified 
during a period of time, cost or utility scores can be attached to their specific health states at each 
cycle, which can be the total cost and outcome summarized for the entire time period.  Suppose a 
person in the model starts in health state I,  which states is he/she going to occupy over the next j 
(j =1, 2,…,n) cycles? 
 
Before considering methods of analysing a Markov model, a particular form of Markov model, 
namely the Markov chain, is reviewed. Markov chains are Markov models with one additional 
restriction, relating to the set of transition probabilities among Markov states from current cycle 
to the next cycle that do not change over time, it is said to have stationary transition probabilities.  
A Markov chain is mathematically tractable ( Hillier & Lieberman, 1990), which will be 
discussed in the next section.  
 
There are three main methods to evaluate a Markov chain: matrix algebra, cohort simulation and 
Monte Carlo simulation.  Each of these three methods will be explored in turn, using the renal 
transplantation model as an example.  
 
5.5.1 Matrix algebra 
 
Suppose all patients started in the graft function state. The initial probability of the Markov 
model is presented as 
 
  )001()( 3210 == PPPA  
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Where A t (t=0, 1, 2, …, n) denotes the probability that patients will be in cycle t.  Pi (i = 1, 2, 3) 
denotes the probability of a patient in each state at the starting point. 
  
At the end of the first cycle (one year): 
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At the end of the second cycle (two years):  
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And so forth …. The probability of a patient starting at graft function state and being in a 
different state at the end of the n-th cycle is as follows: 
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The limitation of matrix algebra is the relative mathematical knowledge required to fulfill the 
calculation aspect. Thus, it needs a special program for conducting the algebra, and it is not 
straightforward for the non-specialist user.   
 
5.5.2 Cohort simulation 
 
Markov cohort simulation refers to a simulation approach assuming a hypothetical and 
homogenous cohort of patients entered into the model at time zero (Sonnenberg & Beck, 1993).  
Here the partitioning is based on the initial distribution across health states. In the renal 
transplantation model we assumed that 1000 patients entered the model at the start of the 
simulation and all started at the graft functional health state.  At each cycle of the model, the 
transition probability was applied to re-distribute that cohort into a new proportion at different 
health states. Table 5.2 illustrates the renal transplantation model over a 10 year period (10 
cycles). The function at the end of the table provides the formula for calculating the cohort 
distribution at each cycle. 
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Table 5.2 Cohort simulation for renal transplantation model 
t 
(cycle) 
Health States 
Total 
A (Graft Function) B (Dialysis) C(Death) 
0 (start) 1000 0 0 1000 
1 920 70 10 1000 
2 846 117 37 1000 
3 779 147 74 1000 
4 716 165 119 1000 
5 659 174 167 1000 
6 606 176 217 1000 
7 558 175 267 1000 
8 513 170 317 1000 
9 472 164 364 1000 
10 434 156 410 1000 
 
At a given cycle t (where t =1, 2, 3, …, 10), the number of patients at each state was calculated 
using the following formulae: 
 
311211111
PCPBPAA tttt ∗++∗= −−− *  
321221121
PCPBPAB tttt ∗++∗= −−− *  
331231131
PCPBPAC tttt ∗++∗= −−− *  
  
In fact, a Markov cohort simulation is a graphic presentation of the matrix algebra in evaluation 
of a Markov model.  By pre-multiplying the total number of the cohort into the matrix formula, 
the exact same result as the cohort simulation will be reached.  
 
However, there are limitations associated with cohort simulations, the most obvious being that it 
gives fixed proportions of the cohort in different states and therefore has no measure of 
variability.    
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5.5.3 Monte Carlo simulation 
 
A Monte Carlo simulation refers to a large number of individuals being followed through the 
model pathway individually (Sonnenberg & Beck, 1993). In the case of a Markov chain, each 
individual is subjected to the same transition probabilities, walking through the model pathway 
defined by probabilities for the next cycle. However, a random process dictates which path of 
states the individual will follow.  The implication for the economic evaluation is that this leads to 
a different cost and outcome for each individual. Therefore, the result of the estimated cost and 
outcome is the mean of all individual costs and outcomes, but their variability can be estimated 
based on the individual cost and outcome (Briggs & Sculpher, 1998).  
 
For example in the renal transplantation model, suppose a patient is in the graft function state at 
the current cycle; diagram 5.1 illustrates the probability of staying in graft function is 0.92, of 
graft failure or transfer to dialysis state is 0.07 and the probability of death is 0.01 in the next 
cycle. In the Monte Carlo simulation, a random number R will be drawn based on uniform 
distribution and the value will be from 0 to 1. If 920.≤R , where the patient will stay in graft 
function state. If 0.92 < R < 0.92 + 0.07 = 0.99 then the patient will move to dialysis state, and if 
1990 ≤< R. , the patient will move to death state. At the start of every cycle, a random number 
will be drawn for each individual, and based on the same rule as previously indicated, this will 
define the patient’s state in the next cycle. Therefore, simulated patients will have different 
disease progressions over their treatment time.   
 
The advantage of the Monte Carlo simulation is that variation amongst patients can be measured.  
Furthermore this simulation approach provides flexibility and allows one to relax a Markov 
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chain assumption and offer an improvement on a Markov model, especially given modern 
computer capabilities.  This will be discussed in detail in the following sections. 
 
The non-memory property of a Markov model is not applicable in many clinical settings. In 
many cases in medicine, a patient’s progression depends on how long the patient has been in the 
current health state and the duration of the patient’s disease. For example, in the renal 
transplantation case a patient is more likely to have failure in graft function within the first year 
of transplantation. After that year, once the body has recognised the new organ, the chance of 
graft failure is greatly reduced.   
 
One way to overcome the non-memory property of a Markov model is through adding further 
health states (Barton et al., 2004). However, when a patient’s graft failure depends on how long 
ago a graft was implanted then the Markov model will be difficult to manage.  Studies also 
targeted the limitations of a Markov model in the fixed cycle length, in which case discrete event 
simulation models can be sought (Caro et al., 2006).  However, this is not the focus of this study.  
In Chapter 2, an overview of different modeling approaches was given, referring to Barton 
(2004) and Brennan (2006).  Both papers review how different terminology is used in modelling 
techniques and refer to individual sampling approaches where individual patients ‘walk through’ 
the model.  
 
In the following section, an individual sampling model based on a Markov framework is 
presented as a means of overcoming three limitations in traditional Markov models: 
1. The non-memory Markov assumption, 
2. The fixed transition probability assumption, and 
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3. The inability to allow temporary events to happen within a health state while 
keeping the Markov health states and fixed cycle length properties intact.    
 
5.6   Individual sampling simulation   
 
In the previous section, three methods to evaluate a Markov model were discussed. With the use 
of modern computers, a set of additional variables can easily be employed to take account of the 
length of time a patient is on treatment when individuals go through the patient’s pathway. This 
could involve an adjustment of the transition probability to be dependent on the duration of 
treatment. In addition, a separate set of variables could be employed to take account of different 
temporary events associated with each health state. Therefore, the potential risk factors could be 
updated accordingly. Furthermore, we can define individual patient characteristics at the start of 
the simulation or update them as the patient goes through the model. Transition probabilities can 
be updated at a given cycle, based on individual characteristics and time on treatment or on their 
current health state.  
 
In the matrix algebra and cohort simulation approaches to evaluation of a Markov model, time 
components into the evaluation equation could be added. For example, if it is assumed that the 
transition probabilities are time dependent )(tPP = , then in every cycle, different sets of 
transition probabilities may be employed.  
 
In the renal transplantation example, a transplanted patient has a risk of acute rejection. If a 
patient experienced acute rejection, the probability of graft failure would be much higher. A 
variable could be assigned to take account of the risk of acute rejection; therefore, the following 
transition probability having graft failure will depend on whether a patient has experienced acute 
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rejection or not. Although the patient is still at the graft function state, if patients do experience 
acute rejection the cost and utility will be adjusted accordingly.  In addition, as the model is 
running over a patient’s lifetime, the risks of death due to other causes will vary depending on 
age and gender.  
 
This last section takes a closer look at the matrix formula.  If the transition matrix is updated in 
every cycle according to the specific risk at that time period, the non-memory and stationary 
transition probability can be overcome and the model becomes much more flexible and able to 
mirror the reality of the clinical situation.   
 
 
 
 
  
Where ),( ktp  is the probability matrix denoting a probability of moving from one state to 
another at a given time t with characteristics k. t is the time since starting the model, while k is a 
set of variables attached to each individual.  
 
The Markov model for renal transplantation is represented in a tree diagram as Figure 5.2 below. 
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Figure 5.2 A Markov model in renal transplantation in tree diagram 
  
This mirrors the diagram in Figure 5.1 but uses the tree diagram instead of the conventional ways 
of presenting the Markov model.  
 
The Markov model can be expanded by additional variables (known as tracker variables in the 
software package TreeAge) attached to each individual. At the start of the simulation, a cohort of 
individual patients was created, based on their gender and age at the start of transplantation. All 
patients begin at the graft functional state.  A tracker variable AR (t) was attached to each 
individual.  This tracker variable records whether patients are having acute rejections or not. If a 
patient has no acute rejection, then they will follow the same pathway as Figure 5.2. However, if 
the patient experiences acute rejection, they will follow a different transition probability as 
shown in Figure 5.3. 
 
In addition, to add the tracker of acute rejection, a set of tracker variables was used to record 
time on treatment. This variable was defined by patient’s age which was updated in every cycle. 
Death due to other causes was dependent upon a patient’s age and gender.   
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Figure 5.3 Schematic illustration of an individual simulation model in renal 
transplantation 
  
5.7   Discussion 
 
This chapter reviewed the basic concept of Markov models and their properties were investigated 
in detail. Specifically discussed were the limitations of the Markovian assumption and stationary 
transition probability properties.  However, those limitations can be easily overcome by modern 
computer capabilities and by employing tracker variables to account for duration of treatment 
and risk factors at each health state.  
 
By using tracker variables in the Monte Carlo simulation, time dependent events associated with 
each health state can be taken into account and their rewards, in terms of costs and QALYs, can 
be easily summarised.  
 
In a clinical trial patient data are collected at an individual level. Each patient has a baseline 
profile when they enter the trial. In order to conduct economic evaluation alongside a clinical 
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trial and to extrapolate beyond the trial based on modeling approaches, it is necessary to model 
individual pathways at the individual level.  
 
The advantage of individual simulation is that it can closely mirror a clinical trial, and by so 
doing, the model can be validated by comparing the model-based results and the trial-based 
results. Once a robust model is created, different cohorts of the population can be generated and 
entered the model. This can provide research to extrapolate beyond a trial, not only in terms of 
the extended time-frame but also horizontally to consider the treatment applied to different 
populations. 
 
In the next chapter, the CARE-HF trial is used to illustrate an individual patient simulation 
model based on a Markov modeling framework.  Detailed methodology and approaches using a 
real trial are presented and validation of the model-based analysis against a trial-based analysis is 
undertaken.    
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CHAPTER 6 CASE STUDY 2 - CARDIAC RESYNCHRONISATION 
THERAPY 
 
6.1 Introduction  
 
The two previous chapters described the common approaches in extrapolating beyond a trial: 
parametric survival functions and the Markov modelling method based on individual patient 
simulation.  Chapter 4 presented the theoretical background on parametric survival functions and 
details of the mathematical properties of different parametric survival distribution functions were 
reviewed.  It focused on how to choose an appropriate survival function based on individual data 
from a clinical trial.  Chapter 5 discussed a Markov modelling approach in economic evaluation 
and methods in relaxing Markov modelling assumptions were explored.  Methodological details 
were discussed and illustrated by using the renal transplantation model. 
 
This chapter describes a model-based study using the CARE-HF study (CArdiac 
REsynchronisation in Heart Failure), which was a follow-up to the economic evaluation within 
the CARE-HF trial (Calvert et al., 2005).  A Markov modelling approach based on individual 
patient simulation was employed. The model provided a practical illustration of model-based 
analysis in which input data was populated from the trial.   
 
Two survival functions were the time to major cardiovascular events without hospitalisation and 
time to hospitalisation. The parameters of those survival functions were estimated from 
individual trial data.  The selection of the best fitted parametric survival functions were based on 
the approaches discussed in Chapter 4, details of which are presented in the later sections. The 
best fitted survival functions were used to extrapolate those survival times beyond the trial 
period.   
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The individual simulation approach was employed to track individual risk profiles and record 
time on treatments. The trial population was mirrored at the beginning of the model simulation. 
The risks of time to hospitalisation and cardiovascular events depend upon the patient’s baseline 
characteristics, duration of treatment and type of interventions.  This chapter is based on a 
published study (Yao et al., 2007) but the analysis presented in this thesis is an extension of the 
original work. 
 
6.2 Clinical background 
 
Heart failure is a common disease and costly in terms of morbidity, mortality and resources 
consumed (Cazeau et al., 2001;  Stewart, 2005).   
 
Randomised controlled trials have demonstrated that cardiac resynchronisation therapy (CRT-P) 
and CRT with an implantable cardioverter–defibrillator (CRT-ICD) improves symptoms, 
exercise capacity, ventricular function, quality of life and reduces mortality in patients with heart 
failure due to cardiac dyssynchrony who have persistent moderate or severe symptoms despite 
standard pharmacological therapy (Young et al., 2003; Bristow et al., 2004; Cleland et al., 
2005). 
  
A within trial cost-effectiveness analysis based on individual patient data from the CARE-HF 
trial and UK cost structures showed that CRT-P was associated with increased costs £2,936 
(95% CI £903 to £5,092) and increased quality adjusted life years (QALYs) (0.22 95% CI 0.13 
to 0.32) (Calvert et al., 2005) compared to medical therapy.  The incremental cost-effectiveness 
ratio was £13,142 per QALY gained. The results were sensitive to the costs of device and 
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procedure, and indicate that treatment with CRT-P was cost-effective at the notional willingness 
to pay threshold of £20,000 per QALY gained.  
 
The within trial analysis demonstrated that CRT+MT compared with MT alone was cost-
effective, based on observed benefits and costs and when limited to mean 29.4 months follow up.  
However, there are a few questions that remain unanswered by the within trial analysis.  What is 
the lifetime cost effectiveness of CRT+MT vs. MT?  Which population parameters determine 
cost effectiveness?  What is the cost effectiveness implication of adding ICD to CRT?   
 
It is possible that CRT-ICD may appear cost-effective compared to medical therapy but the 
incremental benefit of ICD in addition to CRT-P might be beyond the threshold of willingness to 
pay (UK perspective).  This could occur if the additional costs associated with the ICD 
component are high compared to any additional benefits gained (Abraham et al., 2002; Young et 
al., 2003; Bristow et al., 2004; Cleland et al., 2005). The incremental cost-effectiveness of 
combined CRT-ICD devices vs. CRT-P alone remains uncertain. The model based analysis aims 
to answer these questions.  
 
The following section presents an economic model populated with data from CARE-HF (Cleland 
et al., 2005) to evaluate the long-term incremental cost-effectiveness of CRT-P and medical 
therapy (MT) compared to MT alone, on incremental cost per QALY and life year gained.  In 
addition, the cost-effectiveness of CRT-ICD+MT vs. MT and the relative cost-effectiveness of 
CRT-P and CRT-ICD, incorporating estimates of the proportion of sudden deaths that might be 
prevented with CRT-ICD taken from the results of a landmark trial, the COMPANION (Carson 
et al., 2005) is evaluated.  The incremental cost-effectiveness of CRT-P or CRT-ICD in different 
patient subgroups is also evaluated.  
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6.3 Construction of the model 
 
An individual sampling simulation model based on a Markov model framework was constructed 
using the approaches defined in Chapter 5.  Health states were defined by New York Heart 
Association functional class (NYHA) and death.  A monthly cycle was defined in the model.  At 
any given NYHA class, patients face different risks of cardiovascular hospitalisation and death.  
Mortality was sub-classified by cause, including death due to worsening heart failure, sudden 
death or death due to all other causes.  The risk of these events depended upon the duration of 
patients’ treatment, their NYHA class and the treatments they received.   
 
The model had two components: the short-term, representing changes in health status and the 
costs and consequences of the process of device implantation, and the long-term effects of the 
device after successful implantation (Figures 6.1 & 6.2).  In the model, MT patients do not 
receive CRT-P or CRT-ICD during follow up.  The CRT-P and CRT-ICD groups received 
treatment with their assigned therapy in accordance with the successful device implantation rates 
observed in the CARE-HF trial.   
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Start of the simulation 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1  Structure of short term model* 
*Patients had a maximum of 3 implant attempts. Those patients who received a successful 
implant moved to the long term model with an NYHA class according to the transition 
probabilities observed in the CARE-HF trial.  Where implants were unsuccessful the patient 
followed the clinical pathway according to the transition probabilities for the medical therapy 
group. 
 
Figure 6.1 illustrates the patient pathway for implantation of CRT-P and CRT-ICD as defined in 
the short term model.  At the start of the simulation a cohort of hypothetical patients is created.  
Each patient is defined by age, gender and NYHA class.  All patients enter the model at the 
implant phase.  The patients face the probability of implantation, successful implantation or 
failure of implantation or death.  If an implantation is successful, the patient moves to the long 
term model within a NYHA class, according to the transition probabilities observed in the first 
month in the CARE-HF trial.   If the implantation is unsuccessful, the patient will move back to 
implantation for another attempt.  Patients have a maximum of 3 implantation attempts.  Where 
 
Implantation of CRT ± 
ICD 
Successful implant 
attempt 
 
Re-implantation 
No further implant attempts.  
Move to the MT group 
pathway. 
Move to long 
term model  
      
Death   Number of 
attempts ≥ 3 
   No 
Yes 
Unsuccessful implant 
attempt 
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implants remain unsuccessful, no further attempts will be allowed and patients will follow the 
clinical pathway, according to the medical therapy alone group.  
 
In the long term phase patients face different risks of major cardiovascular events without 
hospitalisation, such as sudden death or unplanned hospitalisation.  This is dependent on their 
health state, treatment group and duration of treatment.  All patients are at risk of death due to 
other causes, depending on their age and gender.  Figure 6.2 represents the structure of the long 
term model in NYHA class I, if a patient does not die from other causes.  During each cycle of 
the model, patients could stay in a stable condition state and move among the four NYHA health 
states, experience major cardiovascular events without hospitalisation or have an unplanned 
hospitalisation for a major cardiac event. The structure of the model for other NYHA classes was 
identical but with different transition probabilities and risk of unplanned hospitalisation.  Each 
clone indicates that the patient will follow the pathway indicated at point A on the figure.  
 
Figure 6.2 Structure of long term model (NYHA class I) 
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Stable conditions are defined as no major cardiovascular events.  If no events occur during a 
cycle patients follow the stable branch and could move to a different NYHA class according to 
the transition probabilities at NYHA class and the treatment they receive.    
 
Major cardiovascular events without hospitalisation are defined as acute arrests or a sudden 
death episode.  The proportion of such events can be prevented from the additional component of 
ICD. However, in the CRD-P group or MT group this means sudden death.   
 
Unplanned hospitalisations were categorised by type: procedure related, non-procedure related 
and those leading to death due to worsening heart failure.  As simulated patients pass through the 
model cost and utility weighted life years associated with each state they experience are 
accumulated. 
 
The initial distribution of the NYHA classes, age and gender and subsequent transition 
probabilities and costs associated with treatment by MT or CRT-P+MT were based on the 
intention to treat (ITT) analysis of CARE-HF.  The additional effect of ICD on sudden death was 
based on the observed and projected rate in patients assigned to CRT-P in CARE-HF and the 
proportional reduction in sudden death observed in the COMPANION trial in patients assigned 
to CRT-ICD compared to CRT-P.  Mortality for other causes was derived from the UK 
population (Government Actuary's Department (GAD), 2006), with variation by age and gender.  
A set of tracker variables was used to record duration of treatment and patient’s ages were 
updated in every cycle. 
 
  
119
6.3.1 Efficacy 
Effectiveness is expressed as transition probabilities among the Markov health states.  The 
transition probabilities among NYHA classes differed in the short and long term.  In the short 
term, it was assumed there was an immediate response to the implantation. 
  
Table 6.1a shows the rates of successful device implantation, derived from the total implantation 
experience inclusive of CRT and Control group in the CARE-HF trial.  Table 6.1b shows the 
estimated transition probabilities among NYHA classes after implantation in the short term based 
available data derived from 388 (94.1%) and 380 (94.9%) patients in the CARE-HF CRT-P and 
MT groups, respectively.  
 
The long term treatment effect on NYHA class was assumed to follow constant transition 
probabilities if patient stayed in stable state (non-events).  This is supported by the CARE-HF 
trial data.  In the CARE-HF trial outcomes including NYHA class have been measured at months 
1, 6, 9, and 12, and every 6 months thereafter.  The monthly transition probabilities from one 
NYHA class to another for the long term were derived from NYHA classes assessed at months 1 
and 6.  Monthly transition probabilities were estimated, based on the 5 month data by matrix 
algebra on the assumption of a constant Markov chain property during this period (Table 6.1c). 
 
6.3.2 Estimating baseline risks  
Estimated baseline functions of the time to sudden death and the time to unplanned 
hospitalisation were based on the parametric survival analysis. Five parametric survival functions 
were fitted using an accelerated time failure model and conducted using SAS software.  Akaike 
information criterion (AIC) was employed in choosing the most appropriate model. Weibull 
distribution functions were selected for both of the time-to-events survival time as they had the 
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best model fit based on the AIC. Further details are given in Appendix 3. All parameters of the 
Weibull functions were estimated based on the observed data for the MT group in the CARE-HF 
trial. Table 6.2a shows the estimated parameters in the Weibull functions for those two functions. 
Table 6.2b presents the hazard ratios of CRT-P compared to MT. It was reported in previous 
study (Cleland et al. 2004; Calvert et al., 2005; Yao et al., 2007). They were estimated by 
adjusting NYHA class for the risk of time to those two events, respectively  
 
6.3.3 Estimating the risk reduction from ICD 
The estimated additional benefit of ICD added to CRT in reducing sudden death was based on 
the observed rate of sudden death in patients assigned to CRT-P in CARE-HF and the difference 
in sudden death rates in the COMPANION trial between the CRT-P and CRT-ICD groups, based 
on a median follow up in that trial of 16 months in the device therapy groups (Bristow et al., 
2004; Carson et al., 2005).  No additional benefit, apart from preventing sudden death 
attributable to ICD, was assumed.  The monthly probability of hospitalisation has been reported 
to be similar for CRT-P and CRT-ICD in the COMPANION trial (0.098 and 0.097, respectively) 
(Carson  et al., 2005) so no further penalty was applied to CRT-ICD patients for hospitalisation 
rates due to the presence of the ICD component.   
 
6.3.4 Utility data  
The CARE-HF trial provided EQ-5D score estimates at baseline and 90 days (Table 6.3).  Utility 
scores were assumed to be dependent on the NYHA class of a patient, and otherwise independent 
of treatment. Utility scores measured in the CARE-HF trial were mapped onto NYHA class 
(Calvert et al., 2005). A utility value was assigned to each health state. 
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6.3.5 Cost Analysis 
The economic analysis was conducted from a UK NHS perspective, including device cost of 
CRT-P and CRT–ICD, implantation procedure cost, cost of hospitalisation (hospital stay during 
implantation and unplanned hospitalisation), medical care cost, and drug costs.  Implantation 
cost included device cost, procedure cost, intravenous medication, and hospital stay (including 
ICU and CCU).  
 
Medical care cost included outpatient visits, cardiology or primary care visits, and length of time 
spent in nursing or residential homes or rehabilitation centres. Cost per patient per day for 
medical care and drug cost were estimated from CARE-HF (Calvert et al., 2005). The same drug 
and medical care costs per day for all treatment groups were assumed. 
 
Unplanned hospitalisation for a major cardiac event was characterised by the presence or 
absence of a procedure cost. Procedure costs included ICU, CCU, CABG, PTCA, and heart 
transplantation. Procedure costs were based on the frequency and cost of events, and average 
costs for ICU and CCU.  
 
The unit costs employed have been previously reported (Calvert et al., 2005). In brief, the costs 
of medications were obtained from the British National Formulary (BNF, 2006).  All 
hospitalisation related costs based on National Health Service reference costs (HRG, 2004).  
Table 6.4 summarises the cost data by different categories.  
 
6.3.6 Battery life 
Based upon product specifications, it was assumed that the batteries were replaced for surviving 
patients in the CRT-P group every 6 years, and every 7 years in the CRT-ICD group (Medtronic, 
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2006). In order to examine the influence of battery life on the cost-effectiveness of the CRT-ICD 
device, which will vary with the device used and the specific programming employed, the cost-
effectiveness of CRT-ICD using a device life of 6 years and 8 years were also examined. The 
cost associated with battery replacement was the device cost plus one cardiac outpatient visit 
day. 
 
6.3.7 Probabilistic sensitivity analysis 
Probabilistic sensitivity analysis was conducted across all input values (apart from two fixed 
parameters, the device and lead costs), together with scenario analysis of the assumptions within 
the model. Tables 6.1 to 6.4 list all input values and their respective distributions used to 
examine second order uncertainty (Briggs, 2000). Each set of random input values was drawn 
based on their specific distributions for every 10,000 patients and the results were iterated 1000 
times. Cost-effectiveness acceptability curves were constructed to illustrate the key input 
parameter uncertainty in the model. 
 
The choices of distributions for particular parameters were based on a general approach by using 
the distributional form that relates to the estimation of the parameter of interest (Claxton et al., 
2005). For utility values, which are bounded to be 0 to 1, the beta distribution was assigned. For 
costs of all hospital events and procedure costs, log-normal distributions were assigned. For 
polychotomous transitions, in the case of transition probability among NYHA classes, the 
Dirichlet distributions were assigned (Briggs et al., 2006).  
 
Similarly, all treatment effects such as hazard ratios which were estimated from a Cox 
proportional hazard model in the log hazard scale. Therefore, log-normal distributions were 
assigned to all hazard ratios for unplanned hospitalisation, sudden death and NYHA classes with 
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relative comparitors. For different events during unplanned hospitalization, a Dirichlet 
distribution was assigned. The event rates of implantation failures were based on a beta 
distribution.   
 
There is no clear-cut reference regarding how many runs should be performed for 1st order and 
2nd order uncertainty. Here the choice of the number of runs was based on an iterative process. In 
the case of 1,000 for 2nd order uncertainty, an initial 500 runs were tried in which the result 
showed a high degree of variability. Then the number was increased to 1,000, at which point 
reasonably stable results were achieved from different runs. Similarly, the choice of 10,000 on 
the 1st order uncertainty went through the same trial-and-error approach. The chosen number of 
runs is consistent with current practice as noted by Andronis and colleagues (2009). 
  
6.3.8 Model validation  
The model validation was conducted through replicating exactly the patient cohort observed in 
the CARE-HF trial. The model predicted survival curves which could be compared with 
observed survival results from CARE-HF and the published results from COMPANION 
(Feldman et al., 2005)). 
 
6.4 Results  
6.4.1 Survival  
For the base case analysis, where all mean input values used were based on 10,000 individual 
simulations, and patients started at a fixed age of 65 years, the predicted median survival was 
7.44, 10.53 and 11.98 years for MT, CRT-P and CRT-ICD respectively and 75% of patients were 
dead by 11.33, 15.92 and 17.92 years (Table 6.5, Figure 6.3). The undiscounted life gained for 
CRT-P versus MT was 3.09 years and for CRT-ICD versus CRT-P was 1.45 years. 
  
124
 
 
Figure 6.3 Model predicted survival curves for MT, CRT-P and CRT-ICD 
 
6.4.2 Cost-effectiveness results 
Table 6.6 and 6.7 shows the difference in costs, life years and QALYs by group. The total cost 
per patient was £26,572, £36,732 and £59,422 for MT, CRT-P+MT, and CRT-ICD+MT, 
respectively. The mean life-time QALYs were 4.08, 6.06 and 6.75 and life years were 6.10, 8.23 
and 9.16 for MT, CRT-P+MT, and CRT-ICD+MT, respectively.  
 
For the comparison of CRT-P+MT and MT, the probabilistic sensitivity analysis gave an 
incremental cost of £10,160, QALY score of 1.98 and life year estimate of 2.13. This gave 
incremental cost-effectiveness ratios (ICERs) of £5,128 (95% CI £3,623 to £8,017) per QALY 
gained and £4,769 (95% CI £3,637 to £14,704) per life year gained.  CRT-ICD+MT versus MT, 
the incremental cost was £32,850, the QALY was 2.68 and life year gained 3.02. This led to 
ICERs 13,257 (95% CI £9,864 to £17,055) of per QALY and £10,735 (95% CI £6,254 to 
£13,421) per life year gained.  For CRT-ICD+MT versus CRT-P+MT, the incremental cost was 
£22,690, the QALY score 0.70 and the life years gained 0.93.  The ICER here was £32,529 (95% 
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CI £24,288 to £54,040) per QALY gained, and £24,397 (95% CI £18,169 to £82,839) per life 
year gained.  
 
Figures 6.4 and 6.5 present the cost-effectiveness acceptability curves for CRT-P+MT and CRT-
ICD+MT versus MT, and CRT-ICD+MT versus CRT-P+MT, respectively. Based on a 
willingness-to-pay threshold of £30,000 per QALY, CRT-ICD+MT had a probability of 0.40 of 
being cost-effective compared with CRT-P+MT treatment alone.  
 
 
Figure 6.4   Cost-effectiveness acceptability curves of CRT (+/-ICD) vs. Medical 
Therapy 
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Figure 6.5 Cost-effectiveness acceptability curves of CRT-ICD vs. CRT-P 
 
6.4.3 Analyses by cohort age 
Patient groups who started treatment at age 55, 60, 70 and 75 were modelled. The results are 
shown in Table 6.8 and illustrated in Figure 6.6. If patients received CRT-ICD at age 60, the 
ICER for the comparison with CRT-P alone decreased from £32,591 to £29,048 per QALY 
gained, and for patients starting at age 55, the ICER fell to £25,019. For patients starting at age 
75, the ICER rose to £37,808.  The effect of varying the period of follow-up in the model (Table 
6.9) describes the sensitivity of the results for CRT-ICD from the perspective of the analysis.   
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
10000 20000 30000 40000 50000 60000 70000 80000
Willingness to Pay Per QALY Gained (In Pounds) 
Pr
ob
ab
ilit
y 
of
 
Be
in
g 
Co
st
-
Ef
fe
ct
iv
e
  
127
 
Figure  6.6 Incremental cost per QALY gained by different starting age at treatment 
 
6.4.4 Model validity 
In Table 6.9, the internal validity of the model output is reported, by estimating a variety of 
shorter-term effects to contrast with other models and with the within trial analysis from the 
CARE-HF trial. When the model was restricted to run over 29 months which was close to the 
trial mean follow-up periods 29.4 months, the ICER is £13,441 per QALY gained. This is close 
to the ICER value £13,142 (€1.47 = £1) which was estimated from the trial-based analysis 
(Calvert et al., 2005). When the model was run over 6 years, before a battery replacement was 
applicable in the model, the estimated QALY gained for CRT-ICD and CRT-D compared with 
MT is 0.90 and 0.76 respectively. These results are similar to the estimates from Feldman 
(2005), which were 0.84 and 0.71 respectively.  
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When the trial population defined by age, gender and baseline NYHA class was entered into the 
model, the overall survival predicted by the model compared well with observed survival in the 
CARE-HF trial, as shown in Figure 6.7.  
 
Figure 6.7 Model predicting survival with the CARE HF trial age matched cohort and 
the trial based Kaplan Meier estimates of survival curves 
 
The effect of different battery life for CRT-ICD on the incremental cost per QALY is described 
in Table 6.10. Reducing battery life to 4 years, the cost per QALY for CRT-ICD+MT versus 
CRT-P+MT was increased to £51,769.  Conversely, increasing battery life to 8 years reduced the 
cost per QALY for this to £29,246. 
 
6.5 Discussion  
 
This chapter has presented a full illustration of a case study in model-based analysis with input 
data populated from a clinical trial (CARE-HF). Parametric survival curves of time to 
hospitalisation and time to sudden death were adopted in deriving long term baseline survival 
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functions. The application of adjusting time dependent risk of events in a Markov modelling 
framework was shown in detail. Death due to other causes was separated, traced and modelled 
by using UK life table data. The additional benefit of ICD was investigated and different age 
cohorts at the time of treatment were explored and discussed.  
 
For the base case, CRT-P appears a highly cost-effective addition to medical therapy among 
eligible patients. CRT-ICD+MT also appears to be cost-effective compared to medical therapy. 
From a life-time perspective, assuming a reasonable life expectancy when receiving effective 
treatment for heart failure, CRT-P+MT appeared cost-effective in all age groups. The cost-
effectiveness of CRT-P+MT for patients in the 8th decade of life may seem surprising. This gain 
reflects a substantial benefit on quality of life among survivors, and some increase in longevity.  
The cost-effectiveness of CRT-ICD+MT is substantially greater in younger subjects, due to the 
longer potential period when the subject is at risk of sudden death. The cost-effectiveness of 
CRT-ICD+MT compared to CRT-P+MT was lower in older people partly because these 
treatments exert similar effects on quality of life and because older patients were more likely to 
die of other problems if sudden death was prevented. Varying the period of follow up in the 
model (Table 6.7) indicates the sensitivity of the results for CRT-ICD+MT to the duration of 
follow-up being considered, effectively the duration of the patients exposure to the risk of 
sudden death.  It also indicates the similarity of the model results to the previously reported 
within-trial analysis. 
 
This model derived analysis extends the previously published within trial analysis based upon 
29.4 months of mean follow up.  It also further advances the work described in COMPANION 
cost-effectiveness analysis which provided estimates of benefit at 7 years (Feldman et al., 2005), 
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which are similar to those observed in this model at 6 years.  In addition, this work examines the 
incremental cost-effectiveness ratio associated with adding an ICD component to CRT therapy. 
 
The analysis has a number of strengths.  The existing clinical trials provide considerable 
evidence for the long-term effectiveness of both CRT-P and CRT-ICD but most patients were 
alive and many felt well at the end of the trials.  Patients’ treatment does not cease at the end of 
the trial and it is inappropriate to assume that benefits cease at that point.  In taking a life-time 
approach, important issues, such as device replacement, which none of the existing trials have 
had long enough follow-up periods to address were considered.  Economic modelling also 
enables the inclusion of data and other evidence from a range of sources in order to examine 
health policy questions (Salkeld et al., 2004).  
 
There are a number of limitations to this analysis.  The analysis is based upon simulation rather 
than the direct observation of event rates achieved in a randomised trial, albeit simulation that 
has been constructed from a large scale, long term trial in which the additional benefits of CRT-
ICD are addressed using individual patient data from the CARE-HF trial to identify potentially 
preventable sudden deaths, and a further randomised trial of the effects of ICD on sudden death 
(COMPANION).  Thus the current work may be considered a best-evidence synthesis of the 
likely cost-effectiveness of CRT-P and CRT-ICD, although the strength of that evidence is not as 
high as direct observation from sufficiently powered and appropriately designed randomised 
trials. 
 
Furthermore, the analysis was based on patient level simulation while exploring the second order 
uncertainty using Monte Carlo simulation, which is computationally expensive. In the case of 
baseline analyses in which the model simulated for every 10,000 patients and the results were 
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iterated 1000 times, it consumed approximately 9 hours computing time per case. Several studies 
have developed methods to improve the efficiency of this type of modelling. One of those 
methods is Gaussian process emulation (Stevenson et al., 2004). The Gaussian process uses 
results from the patient simulation model which is run at various input values. Then Gaussian 
process interpolates between these model runs to give sufficiently accurate estimates of the 
model results that would be obtained from any other set of inputs.  O’Hagan and colleagues 
(2007) developed a method using ANOVA for efficient estimation of mean and variance by 
reducing the number of inner and outer loops.  Their model was based on the algebra of analysis 
of variance and Bayesian statistics.  The methods are simple to apply and will typically reduce 
substantially the computational burden when conducting Monte Carlo probability sensitivity 
analysis for patient-level models.  
 
These methods have been shown to reduce the computational demand substantially for suitable 
models.  However, the Stevenson study is based on a Gaussian process emulator which still does 
not replace the patient simulation model. The O’Hagan study was restricted to two treatments. 
Both methods are subject to further research before they can be routinely adopted in practical 
applications. 
 
Several studies in the literature addressed the cost-effectiveness of CRT-P or CRT-ICD 
compared with medical therapy (Nichol et al., 2005; McAllister et al., 2001; Banz et al., 2005; 
Feldman et al., 2005; Fattore et al., 2005; Calvert et al., 2005;  Yao et al,. 2007; Fox et al., 
2007).  Five of these studies were model-based analyses (Nichol et al., 2004; McAllister et al., 
2004; Banz et al., 2005; Fattore et al., 2005 ;  Fox et al. , 2007). Calvert and colleagues (2005) 
conducted trial-based economic evaluation alongside the CARE-HF trial. Yao and colleagues 
further developed a model based analysis to extrapolate the cost-effectiveness result beyond the 
  
132
Care-HF trial and over patient’s life time. Feldman and colleagues (2005) carried out trial-based 
and model-based analyses to extrapolate cost-effectiveness of CRT-P and CRT-ICD compared to 
medical therapy beyond the COMPANION trial to 7 years.  
 
Previous evaluations have provided varying estimates of the cost-effectiveness of CRT-P and 
CRT-ICD relative to medical therapy.  However, all of those studies evaluated the incremental 
benefit of CRT_P or CRT-ICD compared with medical therapy.  Yao and colleagues published 
the first paper that directly addressed the cost-effectiveness of CRT-P compared to CRT-ICD.  
Later that year, Fox and colleagues published their Technology Assessment Report in which a 
model-based analysis was used to estimate the incremental cost-effectiveness of CRT-P versus 
CRT-ICD (Fox et al., 2007).  
 
Fox and colleagues employed a Markov model to compare CRT-P and CRT-ICD directly with 
medical therapy and CRT-P compared with CRT-ICD over patient’s life time for difference age 
cohort. They estimated ICER of £16,735 per QALY gained with incremental QALY at 0.70 and 
costs £11,630 (range £14,630–20,333).  For CRT-D versus CRT-P, their result was incremental 
QALYs gained at 0.29 and cost at £11,689, giving an ICER of £40,160 (range £26,645–59,391) 
per QALY gained for a mixed age cohort.  The QALYs gained are much less and ICERs are 
higher than the results presented in this chapter.  But the differences in cost are similar. This 
could be explained by the fact that FOX study allowed patients on MT group to switch to ICD 
treatment.  
 
A strength of the Fox study is that clinical effectiveness parameters (such as hazard ratio of 
sudden death and hospitalisation among difference treatments) in the model were derived from a 
systematic review. Resource use and costs associated with CRT and treating heart failure in 
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based on the published results largely from CARE-HF study (Calvert et al., 2005) and 
CAMPION study (Feldman et al., 2005).  
 
There were several weaknesses in the Fox study. First, inadequate differentiation between patient 
groups in their risk of hospitalisation or sudden death; second, their work was based on 
published, aggregated results rather than individual patient data; final, there were structural 
limitations that would suggest that patient progression was not sufficiently captured.  Thus the 
Fox paper did not clearly establish a more robust or valid result than the analysis concluded by 
Yao and colleagues (2007).  
 
6.6 Conclusion 
 
The model concluded that long-term treatment with CRT-P+MT appears cost-effective compared 
to medical therapy alone.  The model provided a flexible way of answering several important 
questions, including: what is the additional benefit in adding ICD into the CRT?, and what were 
the implications of battery replacement assumptions at different time points over the patient’s 
life?  The model was validated by observed survival in the trial when trial population data was 
entered into the model.   
 
In the next chapter, a new case study of model-based analysis populated by input trial data will 
be presented.     
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Table 6.1 Input value and distributions 
Table 6.1a Implantation history (inclusive of CRT and control group in CARE-HF) 
 Expected Rate Success Failed Total Distributions 
First attempt 
Second attempt 
Third attempt 
0.87 
0.86 
0.80 
409 
62 
8 
60 
10 
2 
469 
72 
10 
Beta 
Beta 
Beta 
 
Table 6.1b Transition probability in first month after implant between NYHA Class 
CRT(±ICD) 
 
NYHA 
class I 
NYHA class 
II 
NYHA class 
III 
NYHA class 
IV 
Distributions 
NYHA class 
III 
NYHA class 
IV 
0.298 
0.091 
0.459 
0.455 
0.227 
0.409 
0.016 
0.045 
Dirichlet 
(114.96;177.18;87.54;6.33) 
Dirichlet 
(2.34;10.7;9.66;1.3) 
Medical Therapy    
NYHA class 
III 
NYHA class 
IV 
0.103 
0.000 
0.303 
0.200 
0.528 
0.600 
0.067 
0.200 
Dirichlet 
(38.75;114.15;198.97;25.13) 
Dirichlet 
(0.25;5.65;16.45;5.65) 
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Table 6.1c   Long term  monthly transition probability between NYHA Class 
CRT(±ICD) 
NYHA class 
in current 
cycle 
NYHA class I NYHA class 
II 
NYHA class 
III 
NYHA class 
IV 
Distributions 
NYHA class  
I 
NYHA class II 
 
NYHA class 
III 
NYHA class 
IV 
0.906 
 
0.067 
 
0.007 
 
0.048 
0.075 
 
0.896 
 
0.121 
 
0.048 
0.016 
 
0.033 
 
0.864 
 
0.181 
0.003 
 
0.004 
 
0.009 
 
0.723 
Dirichlet 
(92.44;7.70;1.60;0.26) 
Dirichlet 
(92.44;7.70;1.60;0.26) 
Dirichlet 
(0.54;9.64;69.13;0.68) 
Dirichlet 
(0.24;0.24;0.90;3.62) 
Medical Therapy 
NYHA class 
 I 
NYHA class II 
NYHA class 
III 
NYHA class 
IV 
0.7956 
 
0.0710 
 
0.0047 
 
0.0000 
0.1245 
 
0.8448 
 
0.0893 
 
0.1064 
0.0738 
 
0.0765 
 
0.8845 
 
0.1064 
0.0061 
 
0.0077 
 
0.0216 
 
0.7872 
Dirichlet 
(28.1;4.61;2.83;0.46) 
Dirichlet 
(7.63;88.11;8.21;1.05) 
Dirichlet 
(1.09;16.32;159.46;4.13) 
Dirichlet 
(0.25;2.8;2.8;19.14) 
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Table  6.2  Probabilities of events and associated distributions 
Table 6.2a  Weibull baseline survival functions for Major cardiovascular events without or with  
                     hospitalisation 
Without hospitalisation 
 Value 95% CI Lower 95% CI Upper Distribution 
Alpha-scale 
Gamma-shape 
0.0058 
0.9206 
0.005 
0.905 
0.006 
0.936 
Lognormal 
Lognormal 
Unplanned Hospitalisation 
Alpha-scale 
Gamma-shape 
0.051 
0.77 
0.046 
0.69 
0.061 
0.82 
Lognormal 
Lognormal 
 
Table 6.2b  Hazard ratio for major cardiovascular events without hospitalisation 
 HR 95% CI Lower 95% CI Upper Distribution 
CRT-P vs MT 
NYHA Class II vs. I 
NYHA Class III vs. I 
NYHA Class IV vs. I 
0.522 
1.014 
1.014 
0.891 
0.318 
0.532 
0.519 
0.249 
0.858 
1.931 
1.978 
3.187 
Lognormal 
Lognormal 
Lognormal 
Lognormal 
Table 6.2c  Hazard Ratio for Hospitalisation 
 HR 95% CI Lower 95% CI Upper Distribution 
CRT (+/- ICD) vs. MT 
NYHA Class II vs. I 
NYHA Class III vs. I 
NYHA Class IV vs. I 
0.79 
1.184 
1.834 
4.991 
0.613 
0.818 
1.265 
2.974 
1.019 
1.715 
2.659 
8.376 
Lognormal 
Lognormal 
Lognormal 
Lognormal 
 
Table 6.2d  Death probability  given hospitalisation 
 Value 95% CI Lower 95% CI Upper Distribution 
MT Group 
CRT  (+/-) ICD 
0.113 
0.074 
39 
12 
345 
162 
Beta (39; 345) 
Beta (12; 162) 
Table 6.2e  ICD Effect on Probability of Sudden death 
hazard ratio of ICD effect 0.367 0.215 0.626 Lognormal 
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Table 6.2f  Conditional probability of ‘procedures’ given unplanned hospitalisation 
CRT (+/-) ICD Expected mean Observed With continuity  correction Distribution 
ICU 
CCU 
CABG 
PTCA 
Transplantation 
No Procedure 
0.0908 
0.3155 
0.0009 
0.0346 
0.0571 
0.5009 
16 
56 
0 
6 
10 
89 
16.17 
56.17 
0.17 
6.17 
10.17 
89.17 
Dirichlet 
(16.17; 56.17; 0.17; 
6.17; 10.17; 89.17) 
Medical therapy group 
ICU 
CCU 
CABG 
PTCA 
Transplantation 
No Procedure 
0.0715 
0.2562 
0.0033 
0.0204 
0.0260 
0.6226 
25 
90 
1 
7 
9 
219 
25.17 
90.17 
1.17 
7.17 
9.17 
219.17 
Dirichlet 
(25.17, 90.17, 1.17, 
7.17, 9.17, 219.17) 
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Table  6.3 Input values of costs and utilities 
Utility Scores  
 Mean 95% CI Lower 95% CI Upper Distribution 
NYHA class I 0.815 0.781 0.850 Beta 
NYHA class II 0.720 0.693 0.749 Conditional Beta 
NYHA class III 0.590 0.551 0.629 Conditional Beta 
NYHA class IV 0.508 0.412 0.605 Conditional Beta 
Cost     
CRT-P Device and Leads 7,760   Fixed 
CRT-ICD Device and Lead 32,625   Fixed 
Left ventricular leads 574   Fixed 
Drug Cost Per Day 5.84 5.01 6.35 Normal 
Days in hospital during 
implantation - per procedure 
3.3 3 3.6 Normal 
Days in hospital due to unplanned 
hospitalisation (per event) 
11.80 10.8 12.8 Normal 
Days in ICU  Per Event CRT(+/-) 
ICD group 
5.7 5.23 6.17 Normal 
Days in ICU  Per Event MT group 7.6 4.85 10.35 Normal 
Days in CCU Per Event CRT(+/-) 
ICD group 
6.8 6.16 7.44 Normal 
Days in CCU Per Event  MT group 7.8 7.42 8.18 Normal 
Days in Planned hospitalisation 
per event CRT(+/-) ICD group 
5.68 4.59 6.76 Normal 
Days in Planned hospitalisation 
per event MT group 
7.16 4.73 9.58 Normal 
Rate of planned hospitalisation 
CRT(+/-) ICD group 
0.20 81 404 Beta 
Rate of planned hospitalisation  
MT group 
0.17 70 409 Beta 
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Table 6.4 Unit costs of resources use in the CARE-HF trial 
Resource costs Unit Cost (£) 
CRT or CRT-ICD procedure cost - 1072 
Hospital stay (cardiac) Day 163 
ICU stay Day 1167 
CCU stay Day 310 
Cardiac day case Day 112 
Cardiac outpatient visit Visit 62 
Primary care visit (GP) Visit 28 
Residential home (private) Week 373 
Nursing home (private) Week 527 
Rehabilitation centre Day 179 
Heart transplant - 22 558 
CABG - 5 925 
PTCA - 2 283 
*Calvert et al., 2004: Table 1 Unit costs of resources and resource use in the CARE-HF trial 
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Table 6.5 Model predicted survival 
 Mean life Years First  quartile Median Third quartile 
MT 
CRT+MT 
CRT+ICD+MT 
7.44 
10.53 
11.98 
2.00 
4.00 
5.08 
5.50 
9.25 
11.08 
11.33 
15.92 
17.92 
 
Table 6.6 Estimated cost and effectiveness in QALYs and life years 
Strategy Cost (£) QALYs Life year Incremental life years 
MT 26,572 4.08 6.10  
CRT-P +MT 
(vs. MT) 
36,732 6.06 8.23 2.13 
CRT-ICD +MT 
(vs. CRT-P +MT) 
59,422 6.75 9.16 3.06 
CRT-ICD +MT 
(vs MT) 
59,422 6.75 9.16 0.93 
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Table 6.7 Incremental cost-effectiveness Ratios (per QALY and life year) 
Strategy Incremental ICER  with 95% CI 
 
Cost (£) QALYs Life Years £/ per QALYs £ /per Life Year 
CRT-P +MT 
(vs. MT) 
10,160 1.98 2.13 
5,128 
(3,623 - 8,017) 
4,769 
(£3,637- 14,704) 
CRT-ICD +MT 
(vs. MT) 
32,850 2.67 3.06 
13,257 
(9,864 - 17,055) 
10,735 
(6,254 - 13,421) 
CRT-ICD +MT 
(vs CRT-P +MT) 
22,690 0.7 0.93 
32,591 
(24,288 - 54,040) 
24,397 
(18,169 -82,839) 
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Table 6.8  Estimated mean incremental cost per QALY for different starting ages 
Starting age Strategy Cost 
Incremental 
Cost 
QALYs Incremental QALYS ICER 
55 
MT £30,282  4.72   
CRT-P +MT 
(vs. MT) 
£43,404 £13,122 7.42 2.7 £4,856 
CRT-ICD +MT (vs. 
MT) 
£71,245 £40,963 8.54 3.81 £10,751 
CRT-ICD +MT (vs. 
CRT-P) 
£71,245 £27,841 8.54 1.11 £25,019 
60 
MT £28,426  4.39   
CRT-P +MT 
(vs. MT) 
£40,591 £12,165 6.86 2.47 £4,927 
CRT-ICD +MT (vs. 
MT) 
£65,638 £37,212 7.72 3.33 £11,175 
CRT-ICD +MT (vs. 
CRT-P) 
£65,638 £25,047 7.72 0.86 £29,048 
65 
MT £26,572  4.08   
CRT-P +MT 
(vs. MT) 
£36,732 £10,160 6.06 1.98 £5,128 
CRT-ICD +MT (vs. 
MT) 
£59,422 £32,849 6.75 2.68 £12,257 
CRT-ICD +MT (vs. 
CRT-P) 
£59,422 £22,690 6.75 0.7 £32,591 
70 
MT £23,807  3.62   
CRT-P +MT 
(vs. MT) 
£32,304 £8,497 5.25 1.63 £5,215 
CRT-ICD +MT (vs. 
MT) 
£52,387 £28,580 5.78 2.16 £13,231 
CRT-ICD +MT (vs. 
CRT-P) 
£52,387 £20,083 5.78 0.53 £37,808 
75 
MT £21,054  3.16   
CRT-P +MT 
(vs. MT) 
£27,671 £6,617 4.38 1.22 £5,430 
CRT-ICD +MT (vs. 
MT) 
£44,922 £23,867 4.73 1.56 £15,299 
CRT-ICD +MT (vs. 
CRT-P) 
£44,922 £17,251 4.73 0.35 £49,863 
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Table 6.9 Estimated mean incremental cost per QALY at different durations of follow 
up for the base case population 
Time Frame Strategy Cost 
Incremental 
Cost 
QALYs 
Incremental 
QALYS 
ICER 
Life Time 
MT £26,572  4.08   
CRT-P +MT 
(vs. MT) 
£36,732 £10,160 6.06 1.98 £5,128 
CRT-ICD +MT 
(vs. MT) 
£59,422 £32,849 6.75 2.68 £12,257 
CRT-ICD +MT 
(vs. CRT-P) 
£59,422 £22,690 6.75 0.7 £32,591 
6 Years 
MT £17,066  2.52   
CRT-P +MT 
(vs. MT) 
£20,897 £3,831 3.28 0.76 £5,051 
CRT-ICD +MT 
(vs. MT) 
£32,723 £15,480 3.42 0.90 £17,200 
29 months 
MT £9,359  1.28   
CRT-P +MT £12,783 £3,424 1.53 0.25 £13,441 
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 Table 6.10 Estimated mean incremental cost per QALY at different battery life for 
CRT-ICD device 
Battery life  
in years 
Strategy Cost 
Incremental 
Cost 
QALYs Incremental QALYS ICER 
4 
MT £26,565  4.07   
CRT-P +MT 
(vs. MT) 
£36,551 £9,987 6.09 2.01 £4,964 
CRT-ICD +MT 
(vs. MT) 
£71,979 £45,414 6.77 2.70 £16,820 
CRT-ICD +MT 
(vs. CRT-P) 
£71,979 £35,427 6.77 0.68 £51,769 
5 
MT £26,393  4.05   
CRT-P +MT 
(vs. MT) 
£36,906 £10,513 6.16 2.10 £4,996 
CRT-ICD +MT 
(vs. MT) £66,422 £40,029 6.84 2.79 £14,347 
CRT-ICD +MT 
(vs. CRT-P) 
£66,422 £29,516 6.84 0.68 £43,233 
6 
MT £26,634  4.09   
CRT-P +MT 
(vs. MT) 
£36,620 £9,987 6.07 1.98 £5,043 
CRT-ICD +MT 
(vs. MT) £62,099 £35,465 6.77 2.68 £13,233 
CRT-ICD +MT 
(vs. CRT-P) 
£62,099 £25,478 6.77 0.7 £36,232 
7* 
MT £26,572  4.08   
CRT-P +MT 
(vs. MT) 
£36,732 £10,160 6.06 1.98 £5,128 
CRT-ICD +MT 
(vs. MT) 
£59,422 £32,849 6.75 2.68 £12,257 
CRT-ICD +MT 
(vs. CRT-P) 
£59,422 £22,690 6.75 0.7 £32,591 
8 
MT £26,646  4.10   
CRT-P +MT 
(vs. MT) 
£36,562 £9,916 6.10 2.00 £4,958 
CRT-ICD +MT 
(vs. MT) 
£57,153 £30,507 6.80 2.70 £11,299 
CRT-ICD +MT 
(vs. CRT-P) 
£57,153 £20,591 6.80 0.70 £29,246 
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CHAPTER 7 CASE STUDY 3: NEBIVOLOL TREATMENT 
 
 
7.1 Introduction 
 
In the previous chapter, an application of a modelling approach of economic evaluation based on 
the CARE-HF trial was presented and discussed. This chapter describes an economic evaluation 
of a beta-blocker in chronic heart failure for elderly patients.  It seeks to provide further support 
for the application of modelling based analysis in economic evaluations using clinical trial data.   
 
In Chapter 2 the type of the modelling was classified as decision trees, Markov models and 
individual sampling methods.  It was argued that a Markov model is suitable for modelling 
chronic disease with recurrent events.  When the simulation methods were discussed, it was 
stated that individual level simulation methods provided more flexibility in reflecting the 
influence of individual attributes.  
 
A Markov model represents stochastic processes that evolve over time.  A cohort of patients is 
classified by a finite number of states that are mutually exclusive and exhaustive. Patient 
movement among the Markov states over time is defined by a set of transition probabilities.  
Chapter 5 addressed the primary limitation of a Markov model of non–memory, whereby the 
transition probabilities do not depend on how long a patient has been in the current state. With 
modern computing capabilities, an individual simulation model can be developed based on a 
Markov modelling framework, in which additional variables can be attached to each patient to 
record duration of treatment and changes in risk profile, updating transition probabilities where 
appropriate. Thus, when conducting Monte Carlo simulation to evaluate a Markov model, a set 
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of tracker variables can be created to carry a patient’s baseline characteristics and to monitor 
duration on treatments. By doing so, each patient may be followed through the model pathway 
individually and their transition probabilities or risk profiles can be updated at any given time. 
  
This chapter presents a cost-effectiveness analysis of the Study of Effects of Nebivolol 
Intervention on Outcomes and Rehospitalisation in Senior population with heart failure 
(SENIORS).   The study aimed to compare the costs and outcomes for nebivolol and standard 
care in elderly patients with heart failure. An individual simulation model, based on a Markov 
modelling framework, is presented.   The analysis was conducted using the computer program 
TreeAge Pro 2007 (TreeAge Software, Williamstown, MA). The reason for choosing individual 
level simulation was to simulate the trial population and project the cost-effectiveness beyond 
the trial period.  This chapter is based on a published study (Yao et al., 2008) but the analysis 
presented in the thesis is an extension of the original work.  
 
7.2 Background 
 
Heart failure is a common condition with disabling symptoms and a poor prognosis. In Europe, 
around 1% of persons are affected, with both incidence and prevalence increasing sharply with 
age (Cowie et al., 2002; Cowie et al.,1997; Ho et al., 1993). The condition accounts for about 
2% of all health care spending (Stewart et al., 2002). 
 
Several large randomised trials and meta analyses have indicated that beta-blockers reduce the 
risk of hospital admissions for worsening heart failure and the risk of death in patients with mild 
to moderate heart failure (Hall et al., 1995; Packer et al., 1996; The CIBIS-II Investigators and 
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Committees 1999).  Shibata and colleagues (2001) conducted a systematic review which 
identified 22 beta-blocker trials with the mean patient age at baseline for all the studies ranging 
between 48 and 67 years. 
 
7.3 Overview of SENIORS  
 
SENIORS was a randomised, double-blind, parallel-group, multicentre, international trial 
comparing nebivolol with standard care in elderly patients with heart failure on standard therapy 
who were not  treated with beta-blockers (Flather et al., 2005). Eligible patients had to be aged 
70 years or older, provide written informed consent, and have a clinical history of chronic heart 
failure with at least one of the following features: documented hospital admission within the 
previous 12 months with a discharge diagnosis of congestive heart failure or documented left 
ventricular ejection fraction less than 35% within the previous 6 months.  Nebivolol or standard 
care tablets were provided in identical packaging and tablet appearance.  The first patient was 
enrolled in September 2000, the last patient in December 2002.  The date of study end was 
specified as 15 November 2003 for all patients.  A total of 2135 patients were enrolled from 11 
countries.  A total of 2128 patients, 1067 in the nebivolol group and 1061 in the standard care 
group, were followed in the trial. Baseline drug usage was recorded within the trial with Ace 
inhibitors used in 82.1% of subjects at baseline.  Angiotensin receptor blockers were used in 
6.6% of subjects, and aldesterone antagonists were used in 27.6%.   
 
The clinical study demonstrated the direct health benefits in elderly patients with chronic heart 
failure (CHF) treated with nebivolol compared with standard care. The primary outcome of death 
or cardiovascular hospital admission occurred in 332 patients (31.1%) on nebivolol compared 
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with 375 (35.3%) on placebo [hazard ratio (HR) 0.86, 95% CI 0.74–0.99; P = 0.039]. These 
benefits included a 14% reduction in the primary outcome – composite of all cause mortality or 
cardiovascular hospital admission (time to first event).  
 
The aim of this chapter was to evaluate the cost-effectiveness of nebivolol compared with 
standard care in elderly patients with heart failure.  A Markov model based on individual patient 
simulation was developed, populated with input data from SENIORS.  Estimates have been 
provided for the incremental cost per life year and cost per QALY gained based on the 
SENIORS study. 
 
7.4 Model description 
 
A Markov model (Sonnenberg, 1993) based on individual simulation was constructed. The 
model inputs were populated from the clinical data in the SENIORS trial.  In the model structure, 
the treatment effect and age component on mortality are separated.  Death is sub-classified by 
causes of death, including death due to heart failure, sudden death and other mortality.  The 
model serves to extrapolate trial periods to patient’s life time.  It also extrapolated trial 
population to different settings – such as a much younger group and enables comparisons with 
other treatment effects.     
 
Health states were defined by New York Heart Association (NYHA) classification and death.  A 
monthly cycle length is used in the model.  Figure 7.1 illustrates the model structure at a given 
NYHA class and a given cycle.  During each cycle patients could die, be hospitalised for 
cardiovascular disease, or remain stable. Causes of death were sub categorised as: death due to 
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other causes, sudden death, or cardiovascular (CV) death.  The risk for each event depended 
upon how long a patient was on treatment and their NYHA class at that cycle.  Risk for other 
causes of death depended upon the patient’s age and gender.  
 
Figure 7.1* Basic schematic diagram of the model structure at a given NYHA class II 
*The structure of the model for other NYHA classes was identical but with different transition probabilities and risk 
of unplanned hospitalisation. Each clone indicates that the patient will follow the pathway indicated at point A on 
the figure. 
 
Admissions to hospital due to CV causes were classified into myocardial infarction, stroke or 
worsening heart failure, in which risk of in-hospital death was assessed.  The risk of each event 
in a given cycle depended upon the patient’s baseline characteristics, duration of treatment and 
NYHA class.  If no events occurred (e.g. where no death or hospitalisation event occurred) a 
patient was classified as being in a stable condition and the patient’s NYHA class could improve, 
remain constant or deteriorate.  Transition probabilities among NYHA class were assumed to be 
fixed over time when a patient was in a stable disease state, but the probability of remaining in a 
stable disease state reduced over time.   
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At the start of the simulation, a cohort of 10,000 patients was generated. Each patient was 
characterised by age, gender and NYHA class.  A maximum tolerated beta-blocker dose for each 
individual was also specified.  Patients entered the model for different treatment options in 
parallel.   Patients’ baseline characteristics defined their profile of risk of specific events.  
 
7.5 Model assumptions 
 
The SENIORS study (Flather et al., 2005) recruited an elderly heart failure population with a 
mean age at baseline of 76.1 years.  In order to study drug effects on different population 
cohorts, the cause of death was separated by age, based on the UK general population mortality 
rate, excluding cardiovascular (type) deaths.  The study found that nebivolol treatment reduced 
cardiovascular (CV) related hospitalisation and CV related death, and had no effect on non-CV 
events.  By identifying the cause of death in this way in the model we can compare directly the 
effect of nebivolol in different age cohorts. 
 
Any CV death that occurred in hospital involved a hospital stay cost.  Sudden death events that 
happened outside of hospital are assumed to have no additional costs.  
 
7.6 Input data 
 
Tables 7.1-7.6 list all input values used in the model.  The following sub-sections provide details 
on how those input values were derived and estimated. 
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7.6.1 Estimating the baseline functions and risk  
 
Estimated baseline functions of the time to sudden death and the time to hospitalisation were 
based on the parametric survival analysis. Five parametric survival functions were fitted to 
observed time-to-event data using SAS software. Akaike information criterion (AIC) was 
employed in choosing the most appropriate model. Weibull distribution functions were selected 
for both of the time-to-events survival time as they had the best model fit based on the Akaike 
Information Criterion (Appendix 4). The baseline survival function of the time to the first CV 
hospitalisation in standard care was estimated from SENIORS individual patient data. A Weibull 
function was fitted for the baseline with a scale parameter of 0.0386 and shape parameter 0.7957 
(Table 7.1). Similarly parametric survival analysis was employed to estimate survival property of 
time to sudden death based on individual data from the trial. AIC indicated that a Weibull 
function was the best fitted one for the baseline survival function on standard care. It was 
estimated that a scale parameter of 0.007 and shape parameter 0.8535 for the function.   
 
The hazard ratios for time to sudden death and time to CV hospitalisation were reported 
previously for nebivolol treatment compared to standard care ((Flather, et al., 2005; Yao et al., 
2008). Table 7.2 presents the hazard was 0.618 (95%CI 0.420 to 0.910) and 0.8849 (95% CI 
0.7464 to 1.0492) for sudden death and hospitalisation respectively for nebivolol compared with 
standard care. The hazard ratios of NYHA class I/II compared with NYHA class III/IV on 
sudden death and CV hospitalisation were estimated from SENIORS study data.  The hazard 
ratio for sudden death (NYHA class III/IV as base) was 0.511 (95% CI 0.346 to 0.754) and for 
CV hospitalisation was 0.5728 (95% CI 0.481 to 0.682).  The same hazard ratios of NYHA class 
were applied to all treatment groups.   
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7.6.2 Death due to other causes 
The model was based on individual simulation. In the base case scenario, all patients started at 
age 70.  Gender and NYHA class profiles were simulated based on SENIORS trial data.  Tracker 
variables were employed to follow patients’ ages.  Mortality for other causes was derived from 
the UK population based on age and gender specific mortality excluding cardiac related death. 
 
7.6.3 Estimates of transition probabilities among NYHA class 
The SENIORS trial collected individual patient information on NYHA class at baseline and 
every visit thereafter.  It was assumed that the transition between the first visit in the 
maintenance phase and the following visit was three months.  Transition probabilities based on 
those two data points were estimated.  Monthly transition probabilities were derived by assuming 
constant transition probabilities using matrix algebra (Table 7.3). 
 
7.6.4 Estimates of health utility scores 
The SENIORS trial did not identify a difference in the distribution of NYHA classes between the 
treatment and standard care groups, and provided no evidence of improvement or deterioration in 
NYHA classes between the two treatment groups.  Utility scores were applied on the basis of 
patients’ NYHA class regardless of treatment assignment.  Utility scores on each NYHA class  
(Table 7.4) were based on the reported results of the CARE-HF study (Yao et al., 2007).  Life 
years were weighted by the utility scores to estimate QALYs.  
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When a patient experienced a CV hospitalisation a disutility of 0.1 was applied for that event.  
This assumption was based on the difference in utility scores between two consistent NYHA 
classes.  
  
7.6.5 Estimating costs 
The economic analysis was conducted from the National Health Service (NHS) UK perspective, 
hence only costs relevant to the NHS were included.  Costs of CV hospitalization, drug costs and 
GP visit costs were included.  The cost of treatment for severe adverse events was captured in 
CV hospitalisation.  It was assumed that any difference due to nebivolol treatment was captured 
by the different risks of cardiovascular hospitalisation.  Tables 7.5 and 7.6 show the all relevant 
costs.  
 
Drug costs 
The dosage of a patient on nebivolol treatment was based on the maximum dosage, which 
patients maintained during the treatment periods in the SENIORS study (Table 7.5).  The unit 
costs of nebivolol were taken from the British National Formulary (BNF, 2007).  Cost per mg 
was derived based on the available information on specific dosage.   
 
All patients on both treatments incurred costs for other relevant cardiac medication.  The 
baseline daily cost was estimated from case notes which were collected alongside the SENIORS 
trial data.  Unit costs were based on the British National Formulary (BNF, 2007).  Medication 
costs were based on all available information from the SENIORS trial using individual patient 
data usage and dosage.  Missing doses were imputed using the median value on the specific 
items.  The mean daily cost in pounds was estimated to be £0.493, the median £0.302 and 
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standard deviation 0.969. The same value was applied for baseline drug cost to both treatment 
groups.  For probability sensitivity analysis, a lognormal distribution was applied to consider the 
uncertainty related to daily baseline drug costs.  
 
GP visit costs 
Monthly GP visits were assumed for nebivolol patients for the first 3 months.  Subsequently, 
patients were assumed to have a GP visit every three months.  The cost per GP visit was 
multiplied by the number of visits.  For the standard care group we assumed one GP visit every 
three months.  
 
CV Hospitalisation costs 
 
Hospitalisation costs included a subgroup of hospitalisations due to stroke, MI and worsening 
heart failure in which all other CV events and worsening heart failure events were included.  
Rates of events were derived from the SENIORS trial and the National Schedule of Reference 
Costs (Department of Health, 2008) was applied.   Primary care per visit and out-patient 
attendance costs, were based on the Unit Costs of Health and Social Care (Curtis, et al., 2006), a 
standard source. 
 
In the SENIORS trial, no outpatient visit data was available. It was assumed that every CV 
hospitalisation was followed by two outpatient attendances.  The same cost was applied for all 
treatment groups where a patient was admitted to hospital for a CV cause, regardless of which 
treatment group they were in.  Those costs are presented in Table 7.6. 
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7.7 Base case 
 
For the base case, the analysis considered a cohort aged 70 and estimated the lifetime cost per 
life year.  This duration was chosen to capture the whole distribution of survival benefits.  A 
variety of treatment group characteristics, for their implication on cost-effectiveness, were 
investigated. A discount rate of 3.5% annually for costs and benefits was adopted over longer 
time periods.   
 
7.8 Probabilistic sensitivity analysis 
 
Probabilistic sensitivity analysis (Briggs, et al., 1994) across key input values was conducted.  
The key input values and their respective distributions used to examine second order uncertainty 
are listed in table 7-6.  Each set of random input values was drawn based on their specific 
distributions for every 10,000 patients and the results were iterated 1,000 times.  This provided 
us with confidence intervals to illustrate uncertainty for cost per life gained and cost per QALY 
gained. 
 
The choices of distributions for particular parameters were based on a general approach by using 
the distributional form that relates to the estimation of the parameter of interest (Claxton, et al., 
2005).  For binormal data, a beta distribution was used for binormal data and Dirichlet 
distribution function were used for multinormal data. Those are standard and theoretically 
justified (Briggs, et al., 2006). 
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All treatment effects such as hazard ratios were estimated from a Cox proportional hazard model 
in the log hazard scale. Therefore log-normal distributions were assigned to all hazard ratios for 
unplanned hospitalization, sudden death and NYHA classes. For different events of 
hospitalisation, a Dirichlet distribution was assigned.   
 
In the case of unit cost of different hospitalisation events, triangle distribution functions were 
used, due to cost data being positive. Normal distribution would not be appropriate.  Lognormal 
or Gamma distribution may better reflect the potential variability on those items.  However, only 
mean and upper and lower quartile data were available.  Defining these distributions would 
require additional information on the variability.  Here the choice of triangular distributions as a 
convenience 
 
The choice of the number of runs was based on an iterative process.  In the case of 1,000 for 2nd 
order uncertainty, an initial 500 runs were tried in which the result showed a high degree of 
variability. Then the number was increased to 1,000, at which point reasonably stable results 
were achieved from different runs. Similarly, the choice of 10,000 on the 1st order uncertainty 
went through the same trial-and-error approach. The chosen number of runs is consistent with 
current practice as noted by Andronis and colleagues (2009). 
 
7.9 Result 
7.9.1 Base case 
Table 7.7 describes the costs, life years and QALYs accrued by treatment groups.  For the 
standard care and nebivolol groups, the total cost per patient was £4,560 and £6,284, mean life-
years were 7.547 and 8.378, and QALYs were 5.194 and 5.843 respectively. The probabilistic 
  
157
sensitivity analysis provided an incremental cost of £1,742, incremental life years were 0.831 
and QALYs were 0.649.  Thus the incremental cost-effectiveness ratio was £2,074 (95% CI 
1,947 to 1,947) per life year, and £2,656 (95% CI 2,814 to 2,814) per QALY. 
 
Figure 7.2 describes the cost-effectiveness acceptability curves.  At a given willingness to pay 
per QALY of £20,000 the probability of treatment of nebivolol being cost effective compared to 
standard treatment is 100%.   
 
 
Figure 7.2 Cost-effectiveness acceptability curve of nebivolol compared with standard 
treatment 
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Sensitivity analysis for different starting ages of treatment is described in Table 7.8 and Figure 
7.3.  The incremental cost-effectiveness ratios for life years and QALYs increase with age. 
However, they are all well below the UK bench mark of willingness to pay of £20,000 per 
QALY.   
 
 
Figure 7.3 Increment cost per QALY at different ages of starting of nebivolol 
       treatment in Pounds 
 
7.9.3 Model Validity  
 
The internal validity of the model output was assessed by estimating the shorter term effects and 
comparing these with the trial analysis from SENIORS.  
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hospitalisation were almost identical to the trial-based analysis.  Sudden death was slightly lower 
than the trial-based analysis (which is itself estimated with uncertainty).  This data supported the 
assumption that sudden death only occurred outside hospital, with any sudden death occurring in 
hospital included in the CV hospitalisation episodes.  Total cardiac related deaths estimated in 
the model were also confirmed by the trial based results.   
 
Secondly, the model was further validated by running different lengths of treatment by using the 
SENIORS population.  The all cause mortality rate (Figure 7.4) and all clinical events at 
different time points are presented in Table 7.10.  These results reinforced the robustness of the 
model.  
 
 
Figure 7.4 Model predicted mortality rate at different length 
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7.10 Discussion 
 
This chapter described a practical application of using a Markov modelling framework and a 
parametric survival function in extrapolating beyond a trial.  The primary objective of this work 
was addressed, employing a model-based analysis in which input data was populated from a trial.  
By employing individual simulation, a trial population can be mirrored and the result can be 
validated from model based analysis and observed clinical events.  The methodology implication 
proposed in chapters 4 and 5 was revisited and illustrated.  The flexibility of using a Markov 
model to extrapolate cost-effectiveness implications beyond a trial was emphasised.   
 
In this chapter, the cost-effectiveness of nebivolol were estimated in an elderly population with 
chronic heart failure, with severity and patient characteristics based upon the SENIORS trial. 
This is the first study which addressed the cost-effectivenss of beta-blocker treatment in elderly 
patients group.  It was found that the routine use of nebivolol in this population would be a cost-
effective strategy. The estimated results from the model were validated against the actual 
observed events from the SENIORS study. 
 
SENIORS enrolled a population of elderly heart failure patients with a wide range of ejection 
fraction, including about one third with ejection fraction greater than35%.  There were about 
1300 patients aged 70 or over in the MERIT-HF study (The MERIT-HF Study Group, 1999) 
which evaluated metoprolol-XL.  There was reasonable evidence of efficacy of metoprolol XL in 
this elderly subgroup, although data was not published separately, and MERIT did not include 
patients with ejection fraction >40% in contrast to SENIORS.  Other trials, including the 
carvediolol studies and CIBIS-II (The CIBIS-II Investigators and Committees, 1999), do not 
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have large enough numbers of patients to provide reasonable evidence of efficacy of these beta-
blockers in the elderly.  Thus SENIORS is the only large heart failure trial to specifically address 
the role of beta-blockers in the elderly and to provide clear evidence of clinical and cost-
effectiveness. 
 
One of the strengths of this analysis was the utilisation of individual patient data from the 
SENIORS trial in populating the economic model.  A further strength is the appropriate 
sophistication of the model employing tracker variables, which extend the Markov framework to 
enable the risk of events to be varied with time.  In addition, the model was based on individual 
patient simulation.  Each individual was generated with a specific profile at the start of the 
simulation.  This provided considerable flexibility for the model to extrapolate beyond the trial 
periods both in time horizon and for different patient characteristics. 
 
Several other studies suggest that beta-blockers for heart failure could be cost-effective or even 
cost saving to society (Caro et al., 2005; Cowper et al., 2004; Levy et al., 2001; Vera-Llonch et 
al., 2001). Levy and colleagues (2001) demonstrated the incremental cost-effectiveness ratios 
(ICERs) of $4,140 and $8,394 per life-year gained when carvedilol or metoprolol are used 
compared to conventional therapy, respectively. for subjects aged 60 years.  Cowper and 
colleagues (2004) estimated that beta-blocker therapy increased survival by 0.3 years per patient 
and reduced societal costs by $3959 per patient over 5 years.  Caro and colleagues (2005) 
predicted the positive effect of metoprolol succinate on mortality and morbidity, as demonstrated 
in the MERIT-HF trial leading to substantial savings in patients with a mean age of 63.7 years  
over 2 years, from a US perspective. 
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However, no other study has addressed the cost-effectiveness of beta-blocker treatment in elderly 
patients.  Since SENIORS was targeting a population that is not commonly included in clinical 
trials, the current study reported the potential health economic benefit of a strategy which 
incorporated routine nebivolol use for elderly patients with heart failure.  
 
A potential limitation of this study is that the comparator for this analysis is standard care and the 
additional question of the appropriateness of nebivolol or an alternative beta-blocking agent in 
this population has not been addressed. 
 
Furthermore, the analysis was based on patient level simulation while exploring the second order 
uncertainty using Monte Carlo simulation, which is computationally expensive. Methods that can 
be used to improve the efficiency of this type of modelling (O’Hagan et al., 2007 & Stevenson et 
al., 2004).) have not been explored in this study  
 
As discussed above, the only other beta-blocker with reasonable evidence of efficacy in the 
elderly is metoprolol XL which is not available in the UK. The use of other beta-blockers 
including carvedilol and bisoprolol in elderly patients is largely based upon evidence in younger 
patients with a low ejection fraction.  Further, no other beta-blocker has been evaluated in a 
directly similar population to that considered in SENIORS (in particular the age structure) which 
raises questions about the appropriateness of comparing nebivolol (established therapy in an 
elderly population) with an alternative therapy without direct evidence supporting its use in that 
population. 
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However, such a comparison could be realised by modelling-based analysis.  For example, there 
are no direct head-to-head comparison trials between nebivolol and carvedilol, but individual 
trials in which both nebivolol and carvedilol have been studied compared with placebo are, 
respectively, the SENIORS (Flather et al., 2005) and the CAPRICORN (The CAPRICORN 
Investigators, 2001) trials.  The model developed in this chapter could be adopted to assess the 
cost-effectiveness of nebivolol vs. carvedilol.   This thesis focused on economic evaluation based 
on a randomised clinical trial. Indirect comparison of nebivolol with other beta-blocking agents 
was beyond the scope of this work.  
 
7.11  Conclusion 
 
In conclusion, this analysis indicates that nebivolol appears cost-effective when compared with 
standard treatment thresholds (Appleby et al., 2007) and indicates an incremental benefit with 
the use of nebivolol in this setting.  This finding should be interpreted in the context of the 
available evidence for the efficacy of different agents in different settings.  In particular, 
SENIORS provided large scale evidence on the effectiveness of nebivolol in an elderly 
population with heart failure with or without evidence of left ventricular systolic dysfunction. 
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Table 7.1 Baseline survival function of time to first hosiptalisation event and time to 
sudden Death 
 Scale Shape Distribution 
Weibull Baseline hazard Function of 
Hospitalisation (monthly) 
0.0386 0.7957 Fixed 
Weibull Baseline hazard function of sudden death 
(monthly) 
0.007 0.8535 Fixed 
 
Table 7.2 Hazard ratio of hospitalisation and sudden death of Nebivolol vs. standard 
treatment 
 Hazard ratios 
(Expected Mean) 
95% CI Upper 95% CI Lower Distribution 
Time to First Hospitalisation 
Event 
0.8849 0.7464 1.0492 Lognormal 
NYHA class I/II vs. 
NYHA class III/IV 
0.5728 0.4810 0.9147 Lognormal 
Time to Sudden Death 0.618 0.420 0.910 Lognormal 
NYHA class I/II vs. 
NYHA class III/IV 
0.511 0.346 0.754 Lognormal 
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Table 7.3 Transition probabilities among NYHA class (monthly) 
From / to NYHA Class Distribution 
I II III IV 
NYHA class I 0.977 0.019 0.004 0.000 Dirichlet 
(60.25, 1.25,0.25,0.25) 
NYHA class II 0.008 0.981 0.010 0.001 Dirichlet 
(10.25,1169.25,12.25,1.25) 
NYHA class III 0.000 0.034 0.959 0.006 Dirichlet 
(0.25,1.25,5.25,41.25) 
NYHAclass IV 0.000 0.000 0.055 0.945 Dirichlet 
 
 
Table 7.4 Utility scores and initial distribution of NYHA class 
 NYHA Class Distribution 
I II III IV 
Utility Scores 0.815 0.72 0.59 0.508 Conditional Beta 
Initial distribution 0.029 0.564 0.387 0.02 Dirichlet 
(61;1200;824;43) 
  
Table 7.5 Drug dosage and cost 
Maintenance dose (mg) Number People Percentage Unit cost (£ )/mg Distribution on Dosage 
1.25 69 12.4% 0.0663 
 
Dirichlet 
(69 73 127 688) 
 
 
2.5 73 7.2% 0.0663 
5 127 12.5% 0.0663 
10 688 67.9% 0.0663 
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Table 7.6 Hospitalisation, outpatient visits and GP visit cost and related distributions 
Costs of CV hospitalisation Mean cost(£ ) Lower Upper Distribution 
Worsening of heart failure 2875 1076 3361 Triangle distribution 
Occurrence of stroke 2671 977 4006 Triangle distribution 
Occurrence of myocardial infarction 2271 965 3012 Triangle distributions 
Outpatient visit – adult 113 93 153 Triangle distributions 
Prescription GP visit 34.6   Fixed 
  
 
 
Table 7.7 Baseline cost-effectiveness result (age at starting of treatment at 70) 
 
 
 
 
Cost 
(£ ) LYs 
 
QALYs 
 
Incremental 
 
ICER 
(95% CI) 
Cost (£) LYs QALYs £/Life year £/QALY 
Standard care 4560 7.547 5.194      
Nebivolol 6284 8.378 5.843 1724 0.831 0.649 
2074 
(1947 to 1947) 
2656 
(2814 to 2814) 
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Table 7.8 Sensitivity analysis of ICER to age at the beginning of treatment (in QALYs) 
Starting 
Age 
Treatments Cost (£ ) 
Incremental  
Cost 
QALYS 
Incremental 
QALYs 
ICER 
(£/QALY) 
60 
Standard care 5316  6.208   
Nebivolol  7568 2252 7.201 0.994 2265 
65 
Standard care 4889  5.692   
Nebivolol  6862 1973 6.493 0.801 2463 
70 
Standard care 4560  5.194   
Nebivolol  6284 1724 5.843 0.649 2656 
75 
Standard care 3993  4.439   
Nebivolol  5424 1431 4.923 0.484 2957 
80 
Standard care 3463  3.832   
Nebivolol  4634 1171 4.160 0.327 3580 
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Table 7.9 Estimated event rates by model based compared with trial based result 
(SENIORS trial) 
Events Model based SENIORS Trial result 
 
Nebivolol (%) 
( 95% CI) 
Standard care (%) 
(95% CI) 
Nebivolol (%) 
(95% CI) 
Standard care (%) 
(95% CI) 
All causes of death 
15.5 
(14.8 - 16.2) 
18.4 
(17.6 - 19.2) 
15.8 
(13.6 - 18.0) 
18.0 
(15.7 - 20.3) 
Non-CV of death 
5.5 
(5.0 – 5.9) 
5.4 
(5.0 – 5.9) 
5.3 
(4.0 - 6.6) 
4.4 
(3.2 - 5.6) 
Sudden death* 
3.9 
( 3.5 – 4.3) 
6.3 
(5.8 – 6.8) 
4.1 
(2.9 - 5.3) 
6.6 
(5.1 - 8.1) 
HF death 
6.7 
( 6.2 – 7.2 ) 
7.4 
(6.9 – 8.0) 
7.4 
(5.8 - 9.0) 
7.0 
(5.5 - 8.5) 
Hospitalisation 
21.2 
(20.4 – 22.0) 
23.4 
(22.6 – 24.3) 
23.9 
(21.3 - 26.5) 
25.9 
(23.3 - 28.5) 
CV death 
10.6 
(9.7 – 11.5) 
13.8 
(12.7 – 14.8) 
11.5 
(9.6 - 13.4) 
13.6 
(11.5 - 15.7) 
All patients started treatment at age 76.1 and time frame for the model was 21 months.   
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Table 7.10 Model predicted events at different time length 
Events Months Nebivolol Standard care 
Death all 
12 8.4% 9.8% 
24 17.3% 20.2% 
36 24.1% 27.9% 
48 31.9% 36.8% 
60 37.5% 42.2% 
Non CV death 
12 2.7% 2.7% 
24 5.8% 5.8% 
36 9.5% 9.1% 
48 12.7% 12.3% 
60 15.3% 14.7% 
HF death 
12 4.1% 4.5% 
24 7.5% 8.3% 
36 9.3% 10.4% 
48 12.0% 13.0% 
60 13.2% 14.8% 
Sudden death 
12 2.4% 3.6% 
24 4.6% 6.8% 
36 5.7% 8.9% 
48 7.7% 12.1% 
60 9.4% 13.2% 
CV hospitalisation 
12 14.0% 15.6% 
24 23.9% 26.2% 
36 30.3% 32.9% 
48 36.3% 39.0% 
60 39.9% 43.3% 
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CHAPTER 8 GENERAL DISCUSSION AND CONCLUSIONS 
 
8.1  Introduction           
 
The aim of this chapter is to revisit the objectives proposed at the beginning of the thesis and 
review how these have been achieved.  The chapter then summarises the major findings reported 
in previous chapters, followed by comparison with similar work reported in the literature. The 
main contributions of the thesis are highlighted and its limitations and recommendations for 
further research are also addressed.   
 
The primary aim of the thesis is to report new evidence of cost-effectiveness studies in heart 
disease. This was realised by three cost-effectiveness studies: one in nurse-led secondary 
prevention clinics for coronary heart disease in primary care, one on cardiac resynchronisation 
therapy with or without an implantable cardioverter defibrillator in chronic heart failure, and the 
final one on a new drug therapy, nebivolol, compared with standard treatment in elderly patients 
with heart failure. 
 
The second aim of the thesis regarded the application of modelling methodology, with a view to 
providing general recommendations in using Markov modelling approaches in economic 
evaluation conducted in the heart disease area. Emphasis was on the provision of practical 
guidance on how to conduct model-based analysis, in which the primary input data for the model 
were from a trial.  The focus was on extrapolation of cost-effectiveness of an intervention 
beyond a trial both in terms of the time horizon of the analysis and in relation to the population 
involved.  
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The first step of this thesis was to provide a general review of current cost-effectiveness analysis 
and methodological aspects in economic evaluation conducted in heart disease.  The literature 
search was conducted in a thorough and rigorous manner and provided a broad view of the 
approaches to conducting economic evaluation based on clinical trials in the clinical area of heart 
disease.     
 
This was followed by a case study on the nurse-led secondary prevention clinical study, 
presented in Chapter 3. This was a trial based analysis without seeking long-term cost-
effectiveness results over longer periods.  The study highlighted potential limitations of within 
trial period analysis in economic evaluation.       
 
The applications of methodology reported in the thesis were on methods in economic evaluation 
when extrapolating beyond trials. First, the use of parametric distribution functions in 
extrapolating survival curves beyond a trial was explored, and second, a Markov modelling 
framework based on individual patient simulation was discussed.   
 
Two empirical studies were then presented in Chapters 6 and 7, both of which employed model-
based analysis. Parametric survival functions were fitted into observed data and the most 
appropriate distribution functions were adopted to extrapolate survival curves beyond the trial 
periods.  Markov modelling approaches based on individual patient simulation were later 
presented. The risk of different events over time and beyond the trial periods were estimated 
from the best fitted distribution functions.  
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8.2 The contributions of the thesis 
 
The substantive contributions from this thesis research fall under two main areas: contributions 
from the empirical components, where the focus is the three case studies of the thesis; and the 
contributions from the application of methodological issues in economic evaluation, focusing on 
an illustration of applying Markov modelling methods in conducting economic evaluation in 
situations where extrapolating beyond a trial was needed.  
 
8.2.1 Empirical contribution 
The primary contributions of this thesis were on the new evidence on the costs, effects and cost-
effectiveness of interventions in heart disease.  Each of the three case studies was novel in an 
empirical sense, representing the first cost-effectiveness study to address the clinical question at 
hand. 
 
The first case study presented in Chapter 3 reports on the cost-effectiveness of nurse-led 
secondary prevention clinical study.  This study was the first to examine the cost-effectiveness of 
nurse-led secondary prevention clinics in primary care.  The cost-effectiveness analysis by the 
end of the trial period demonstrated that nurse-led clinics are highly cost-effective when 
compared with usual care.  The findings were more consistent with current recommendations and 
practice on secondary prevention and provide a plausible explanation for the observed reduction 
in mortality.  
 
 The second case study, presented in Chapter 6, was on the cost-effectiveness analysis of a 
cardiac resynchronisation device.  This study was the first to address directly the cost-
effectiveness of CRT-P compared to CRT-ICD.  In addition, the study took a life-time approach 
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and so extrapolated well beyond the trial period, for example with regard to important issues 
such as device replacement, which none of the existing trials had had long enough follow-up 
periods to address.   
 
The third case study, presented in Chapter 7, was on the cost-effectiveness of nebivilol in elderly 
patients. The study was the first paper to address the cost-effectiveness of beta-blocker treatment 
in an elderly patient group.  Since the SENIORS trial targeted a population that was not 
commonly included in clinical trials, the current study reported the potential health economic 
benefit of a strategy which incorporated routine nebivolol use for elderly patients with heart 
failure.    
 
8.2.2 Contribution on application of methodological approaches 
The major contribution of this work on the application of methodological approaches was to 
provide an illustrative guidance on conducting model-based economic evaluation when 
individual data from a trial is available.  It provides real world examples of developing model-
based analyses.  This was achieved by revisiting fundamental issues in parametric distribution 
functions and Markov modelling approaches. It adds value to the current health economics 
literature in heart disease, enriching the literature with its detailed consideration of which 
parametric distribution functions should be employed when extrapolating survival beyond a trial 
and how they could be adopted into model-based analyses.  Chapter 4 provided detail of the 
systematic steps that should be followed when choosing a candidate function based on observed 
data.  Chapter 5 provided a stepwise illustration of a Markov modelling property and how to 
relax the classical assumptions, providing a solid view of different simulation methods, the 
weakness and strength of which were discussed.   
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These methods were then applied in Chapters 6 and 7 to provide examples of real case studies of 
conducting economic evaluation alongside clinical trials, how to fit survival functions based on 
individual trial data and how to conduct model-based analyses. 
 
8.3 New evidence of cost effectiveness findings in heart disease 
 
8.3.1 Major findings in case study 1 
Chapter 3 presented a case study of an economic evaluation conducted within a trial analysis, 
where the focus was nurse-led secondary care prevention for coronary heart disease. The study 
revealed that the mean cost per patient for standard care within the trial period was £879 (95% 
CI 824 to 934) compared with £1015 (95% CI 956 to 1074) per patient in the nurse-led clinics 
group.  Within the trial period, the incremental QALYs gained were 0.11 (95% CI 0.02 to 0.20) 
and the incremental costs per QALY gained was £1261 (95% CI £913 to £23,516) for the nurse-
led clinic compared with the control group. The estimated mean QALY was below the notional 
willingness-to-pay threshold of £20,000/QALY.  
 
The cost-effectiveness result by the end of the trial period presented favourable cost 
effectiveness results for nurse-led clinics.  The initial set-up cost for running nurse-led clinics 
was generally balanced within the trial periods.  Even if one was to extrapolate beyond the trial, 
the expected result would be that the intervention could still have a very low incremental cost-
effectiveness ratio.  
 
However, what was observed in this clinical study, in terms of such a long follow up in a clinical 
trial, is very rare.  Most clinical trial data aims for a short-term clinical outcome.  In most 
economic evaluations researchers are faced with the need to seek longer-term implications for 
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cost-effectiveness results. Reliance on measurement of short-term outcomes is justified if the 
intervention will not also have long-term effects on outcome but most interventions have much 
longer clinical and economic benefits than those captured in the trial period.  Extrapolating 
beyond a trial is therefore needed in most studies when trial-based economic evaluation is carried 
out.  
 
8.3.2 Major findings in case study 2 
Chapter 6 presented a model based analysis populated with data from CARE-HF to evaluate the 
long-term incremental cost-effectiveness of cardiac resynchronisation therapy (CRT-P) and 
medical therapy (MT) compared to MT alone.  In addition, the cost-effectiveness of adding an 
implantable cardioverter-defibrillator (CRT-ICD) plus MT vs. MT and the relative cost-
effectiveness of CRT-P and CRT-ICD were also evaluated by incorporating estimates of the 
proportion of sudden deaths that might be prevented with CRT-ICD from a different trial 
(COMPANION).  
 
The total cost per patient for CRT-ICD+MT was £59,422 compared with £36,732 and £26,572 
for CRT-P+MT and MT, respectively. The mean life-time QALYs were 6.75, 6.06 and 4.08 and 
life years were 9.16, 8.23 and 6.10 for CRT-ICD+MT, CRT-P+MT and MT, respectively.  
   
The probabilistic sensitivity analysis showed that in comparison with MT, CRT-P+MT gave an 
incremental cost of £10,160, a QALY score of 1.98 and a life year estimate of 2.13. This gives 
an incremental cost-effectiveness ratio (ICER) of £5,128 (95% CI £3,623 to £8,017) per QALY 
gained.  The incremental cost-effectiveness of CRT-ICD+MT versus CRT-P+MT, the 
incremental cost is £22,690, the QALY score is 0.70 and the life years gained was 0.93. The 
ICER here was £32,591 (95% CI £24,288 to £54,040) per QALY gained.   
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The study concluded that long-term treatment with CRT-P+MT appeared cost-effective 
compared to medical therapy alone. When considering the addition of the ICD component, CRT-
ICD+MT was beyond a notional threshold at a willingness-to-pay of £20,000 per QALY, in the 
treatment of patients with moderate to severe heart failure characterised by dyssynchrony, except 
in those who have a poor life expectancy.  
 
The analysis reported in this thesis is a further development of earlier work on a within trial cost-
effectiveness analysis using individual patient data from the CARE-HF trial (Cleland et al., 
2005). The result of the within trial analysis showed that CRT-P was associated with increased 
costs, increased survival and increased quality adjusted life years (QALYs). The within trial 
analysis suggests that CRT-P might be cost-effective over a patient’s lifetime, but this had not 
been established with trial evidence.   
 
This model-based analysis extends the previously published within trial analysis and also further 
advances the work described in the COMPANION cost-effectiveness analysis which provided 
estimates of benefit at 7 years, which were similar to those predicted by the model at 6 years.  In 
addition, the modelling work examined the incremental cost-effectiveness ratio associated with 
adding an ICD component to CRT therapy. 
  
The existing clinical trials provide considerable evidence for the long-term effectiveness of both 
CRT-P and CRT-ICD but most patients were alive and many felt well at the end of the trials.  
Patients’ treatment does not cease at the end of the trial and it is inappropriate to assume that 
benefits cease at that point. In taking a life-time approach, an important issue is device 
replacement which none of the existing trials had had long enough follow-up in order to address.  
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The model also enables the inclusion of data and other evidence from a range of sources in order 
to examine broader health policy questions.  The model provides a best-evidence synthesis of the 
likely cost-effectiveness of CRT-P and CRT-ICD. 
 
8.3.3 Major findings in case study 3 
Chapter 7 presented a model based economic evaluation populated from the SENIORS trial.  An 
individual patient based simulation model was developed to evaluate the cost-effectiveness of 
nebivolol compared with standard care in elderly patients with heart failure. Since SENIORS 
targeted a population, a group that are not commonly included in clinical trials, it is important to 
understand the potential health economic impact of a strategy incorporating routine nebivolol use 
in elderly patients with heart failure.  In this model, patient characteristics were estimated, based 
upon the SENIORS trial and demonstrated that the routine use of nebivolol in this population 
would be a cost-effective strategy.  
 
The cost-effectiveness result suggested the total cost per patient was £4,560 and £6,284; mean 
life-years were 7.547 and 8.378; and QALYs were 5.194 and 5.843 for the standard treatment 
and nebivolol groups, respectively. The probabilistic sensitivity analysis provided an incremental 
cost of £1,742, incremental life years were 0.831 and QALYs were 0.649.  Thus the incremental 
cost-effectiveness ratio was £2,074 (95% CI 1,947 to 1,947) per life year gained, and £2656 
(95% CI 2,814 to 2,814) per QALY gained. The analysis indicates that nebivolol appears cost-
effective when compared with standard treatment under notional thresholds of willingness-to-pay 
per QALY gained were £20,000.  It indicates an incremental benefit with the use of nebivolol in 
this setting.   
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An important strength of the model-based analysis was the utilisation of individual patient data 
from the SENIORS trial in populating the economic model.  The model was validated against the 
actual SENIORS results providing excellent concordance. 
 
A further strength was the appropriate sophistication of the model employing tracker variables 
which extend the Markov framework to enable the risk of events to be varied with time. In 
addition, the model was based on individual patient simulation. Each individual was generated 
with a specific profile at the start of the simulation. This provided considerable flexibility for the 
model to extrapolate beyond the trial periods both in time horizon but also for different patient 
characteristics. 
 
8.4 Major findings in application of methodology    
 
The methodology focus of the thesis has attempted to serve as an illustration of applying Markov 
modelling methods in conducting economic evaluation in situations where extrapolating beyond 
a trial is needed.  The methodology aspects in using parametric survival function in exploring the 
longer-term property of an intervention were presented in Chapter 4. This chapter focused on 
how to fit parametric survival functions based on observed data, drawing on authoritative and 
standard sources (Collet, 1994),  often used in conducting parametric survival analysis in 
medical statistics.  Methods on how to choose the best fitting survival curves and how to 
estimate parameters in a chosen distribution function were discussed and illustrated by the 
CARE-HF trial data.  
 
The research was inspired by the lack of detailed consideration in the current health economics 
literature on which parametric survival functions should be employed when extrapolating 
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survival property beyond a trial. In most cases, exponential distribution or Weibull distribution 
functions were commonly assumed and used without examining the property of the underlying 
data.  Chapter 4 concluded that more systematic steps should be followed and examined before a 
candidate function is chosen based on observed data.  
 
Parametric survival functions are useful in most cases if one wants to investigate long-term 
implications for time-to-events or survival.  However, to investigate longer-term costs or 
QALYs, it depends on health states and further events and also potentially other costs. For 
example, it is difficult to use parametric survival to cope with future events such as battery 
replacement and further CV related hospitalizations, as was seen in Chapter 6. Given that 
individuals have different risk profiles based on their age and gender, the choice of most cost-
effective options for different age cohorts is of policy and clinical relevance. 
 
In this case, a simulation model would provide a tool to incorporate further events and use 
evidence from observational studies or the literature. The future costs would more accurately be 
counted, which would never have been captured within a limited trial period.  It is more flexible 
to build a model to simulate the longer-term implications, both in cost and in QALYs.  In 
addition, a model developed based on the trial data would provide a tool to extrapolate into 
different patient groups and different clinical settings.   
 
In Chapter 5, an individual patient simulation model based on a Markov modelling framework to 
extrapolate beyond a trial was presented.  A general introduction to a Markov model and the 
overall methodological aspects of a Markov modelling framework were provided. The basic 
concept of Markov models and their properties was reviewed and mathematical formulae were 
presented for the estimation of a Markov chain model.  Limitations of the classical Markov 
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model were discussed, methods for relaxing the assumptions inherited in a classical Markov 
model were unveiled and mathematical formula for estimating transition probabilities were 
discussed and enhanced by the support of the methods presented in Chapter 4.   
 
An individual sampling approach was introduced and methods on how to adjust this into a 
Markov modelling framework proposed. By employing tracker variables for each individual 
patient in the Monte Carlo simulation to account for time on treatment and risk factors at each 
health state, time dependent events associated with each health state could be taken into account 
and their rewards in the terms of cost and QALYs could be easily summarised.  The 
methodology aspects of this approach were supported by a renal transplantation model. 
 
Two completed case studies in applying the methods presented in Chapters 4 and 5 were applied 
in Chapters 6 and 7.  Individual simulation models based on a Markov modelling framework 
were constructed. Tracker variables were used in recording individual patient’s characteristics 
and risk profiles. Time-to-event survival data were examined using accelerated time-to-failure 
models and parametric survival analysis was fitted to all time-to-event data.  Baseline functions 
on time-to-event data were fitted by the best selected distribution functions, risk profile beyond 
the trial periods were estimated and used in model transition probabilities in the Markov models.  
Model validations were presented.  The two cases studied served to illustrate how to conduct 
model-based analysis when individual data are available.  
 
The application of methods in Chapters 6 and 7 demonstrated that individual patient simulation 
based on a Markov model framework is a promising and flexible approach in extrapolating 
beyond a trial period.  Trial data provide a realistic way in deriving model parameters and a 
model framework can cope with different events and associate cost and QALYs.  The model can 
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be extrapolated beyond a trial period and, in addition, it can be used on different population 
groups by setting different characteristics for different patient populations.  
 
8.5 Comparison with other contributions 
 
Buxton and colleagues (1997) stated that trial-based economic evaluations were necessary 
although modelling analysis is essential in reality. They argued that clinical trials give high 
internal validity for comparing different treatments but were often bounded by limited outcome 
data usually collected during a short follow-up period. Unless the effect of an intervention is 
believed to stop after the trial period, reliance on measurement of short-term outcomes could not 
be justified.  This was because economic evaluation and policy-making depend upon the effect 
of longer-term outcomes, in which the interest is to improve future health with limited health 
care resources.  Therefore, economic evaluations based on clinical trials often need to extrapolate 
beyond the trial. 
 
The studies in this thesis have proved the claims made by Buxton and his colleagues that trial-
based economic evaluation were not always the ideal.  The advantage of developing model-based 
analysis methods has been illustrated. This was achieved by the economic evaluation of CRT 
compared with MT in heart failure patients, through the within trial analysis and model-based 
analysis for the CARE-HF trials.  The difference in the ICERs was compared and the advantage 
in using model-based analysis was illustrated in Chapter 6.  Chapter 7 took further steps in 
developing the model-based analysis. 
  
Philips and colleagues (2004) undertook a review of modelling in health economics and 
recommended that methods and assumptions in extrapolating beyond a trial should be 
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documented and that validation of the methodology should be conducted, for example the choice 
of survival functions should be justified.  Furthermore, they argued that life tables should be 
based on all cause mortality.  Chapters 6 and 7 serve as practical examples in following these 
guidelines.  
 
Sonnenberg and Beck (1993) provided an introduction to the Markov modelling approach in the 
medical field.  Briggs and Sculpher (1998) offered further details on the use of Markov 
modelling when performing economic evaluation. However, these two papers focused on 
methodological issues. In this thesis, I not only reviewed the methodological background of 
Markov modelling in principle, but further emphasised the flexibility and advantages of Markov 
modelling used in economic evaluation by relaxing some of the core assumptions and introduced 
individual patient simulation approaches.  
 
Sculpher and colleagues (2006) stated that clinical trials usually provide a major source of data 
in economic evaluation but also indicated that there are several limitations in a trial-based 
analysis. They recommend that a suitable time horizon should be considered.  In many situations, 
an analysis should seek a lifetime time horizon if an intervention impacts on mortality. Costs and 
benefits of interventions in health care most likely present different outcomes in the short-term.  
In Chapter 6, I further progressed the within trial-based analysis to develop a Markov model to 
extrapolate the survival and cost beyond the trial and incorporate further evidence from the 
COMPANION trial, extending the trial population into different age cohorts. Chapter 7 moved to 
directly develop a model-based analysis and provide the potential to compare other similar 
treatment instead of standard or placebo as the trial frame.  
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8.6 Strengths and limitations of the thesis 
 
One of the major strengths of the thesis is that it is based on a thorough and rigorous literature 
review on economic evaluation in cardiovascular heart disease. The inconsistencies in 
methodological approaches and lack of detail on how the analysis was conducted, highlighted 
from the review, has encouraged the development of a general guideline on how to conduct 
economic evaluation when individual data is available from a trial.   
 
Another strength of the thesis is that methods derived from other fields, including medical 
statistics and operational research, that have traditionally been used sparingly in health economic 
literature, are discussed and applied.  Chapter 4 is based on probability theory and survival 
analysis methodology, and presented the hidden properties of hazard functions which are more 
intuitive to economic evaluation when cost and effectiveness highly depend on future events.  
Chapter 5 revisited the Markov modelling property, based on operational research and utilised 
more computational advantages in developing individual patient simulations based on the 
Markov modelling framework. While the advantage of individual simulation approaches 
provided flexibility to mirror a trial population and equally provide a tool to be used on different 
populations, the clear properties in Markov model framework gives a more straight forward 
modelling structure.    
 
Furthermore, the thesis employed data from three real world RCTs, as an illustration, on novel 
and important clinical and policy questions.  All of these trials were conducted to the highest 
research standards, evidenced by their publication in high-ranking clinical journals, and provide 
real evidence of cost-effectiveness results in heart disease.  Chapters 6 and 7 were model based 
analyses, providing several additional answers beyond the trials, making them more relevant to 
policy-making, and helped answer several ‘what if’ questions.  
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Finally, the thesis reviewed the methodological background in time-to-event analysis and 
adopted a Markov modelling methodology in trial based analysis. It then presented completed 
illustrations from deriving data inputs from a trial building, model structures and validation of 
the models.   
 
There are several limitations of the thesis. Firstly, alternative modelling approaches in using 
trial-based analysis have not been investigated and it did not compare the relative efficiency of 
using other methods.  The foci of the thesis were mainly on the most frequently used Markov 
modelling approaches and so it provides guidelines in applications with particular focus on these 
methods.   
 
Furthermore, the thesis focused on a particular disease area – heart disease. Methods discussed in 
the thesis might limit its use in other disease areas. Different methodology should be explored 
when economic evaluation is conducted in other different disease areas, especially in the setting 
of infectious diseases where interaction between individuals is important. Markov models fail to 
capture such interaction. 
 
Finally, I should emphasise that the thesis is based on application of methods rather than 
methodological development.  In the thesis I focused on individual trials and aimed to provide 
guidelines for extrapolating beyond a trial.  The analysis did not include evidence synthesis for 
data input as proposed by Sculpher and colleagues (Sculpher et al., 2006).   
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8.7 Recommendations for policy and future research 
 
On a methodological note, when conducting extrapolation of a time-to-event survival beyond a 
trial, the choice of survival functions should be based, where possible, on observed data from a 
trial as the best evidence instead of making assumptions. Investigating different alternatives in 
sensitivity analysis should be encouraged.   
 
There would be great benefit derived from more empirical research to investigate the comparison 
of alternative methods in extrapolating beyond a trial. This could be achieved by employing 
longer follow up data from a trial and exploring the potential bias by artificially cutting off the 
end point earlier and investigating potential bias by employing different approaches. 
 
This thesis has used both within trial analysis and model-based analysis, with a particular focus 
on three case studies. Further research should be conducted on the relative impact of using 
different analytic approaches and using more case studies on different disease areas. This would 
provide more insight and recommendations on best practice of trial-based economic evaluations.   
 
This thesis has revisited the fundamental issues in parametric distribution functions and Markov 
modelling approaches.  The methodology aspects in using parametric survival functions in 
exploring a longer-term property of a disease profile were presented in Chapter 4. This chapter 
focused on how to fit parametric survival functions based on observed data.  The distribution 
functions and their hazard functions were discussed.  It appears that the hazard function is more 
intuitive in choosing a candidate model.  By investigating the hazard property, a best fitting 
distribution function can be chosen to represent the underlying risk profile over time.  Methods 
on how to choose the best fitting distribution functions over observed data were illustrated by 
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real trial data from the CARE-HF study.  This is a fundamental step in estimating risk profile 
beyond a trial period for use in a modelling framework. 
 
Finally, on an empirical note, the three clinical case studies in the thesis indicate their cost-
effectiveness results related to policy making.  Nurse-led clinics in primary care are highly cost-
effective. They should be recommended in a general health care setting. The study of the 
nebivolol based on SENIORS concluded that nebivolol is a cost-effective treatment to an elderly 
(mean 76.1 years) population with chronic heart failure.  It found that the routine use of 
nebivolol in this population would be a cost-effective strategy and should be considered by 
policy makers.   
 
The long-term cost-effectiveness analysis of CARE-HF trial data concluded that cardiac 
resynchronisation therapy (CRT-P) was a cost-effective treatment option compared with medical 
therapy (MT) alone.  However, adding an implantable cardioverter-defibrillator to CRT appears 
to be beyond the traditional willingness-to-pay threshold £20,000 per QALY gained and might 
not be a cost-effective option compared to CRT-P.  
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APPENDIX 1 SEARCH STRATEGY IN THE LITERATURE REVIEW 
 
 
Database: Ovid MEDLINER <2004 to August Week 1 2007>  
Search Strategy: 
#1     economic$ adj3 evaluation$.mp.  
#2     economic adj3 analy$6.mp.  
#3     cost$2 adj5 benefit$2.mp.  
#4     cost$2 adj5 effect$7.mp.  
#5    cost$2 adj5 utilit$4.mp.  
#6     #1 or #2 or #3 or #4 or #5  
#7     heart$2.ab,ti.  
#8     Heart Diseases.mp. 
#9     #7 or #8 
#10     trial$2.ab,ti. 
#11     6 and 9 and 10  
All     limited to abstracts and english language and yr="2005 - 2007" 
mp = title, original title, abstract, name of substance word, subject heading word    
ab = abstract 
ti = title  
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APPENDIX 2 DETAILS OF PAPER SELECTION IN THE LITERATURE 
REVIEW 
 
No. Study Scope of the 
Review 
Reasons for 
Exclusion 
1 Ali and Antezano 2006 Title Review 
2 Andriolo 2005 Title Review 
3 Ballok 2005 Title Review 
4 Barnes and Howards 2005 Title Review 
5 Bartlett 2001 Title Review 
6 Bieniarz and Delgado 2007 Title Review 
7 Bjork-Eriksson 2005 Title Review 
8 Boersma 2006 Title Review 
9 Bryant  2005 Title Review 
10 Bryant  2007a Title Review 
11 Bryant  2007b Title Review 
12 Burnier  2006 Title Review 
13 Castelnuovo  2001 Title Review 
14 Chattipakorn  2007 Title Review 
15 Chaudhry  2007 Title Review 
16 Cheng 2006 Title Review 
17 Chiappa  2007 Title Review 
18 Chiasson 2006 Title Review 
19 Chircop and Jelinek 2006 Title Review 
20 Clark  2007 Title Review 
21 Clegg  2006 Title Review 
22 Clegg  2007 Title Review 
23 Collins and Gurm, 2007 Title Review 
24 Cooper  2006b Title Review 
25 Croom and Plosker, 2005 Title Review 
26 Croom  2005b Title Review 
27 Dauerman  2007 Title Review 
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28 Daviglus  2006 Title Review 
29 Ebrahim  2006 Title Review 
30 El-Menyar 2005 Title Review 
31 Ermis and Benditt 2006 Title Review 
32 Feringa  2007 Title Review 
33 Field and Sweeney 2006 Title Review 
34 Franco  2005 Title Review 
35 Garner  2005a Title Review 
36 Garner  2005b Title Review 
37 Gendo  2005 Title Review 
38 Gillis and Willems 2005 Title Review 
39 Hadian and Pinksky 2006 Title Review 
40 Hancock  2005 Title Review 
41 Holmes and Wood, 2006 Title Review 
42 Jamieson and Naghavi 2007 Title Review 
43 Jolly 2006 Title Review 
44 Kapur 2007  Title Review 
45 Lazzaroni  2005 Title Review 
46 Lim  2007 Title Review 
47 Lowe 2005 Title Review 
48 Macdonald and Taghian 2007 Title Review 
49 Maclure 2006 Title Review 
50 Mangoush 2007 Title Review 
51 Menasche  2006 Title Review 
52 Menasche  2006a Title Review 
53 Merchant and Laborde 2005 Title Review 
54 Naccarelli 2005 Title Review 
55 Nielsen  2006 Title Review 
56 Nilsson 2006 Title Review 
57 Novak  2007 Title Review 
58 Papadakis  2005 Title Review 
59 Parry and Fetridge-Durdle 2006 Title Review 
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60 Pell  2007 Title Review 
61 Petchetti  2007 Title Review 
62 Psychosocial Outcomes Workgroup of 
the Nursing and Social Sciences Council 
of the International Society for Heart and 
Lung Transplantation  2006 
Title Review 
63 Ryan and Rittershaus 2006 Title Review 
64 Sackner-Bernstein 2005 Title Review 
65 Sharples  2006 Title Review 
66 Siddiqui and Scott 2005 Title Review 
67 Solheim 2006 Title Review 
68 Stevenson  2005 Title Review 
69 Taylor  2005 Title Review 
70 Thomas  2006 Title Review 
71 van Geijn  2005 Title Review 
72 Vidaillet, 2005 Title Review 
73 Vidaillet and Greenlee 2005 Title Review 
74 Ward  2007 Title Review 
75 Wyse 2005 Title Review 
76 Yokota  2007 Title Review 
77*  Title Review 
78 Anderson 2005 Title and abstract Not EE 
79 Ashraf  2005 Title and abstract Not EE 
80 Bentkover  2007 Title and abstract Not EE 
81 Danilouchkine  2005 Title and abstract Not EE 
82 Duffy  2005 Title and abstract Not EE 
83 Fischell  2007 Title and abstract Not EE 
84 Fox  2006 Title and abstract Not EE 
85 Hacker  2005 Title and abstract Not EE 
86 Horn  2006 Title and abstract Not EE 
87 Huybrechts et al, 2005 Title and abstract Not EE 
88 Ishikawa  2007 Title and abstract Not EE 
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89 Kristiansen  2006 Title and abstract Not EE 
90 Miraldi  2007 Title and abstract Not EE 
91* Non English Title and abstract Not EE 
92 Newcomb  2005 Title and abstract Not EE 
93* Non English Title and abstract Not EE 
94* Non English Title and abstract Not EE 
95 Ogah  2006 Title and abstract Not EE 
96 Rashba  2006 Title and abstract Not EE 
97 Richards  2005 Title and abstract Not EE 
98 Seow  2006 Title and abstract Not EE 
99 Shelton  2005 Title and abstract Not EE 
100 Slagboom  2005 Title and abstract Not EE 
101 Smith  2005a Title and abstract Not EE 
102 Smith  2005b Title and abstract Not EE 
103 Smith  2005c Title and abstract Not EE 
104 Stramba-Badiale  2006 Title and abstract Not EE 
105 Vanek  2005 Title and abstract Not EE 
106 Varga  2005 Title and abstract Not EE 
107 Yan  2007 Title and abstract Not EE 
108 Alisky 2007 Title and abstract comments 
109 Speidel and Hilleman 2006 Title and abstract comments 
110* Non English Title and abstract comments 
111 Inaguma  2006 Title and abstract Heart disease is not 
the main study area 
112 Nuijten  2007 Title and abstract Heart disease is not 
the main study area 
113 Simpson 2007b Title and abstract Heart disease is not 
the main study area 
114 Zethraeus 2005 Title and abstract Heart disease is not 
the main study area 
115* Non English Title and abstract Heart disease is not 
the main study area 
116 Willan  2005 Title and abstract Methodology 
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118 Fenwick 2006 Title and abstract methodology study but 
based on individual 
trial 
119 Hallstrom 2006 Title and abstract methodology study not 
based on individual 
trial 
120 Fintel 2007 Title and abstract Not base on individual 
data 
121 Gerber 2006 Title and abstract Not base on individual 
data 
122 Gerhard 2006 Title and abstract Not base on individual 
data 
123 Hay and Sterling 2005 Title and abstract Not base on individual 
data 
124 Hirsch 2005 Title and abstract Not base on individual 
data 
125 Jongerden 2007 Title and abstract Not base on individual 
data 
126 Martikainen 2007 Title and abstract Not base on individual 
data 
127 Pignone 2007 Title and abstract Not base on individual 
data 
128 Sanders 2005 Title and abstract Not base on individual 
data 
129 Shrive 2005 Title and abstract Not base on individual 
data 
130 Bampidis 2005 Title and abstract Not heart disease  
Hypertension 
131 East 2006 Title and abstract Not heart disease  
Hypertension 
132 Haas 2006 Title and abstract Not heart disease  
Hypertension 
133 Joffres 2007 Title and abstract Not heart disease  
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Hypertension 
134 Love and Benson 2006 Title and abstract Not heart disease  
Hypertension 
135 Plans-Rubio 2006 Title and abstract Not heart disease  
Hypertension 
136 Saito 2006 Title and abstract Not heart disease  
Hypertension 
137 Siddiqui and Scott 2006 Title and abstract Not heart disease  
Hypertension 
138 Storrow  2005 Title and abstract Not heart disease 
139 Tokatli  2006 Title and abstract Not heart disease  
Hypertension 
140 Zeeuwe  2006 Title and abstract Not heart disease  
Hypertension 
141 Ara and Brennan. 2007 Title and abstract Not heart disease 
142 Brennan  2006 Title and abstract Not heart disease 
143 Fernandez and Griffiths 2005 Title and abstract Not heart disease 
144 Gokce 2007 Title and abstract Not heart disease 
145 Kilonzo 2007 Title and abstract Not heart disease 
146 Lester  2007 Title and abstract Not heart disease 
147 Lofdahl  2005 Title and abstract Not heart disease 
148 Lundkvist  2007 Title and abstract Not heart disease 
149 Marcus  2007 Title and abstract Not heart disease 
150 Mason  2005 Title and abstract Not heart disease 
151 Obuchowski and Modic 2006 Title and abstract Not heart disease 
152 Ritzwoller 2006 Title and abstract Not heart disease 
153 Simpson 2007a Title and abstract Not heart disease 
154 Slichter 2006 Title and abstract Not heart disease 
155 Smith  2006 Title and abstract Not heart disease 
156 Tracy  2006 Title and abstract Not heart disease 
157 Bramkamp 2005 Title and abstract Review 
158 Cooper 2006a Title and abstract Study design 
159 Hochman 2005 Title and abstract Study design 
  
231
160 Jolly 2007 Title and abstract Study design 
161 Kapur 2005 Title and abstract Study design 
162 Krumholz 2005 Title and abstract Study design 
163 Matchar 2005 Title and abstract Study design 
164 McQueen 2005 Title and abstract Study design 
165 Nichol 2005 Title and abstract Study design 
166 Rose 2007 Title and abstract Study design 
167 Rosenman 2006 Title and abstract Study design 
168 Sweeney 2006 Title and abstract Study design 
169 Pietrasik 2007 Full paper within trial analysis 
170 McMurray 2006 
 
Full paper within trial analysis 
171 Inglis 2006 Full paper within  trial based-
longer follow up 
172 Paez and Allen 2006 Full paper Not EE 
173 Mueller 2006 Full paper within trial 
174 Pearson 2006 Full paper Not based on 
individual data 
175 Di 2005 Full paper within trial analysis 
176 Briffa 2005 Full paper within trial analysis 
177 Reed 2005 Full paper within trial analysis 
178 van  Huslt 2005 Full paper within trial analysis 
179 O'Brien  2005 Full paper within trial analysis 
180 Raftery  2005 Full paper within trial analysis 
181 Radeva  2005 Full paper within trial analysis 
182 Szucs  2006 
 
Full paper within trial and  
beyond trial 
183 Mark  2006 
 
Full paper within trial and  
beyond trial 
184 Feldman  2005b 
 
Full paper within trial and 
beyond trial 
185 Angus  2005 Full paper within trial and 
beyond trial 
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186 Calvert  2005 Full paper Within trial 
187 Beinart  2005 Full paper Within a trial and  
beyond a trial 
188 Weintraub  2005a Full paper within trial and 
beyond a trial 
189 Weintraub  2005b Full paper within trial and 
beyond a trial 
190 Briggs  2007 Full paper yes - model based 
191 Yao 2007 Full paper yes - model based 
analysis 
192 Scuffham and Chaplin 2006 Full paper yes- model based 
analysis 
193 Cram 2006 Full paper yes - model based 
analysis 
194 Caro 2006 Full paper yes- model based 
analysis 
195 Stecher 2006 Full paper Not based on 
Individual data 
196 Scuffham and Kosa 2006 Full paper yes - model based 
197 Rinfret 2005 Full paper yes- within trial and 
model based 
198 Mihaylova 2005 Full paper yes - within trial 
analysis 
199 Bond 2007 Full paper yes - within trial 
analysis 
200 Taylor 2007 Full paper yes- within trial 
analysis 
201 Murray 2007 Full paper yes- within trial 
analysis 
202 Walker  2006 Full paper yes - cost study 
203 Caro 2005 Full paper Not full EE 
204 Dawkins 2006 Full paper Not full EE 
205 Del 2007 Full paper Not full EE 
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206 Feldman 2005c Full paper Not full EE 
207 Giada 2007 Full paper Not full EE 
208 Girling 2007 Full paper Not full EE 
209 Gregory 2006 Full paper Not full EE 
210 Kaul  2005 Full paper Not full EE 
211 Lopez  2006 Full paper Not full EE 
212 Mozaffarian 2007 Full paper Not based on 
individual patient data 
213 Banz 2005 Full paper Not based on 
individual patient data 
214 Kohli 2006 Full paper Heart disease is not 
the study focus 
215 Lindgren 2005 Full paper Heart disease is not 
the study focus 
216 Miller 2005 Full paper Heart disease is not 
the study focus 
217 O'Connor 2005 Full paper Heart disease is not 
the study focus 
218 Olsen 2005 Full paper Heart disease is not 
the study focus 
219 Hallstrom 2005 Full paper Not EE 
220 Quist-Paulsen 2006 Full paper Not EE 
* No authors listed on Medline 
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APPENDIX 3 MODEL FIT INFORMATION FOR CHAPTER 6 
 
Table 1  Model fit information for time to sudden death 
Model Model Akaike information criteria 
Weibull 690.4505951 
Exponential 726.4328276 
LLogistic 727.5760968 
Lognormal 733.5597493 
Gamma 725.3366251 
*The smallest AIC produced the best fit 
 
 Table 2  Model fit information for time to hospitalisation 
Model Model Akaike information criteria 
Weibull 1870.338 
Exponential 1871.126 
Gamma 1881.631 
LLogistic 1887.1 
Lognormal 1934.674 
*The smallest AIC produced the best fit 
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APPENDIX 4 MODEL FIT INFORMATION FOR CHAPTER 7 
 
Table 1  Model fit information for time to sudden death 
Model Model Akaike information criteria 
Weibull 660.8083 
Lognormal 662.4853 
Exponential 663.4678 
LLogistic 663.8212 
Gamma 664.1923 
*The smallest AIC produced the best fit 
 
 Table 2  Model fit information for time to hospitalisation 
Model Model Akaike information criteria 
Weibull 3692.615 
Lognormal 3696.761 
LLogistic 3702.224 
Gamma 3711.657 
Exponential 3738.396 
*The smallest AIC produced the best fit 
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